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ABSTRACT

CHEMICAL MODIFICATION METHODS FOR PROTEIN MISFOLDING STUDIES
Yanxin Wang
E. James Petersson

Protein misfolding is the basis of various human diseases, including Parkinson’s
disease, Alzheimer’s disease and Type 2 diabetes. When a protein misfolds, it adopts the
wrong three dimensional structures that are dysfunctional and sometime pathological.
Little structural details are known about this misfolding phenomenon due to the lack of
characterization tools. Our group previously demonstrated that a thioamide, a single atom
substitution of the peptide bond, could serve as a minimalist fluorescence quencher. In
the current study, we showed the development of protein semi-synthesis strategies for the
incorporation of thioamides into full-length proteins for misfolding studies.

We adopted the native chemical ligation (NCL) method between a C-terminal
thioester fragment and an N-terminal Cys fragment. We first devised strategies for the
synthesis of thioamide-containing peptide thioesters as NCL substrates, and demonstrated
their applications in generating a thioamide/Trp-dually labeled α-synuclein (αS), which
was subsequently used in a proof-of-concept misfolding study. To remove the constraint
of a Cys at the ligation site, we explored traceless ligation methods that desulfurized Cys
into Ala, or β- and γ- thiol analogs into native amino acids after ligation in the presence
of thioamides. We further demonstrated that selective deselenization could be achieved in
vi

the presence of both Cys residues and thioamides, expanding the scope of thioamide
incorporation through traceless ligation to proteins with native Cys. Finally, we showed
that hemiselenide protected selenocysteines (Sec) can be incorporated onto the protein Nterminus through chemoenzymatic modification by aminoacyl transferase (AaT) as
ligation handles. Further developments are underway in our laboratory to expand the AaT
substrate scope for β- and γ- thiol amino acid analogs. In summary, we developed a set of
methods that allowed the incorporation of thioamide probes into full-length protein,
which enabled the application of this minimalist probe in protein misfolding studies.
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Chapter 1 . Introduction

Part of the content in this chapter was originally published in Organic & Biomolecular Chemistry. It is
adapted here with permission from the publisher:

Reprinted and adapted with permission from Wang, Y. J.; Szantai-Kis, D. M.; Petersson, E. J., SemiSynthesis of Thioamide Containing Proteins. Org. Biomol. Chem. 2015, 13, 5074−5081. Copyright 2015
Royal Society of Chemistry.
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1.1 Protein Misfolding and Human Diseases
Protein Misfolding

Proteins are an important class of biological macromolecules,

and key building blocks of life1. They are responsible for the majority of cellular
activities in living organisms, from maintaining cell morphology and catalyzing
metabolic reactions, to signaling and homeostasis2. All proteins are constructed from a
simple scaffold of linear chains of amino acids that are joined together through peptide
bonds3. The classic view − as represented by the “central dogma”4 and the Anfinsen
hypothesis5 − states that the structures and functions of proteins are largely encoded by
their amino acid sequences; a defined sequence is transcribed from genetic information
stored in DNA into RNA, which is in turn translated into a protein that folds into a
defined three-dimensional structure to serve a set of defined biological functions.

With the emergence of the “energy landscape” theory for protein folding6 and
empirical characterization of protein dynamics7,8,9, we now understand that proteins may
assume a variety of conformations and that the amino acid sequence per se is not sufficient to determine its three-dimensional structure. For many proteins, their biologically
active conformations are not the “global energy minimum”, but rather a “local energy
minimum” that is either stabilized by a binding partner or trapped by kinetic barriers to
the next available conformation (Figure 1-1)10. As proteins sample various energy
minima on their folding energy landscapes, they can also “misfold” into wrong
conformations that are dysfunctional and sometimes pathological. In our laboratory, we
strive to construct chemical tools for the characterization of this misfolding phenomenon.
2

Figure 1-1. A Unified View of Protein Folding and Misfolding.
10

Various folding states on a protein energy landscape. Graphics adapted from Stefani .

Protein Misfolding Diseases

Protein misfolding is of great significance to human

health, particularly in the context of aging-associated diseases. The majority of “degenerative diseases” (including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Type
2 diabetes) involve toxic loss-of-function or gain-of-function in particular tissues, which
at the molecular level, can be attributed to protein misfolding11,12,13. Table 1-1
summarizes some of the most well-studied protein misfolding diseases14,15; it is worthnoting that many of these diseases are sporadic rather than hereditary – the misfolded
protein originates from a normally folded, functional protein that becomes pathological
(or accumulates to a critical amount that overwhelms the cell’s ability to clear misfolded
proteins) at the onset of the disease16. The accumulation of misfolded proteins leads to a

3

variety of consequences such as oxidative stress and cell deformation, which ultimately
results in cell death and thus the “degenerative” symptoms (Figure 1-2)14.
Table 1-1. Selected Protein Misfolding Diseases in Human.
Human Disease

Associated Protein(s)

Affected Tissue

Alzheimer’s disease (AD)

Amyloid β, tau

Brain

Parkinson’s disease (PD)

α-Synuclein, tau

Brain

Lewy-body dementia (DLB)

α-Synuclein

Brain

Huntington’s disease (HD)

Hungtintin

Brain

Tau

Brain

Superoxide dismutase 1

Brain

Primary systemic amyloidosis (PSA)

Ig light chain

Systemic

Senile systemic amyloidosis (SSA)

Transthyretin

Microvasculature

Low-density lipoprotein (LDL)

Arteries

Crystallin

Eye

Amylin

Pancreas

Neurodegenerative Diseases

Frontotemporal dementia (FTD)
Amyotrophic lateral sclerosis (ALS)
Other Aging-Related Diseases

Atherosclerosis
Cataract
Type 2 diabetes (T2D)

* Adapted from Christensen et al.14 and Gebbink et al.15

Figure 1-2. Cellular Consequences of Pathological Protein Misfolding.
Graphics adapted from Christensen et al.
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At the molecular level, the most common type of pathological protein misfolding is
aggregation – in particular, the transformation of a natively folded or unfolded protein
into β-sheet rich aggregates known as “amyloids”17. Due to the nature of the β-sheet
secondary structure, these aggregates have unsatisfied backbone hydrogen bond donors
and acceptors on either ends of the β-sheets, and have a tendency to propagate by
recruiting additional proteins and templating their folding into β-sheets (Figure 1-3)15,18.
Once a small population of misfolded monomers and/or oligomers is formed, a vicious
self-propagation cycle is initiated18. Additionally, amyloids are more resistant to
proteolytic degradation than their natively folded or unfolded counterparts19, making it
difficult to reverse the misfolding. This amyloidosis phenomenon is the basis for many of
the most infamous aging-related diseases, including AD and PD12,18.

Figure 1-3. Generalized Scheme: the Molecular Basis of Amyloid Formation.
Graphics adapted from Gebbink et al.
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α-Synuclein (αS) Misfolding and Parkinson’s Disease

PD is the second most

common neurodegenerative disorder that affects approximately 7 million people
worldwide20. It was first described by British doctor James Parkinson in 1817 as a
5

“shaking palsy”21, and later fully characterized as a progressive degenerative disorder
with motor impairments as the initial symptoms22. The physiological basis of PD was
discovered in the 1960s, where loss of dopaminergic neurons in the substantia nigra were
observed by post-mortem analyses of PD patients, leading to the introduction of levodopa
as a dopamine supplement (which is still the “gold standard” for PD treatment today)23.
In 1912, Lewy body inclusions were found as the “pathological hallmark” of PD24; in
1997, αS was characterized as the major component of Lewy body inclusions, and the
first familial PD mutation A53T was identified.25 Since its initial discovery, the central
role of αS in PD pathogenesis has been extensively studied – currently, the extent of
“synucleopathy” is commonly recognized as the most important parameter for PD
diagnosis and disease stage classification26,27.

αS is a 140 residue protein that is abundantly expressed in pre-synaptic terminals, and
is estimated to “comprise 1% of total cytosolic proteins in the brain”28. Its physiological
function has not been fully characterized, but current evidences suggest that it is involved
in synaptic transmission29 – in one study, fluorescently labeled αS was observed to
dissociate from synaptic vesicles upon neuronal firing, and then gradually re-associate
with newly formed vesicles during resting30. The sequence of αS consists of three
different regions (Figure 1-4) – an N-terminal region (residues 1−60) that contains seven
imperfect repeats of lipid-binding KTKEGV motifs and confers α-helical propensity, a
central hydrophobic region (residues 61−95) known as the non-amyloid β component
(NAC) domain that has β-sheet formation potential, and a highly acidic C-terminal region

6

(residues 96-140) that is largely disordered under physiological pH31. Known mutations
that result in early onset of PD include A30P32, E46K33, H50Q34, G51D35 and A53T25.

Figure 1-4. Amino Acid Sequence of Human αS.
Graphics adapted from Lee et al.

31

αS can adopt three distinct types of structures depending on its environment − it is αhelical when bound to micelles or vesicles36, disordered when in aqueous solution37, and
β-sheet rich during in vitro or in vivo aggregation38. In its micelle bound form, αS adopts
a well-defined helical structure that has been characterized by both nuclear magnetic
resonance (NMR) spectroscopy and electron paramagnetic resonance (EPR) spectrscopy,
where two helices (residues 1−41 and 45−94) and a disordered C-terminal region were
observed (Figure 1-5)36,39. When bound of unilamellar vesicles, the two helices has been
shown to stretch into an extended helical conformation in response to membrane
curvature by single molecule Förster resonance energy transfer (smFRET) studies from
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the Rhoades group40. Additional studies using truncated αS fragments determined that the
first 25 residues in the N-terminal domain were most crucial for membrane binding41.

36

Figure 1-5. Membrane Bound Structure of αS as Determined by NMR (PDB 1XQ8) .

In comparison, the structures of lipid-free αS monomer and fibrils are not nearly as
defined. αS monomers are largely unstructured as determined by circular dichroism
spectroscopy (CD) and Fourier transform infrared spectroscopy (FT-IR)37. However, αS
does exhibit some level of compaction as evidenced by the smaller radius of gyration
than that expected of a fully unfolded conformation (40 vs. 55 Å)42. Other studies also
suggested the potential for transient tertiary contacts between the N- and C-terminal
regions, which were postulated to be protective against αS aggregation.43,44,45

The overall morphology of αS fibrils has been well-documented, but their molecular
details are poorly understood. Transmission electron microscopy (TEM) studies showed
that both patient-derived and in vitro aggregated αS fibrils exhibited long, unbranched
morphology with a uniform width of 5−10 nm46,38; two fibril strands may further
assemble into “mature fibrils” with a straight or twisted orientation47. At the molecular
level, various secondary structure assignments have been proposed by different group
8

using NMR methods, but a clear three-dimensional structure model has yet to be
constructed (Figure 1-6)47,48,49,50. Recently, Eisenberg et al. used an innovative microelectron diffraction method and obtained structures of fibrillized αS-derived peptides.51

Figure 1-6. Proposed Secondary Structures for αS Fibrils.
Graphics adapted from Bennati et al.

52

In terms of the αS aggregation process where monomers convert into pathological
fibrils, even fewer structural details are known. Most studies of αS aggregation were
based on global monitoring of the “extent of aggregation”, where fibril-binding dyes or
band intensities on SDS-PAGE gels were used to quantify monomer/fibril concentrations46,53. The most commonly used dye is thioflavin T (ThT) – it consists of two
aromatic rings, and exhibits turn-on fluorescence when the relative rotations of the two
rings are restricted, preventing, internal charge transfer, as it binds to hydrophobic
surfaces on amyloid fibrils54. Data from these crude global monitoring methods revealed
that αS aggregation was a nucleation-elongation process: it exhibits a lag phase that
9

corresponds to the formation of nuclei, followed by a rapid growth phase where β-sheet
propagation takes place (Figure 1-7)55,28. Additional studies showed the significance of
seeding and fibril fragmentation, which could significantly accelerate aggregation56,57.
The aggregation process is also dependent on salts and buffer conditions 58, and most
intriguingly, it was found that dopamine itself may interact with αS oligomers/fibrils and
contribute to their cytotoxicity59,60,61 – the current standard of care with levodopa may
actually exacerbate PD progression, while temporarily compensating for the diminished
neuronal function62.

Figure 1-7. αS Aggregation Process as Characterized by Thioflavin T (ThT) Monitoring.
Graphics adapted from Jucker et al.
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Last but not least, αS fibrils were found to transmit from cell to cell, and propagate in
the brain in a “spatiotemporal manner”63,64,65. In particular, two conformational “strains”
of αS fibrils were identified, where strain B evolved from strain A after 6~7 rounds of
fibril propagation and gained the ability to cross-seed tau aggregation, without exhibiting
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much difference in conventional CD or FT-IR characterizations66. To date, neither the
structures nor the formation processes of these strains are known.

Challenges in Protein Misfolding Studies

Obtaining clear structural information

on protein misfolding is extremely challenging because of the polymorphism, or heterogeneity, in amyloid structures and formation processes48,67. As summarized in Eisenberg
et al.53, there are eight possible structure elements in β-sheet rich aggregates, depending
on the parallel/antiparallel nature within one β-sheet and the relative orientations of
different layers of β-sheets (Figure 1-8). For most misfolded proteins such as αS, there
are multiple β-strand segments in the sequences, giving rise to various possible combinations of the structural elements, and thus different fibril conformations (see Figure 1-6).
Therefore, it is very difficult to determine fibril structures by conventional structural
biology methods such as X-ray crystallography and NMR spectroscopy, which frequently
require the preparation of a homogenous material68.

In comparison, fluorescence spectroscopy, particularly single molecule fluorescence
spectroscopy, is a much more powerful tool in the context of protein misfolding studies69:
1) it has nanosecond temporal resolution, and can be conducted in real time to capture the
dynamic conformational changes in the aggregation process; 2) using Förster resonance
energy transfer (FRET, see next section) between a fluorescence donor and an acceptor/
quencher, the distance between the two labels can be accurately extrapolated, yielding
structural information about aggregation intermediates and the final fibrils; 3) in addition
to the most common steady state fluorescence intensity measurements, one could also
11

utilize florescence life-time measurements, fluorescence correlation spectroscopy (FCS),
fluorescence anisotropy, and fluorescence imaging techniques to obtain in vitro and in
vivo properties of the target protein at various stages of aggregation; 4) it is amenable to
single molecule measurements, where a heterogeneous ensemble of conformations can be
each accounted for as distinct populations in fluorescence spectroscopy. In fact, some of
the most useful information about αS monomers and oligomers were obtained through
single molecule fluorescence studies70,71.

Figure 1-8. Structural Elements of β-Sheet Rich Fibrils.
Adapted from Eisenberg et al.

53

and Gebbink et al.
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Our challenge was to identify and incorporate the appropriate chromophores to
realize our vision of characterizing the molecular details behind the protein misfolding
phenomenon using fluorescence spectroscopy (we use the term “chromophore” to include
both fluorophores and quenchers). In addition to the photophysics and stability require12

ments, our chosen chromophores must also be amenable to positional scanning, i.e. it
should be minimally perturbing when incorporated at any desired position, including the
β-sheet rich fibril core. Traditional chromophores such as fluorescent proteins (FPs) and
organic fluorophores/quenchers are too bulky for such applications72. Therefore, our
group set out to investigate a novel fluorescence quencher, a thioamide.
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1.2 Thioamides as a Minimalist Probes
Properties of the Thioamide Bond

A thioamide is a single-atom substitution of

the standard amide functional group (herein referred to as “oxoamide”), where the
carbonyl oxygen is replaced with a sulfur. It is nearly isosteric to the amide group, while
exhibiting different physical and chemical properties (Table 1-2)73,74. The sulfur atom is
slightly larger than the oxygen atom (van der Waals radii 1.85 Å vs. 1.40 Å)75, and the
C=S bond is slightly longer than the C=O bond (1.71 Å vs. 1.23 Å)76. Due to the
additional electron shell in sulfur vs. oxygen, the overlap is less strong with carbon 2sp2
and 2p orbitals, therefore the C=S bond is weaker than the C=O bond (average bond
energy 130 kcal/mol vs. 170 kcal/mol)77 and more polar (5.07 D vs. 3.79 D)78. The
rotation energy barrier for thioamide cis-trans isomerization is greater that of oxoamides
(22−25 kcal/mol vs. 20 kcal/mol) due to “a considerable transfer of charge density from
N to S” that elevates energies of the transition states as characterized by Wiberg,79 which
is also reflective of the less electronegative nature of sulfur than oxygen (2.58 vs 3.44)80.

Thioamides are stronger hydrogen bond donors than oxoamides, but weaker
acceptors. Based on experimental studies81,82 and theoretical modeling83 from various
groups, the C=S ∙∙∙ H−N hydrogen bond has been characterized as 0.6 Å longer and 2
kcal/mol weaker than its oxoamide counterpart, due to the larger van der Waals radius of
sulfur, as well as the less effective orbital overlap between the sulfur 3sp2 orbital (as
compared to the 2sp2 orbital of oxygen) and the hydrogen 1s orbital. In contrast, the
CSN−H ∙∙∙ O=C bond is approximately 1 kcal/mol more favorable, due to more polarized
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N−H bond in the thioamide, which is also reflected in its lower pKa (18.5 vs. 25.5).84 In
addition, the presence of a sulfur atom gives the thioamide higher nucleophilicity85 as
well as greater affinity for soft metals86 in terms of chemical reactivity.

Of particular interest to our group is the π–π* absorption and oxidation potential of
thioamides. The thioamide absorption is red-shifted as compared to that of an oxoamide
(270 nm vs. 200 nm)87, allowing the selective excitation of thioamide in a background of
oxoamides. Similarly, a thioamide is easier to oxidize than an oxoamide (1.21 V vs. 3.29
V)84, allowing the specific oxidation of thioamide when the reduction potential of the
electron acceptor is carefully controlled. The exact photophysical applications of these
properties will be discussed in later sections. In early studies of thioamide-containing
peptides, the stability of the thioamide group in aqueous buffer was well-established.88,89
Overall, thioamides are excellent isosteric replacements for the natural oxoamides in
peptides and proteins, where one could leverage their unique chemical and physical
properties without major concerns on steric perturbation or stability.

Table 1-2. Selected Properties of Thioamides.
Property

Oxo

Thio

Van der Waals radius (Å)

1.40

1.85

C=X bond length (Å)

1.23

1.71

Electronegativity

3.44

2.58

C=X∙∙∙H–N bond dissociation energy (kcal mol-1)

6.1

4.8

π–π* absorption (nm)

200

270

EOx (V vs. S.H.E.)

3.29

1.21

* S.H.E. = Standard hydrogen electrode
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Thioamides in Nature and in Medicinal Chemistry

In nature, thioamides are

found in small molecules and at least one folded protein. To our knowledge, there are
five natural products with thioamide bonds, namely cycasthioamide from the seeds of
Cycas revoluta90, (4-methoxyphenyl)-N-methyl-2-oxothioacetamide from Polycarpa
aurata91, apo-methanobactin from Methylosinus trichosporium92, thioviridamide from
Streptomyces olivoviridis93, and closthioamide from Clostridium cellulolyticum94. Among
these compounds, closthioamide has been most thoroughly characterized (Figure 1-9)94,95
– it has six thioamide bonds and exhibits strong antibiotic activity against S. aureus; the
compound was fully inactive when all thioamides were substituted with oxoamides, and a
significant reduction in potency was observed even with a single thio-to-oxo substitution.
A recent study showed that the biological activity of closthioamide was related to its
copper binding ability, which explained the importance of the thioamides96. The only
known protein with a thioamide bond is methyl-coenzyme M reductase, an enzyme
involved in archeal methane formation97. It was shown to possess a thioglycine residue
near its active site by X-ray crystallography and mass spectrometry, which presumably
facilitates the oxidation and reduction of cofactor and substrate.

Figure 1-9. Chemical Structure of Closthioamide.
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In medicinal chemistry, thioamides are frequently used as an amide bond derivative
for structure-activity relationship (SAR) studies of natural products; they may also be
subsequently derivatized into thiazoles, thiazolines, thiazines, or amidines to expand the
candidate library98. Representative examples include thioamide derivatization of oxytocin
by du Vigneaud and coworkers99, of leucine enkephalin by Lawesson and colleagues100,
and of vancomycin by the Boger group101. Interestingly, in the case of leucine enkephalin, thioamide substitution at Tyr1 completely eliminated its biological activity, while
substitution at Gly2 enhanced its activity by 3−14 fold100. There are several approved
drugs that contain thioamides, the most notable of which is 6-n-propyl-2-thiouracil (PTU)
that derives its anti-hyperthyroidism activity from the thioamide moiety102.

Early Applications of Thioamides in Peptides and Proteins

An early example for

applying thioamides to studying peptides and proteins was a carboxypeptidase A kinetic
analysis, where thioamide-modified short peptide substrates were evaluated for their
enzymatic activity.103 With a thioalanine or thiophenylalanine (AlaS or PheS; we use a
superscript “S” to denote thioamide-containing residues) at the scissile bond, the authors
demonstrated that thioamides can function as effective substrates. More interestingly,
utilizing the affinity of sulfur to soft metals, they were able to identify cadmium as a
more effective metal cofactor as compared to the native zinc, where the kcat/Km was 2.4–
9.7 fold higher for the Cd(II) carboxypeptidase than for the Zn(II) carboxypeptidase
when thioamide-containing peptides were used as substrates.
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More recently, Raines et al. have utilized the differences in the electronic properties
of C=S and C=O bonds to study the n-π* interactions between two adjacent peptide
bonds.104 The n-π* interaction is characterized as the donation of one of the non-bonding
lone pairs (n) of a carbonyl into the antibonding orbital (π*) of an adjacent carbonyl.
Since sulfur is a better electron donor, the n-π* interaction is proved to be stronger for
thioamides (Figure 1-10). Based on these data, the authors argued that n-π* interactions
were a protein stabilizing force that were complimentary to hydrogen bonds105.

Figure 1-10. Strength of n-π* Interactions as Measured in cis-trans Equilibrium

106

.

Several direct studies on the effects of thioamides in protein secondary structures
have also been conducted, where thioamides were incorporated into different model
peptides for conformational studies. Reiner et al. incorporated a thioamide near the Nterminus of an α-helical peptide, and demonstrated its structural similarity to the
oxoamide peptide using NMR spectroscopy, as well as a 1.6 kcal/mol stabilization to the
oxopeptide88. Miwa et al. conducted a similar study with a thioamide near the C-terminus
of a model α-helical peptide, and reached the same conclusion that the thiopeptide
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exhibited a nearly identical structure to the oxopeptide89. The same group also tested the
compatibility of thioamides with β-sheets, by incorporating a thioglycine (GlyS) at the βturn in a β-hairpin model peptide, and showed structural compatibility107. As a follow-up,
Culik et al. incorporated thioamides into other positions in a β-hairpin tryptophan zipper,
and showed that the substitution was well-tolerated except when it was placed directly
next to the β-turn108. Most recently, Raines et al. incorporated thioamides into the
collagen triple helix and observed minimal perturbation to its structural stability; in fact,
the authors noted that the thioamide was “the first in the collagen backbone that does not
compromise thermostability”109. These studies showed that while thioamides may subtly
affect folding pathways, they are generally well-tolerated in these secondary structures.

Thioamide as a Minimalist Fluorescence Quencher

Thioamides are particularly

appealing modifications for our vision of using a “minimalist” chromophore to monitor
protein misfolding. With the abundance of peptide bonds and side chain oxoamides in
peptides and proteins, one could envision placing thioamides at any residue along the
protein sequence as probes for mechanistic and/or structural studies. Earlier experiments
showed that thioamides exhibit unique circular dichroism signature around 272 nm89 and
can be selectively photo-isomerized110 in a background of oxoamides. In our own group,
we have extensively explored the utility of thioamides as fluorescence quenchers through
FRET or photo-induced electron transfer (PET).

FRET is a non-radiative energy transfer phenomenon, where the excited state of a
donor fluorophore transfers its energy to a ground state acceptor fluorophore; as a result
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of this process, the donor will relax back to ground state, while the acceptor enters an
excited state and subsequently relaxes back either through release of a photon or through
thermal or collisional relaxation (see Figure 1-11)69. The energy transfer efficiency (EQ)
is distance dependent, and can be described by the following equations:
𝐸Q =

1
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where R is the distance between acceptor and donor fluorophores, and R0 is the
Förster distance at which the transfer efficiency is 50%. R0 can be experimentally
determined from EQ or theoretically calculated – experimentally, EQ can be measured
from donor fluorescence in the presence (F) or absence (F0) of the acceptor chromophore,
and fitted to the Förster equation; theoretically, the parameters needed include the
spectral overlap integral between donor emission and acceptor absorption (J), an
orientation factor to describe the interaction of the transition dipoles of the donor and the
acceptor (κ2), the quantum yield of the donor (ΦD), index of refraction of the solvent (n),
and Avogadro’s number (NA).

UV wavelength dyes, such as p-cyanophenylalanine (Cnf) and the natural amino acid
Tyr, are quenched by thioamides through a FRET mechanism, where the emission spectra
of these chromophores exhibit overlap with the absorption spectra of thioamides.

111,112

Using rigid “polyproline rulers”, we determined the empirical Föster distances (R0) to be
16.5 Å for Cnf, and 16.2 Å for Tyr (Figure 1-11). These R0 values translate for an
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effective monitoring distance of 10−25 Å (where EQ is approximately between 10% and
90%), a very useful scale to monitor protein conformational changes at the secondary or
tertiary structure level, as well as tight protein-protein binding interactions. As proof-ofconcept examples, we also demonstrated the application of the Cnf-thioamide
fluorophore-quencher pair to monitoring thermal denaturation of a 35-residue model
peptide through intramolecular quenching111, and the utilization of the Tyr-thioamide pair
in quantifying protein-peptide binding through intermolecular quenching112.

Figure 1-11. Thioamide Quenching of Fluorescence through FRET.
Left: distance dependent quenching as measured by “proline ruler”. Right: Jablonski diagram
111-112
showing the FRET process. Graphics adapted from Goldberg et al.
and Olympus Inc.

PET is also a distance-dependent non-radiative energy transfer phenomenon, but is
achieved through electron transfers between the excited state donor and the ground state
acceptor chromophore69. For two chromophores to be a PET pair, they must have
matching oxidation/reduction potentials, and be present in sufficient proximity to enable
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the physical transfer of an electron. PET favorability can be determined by the Gibbs free
energy in the Rehm-Weller model113 with the following equation:
Δ𝐺𝐸𝑇 = 𝐹[𝐸𝑜𝑥 (𝐷) − 𝐸𝑟𝑒𝑑 (𝐴) − 𝐸0,0 ] + 𝐶
where F is the Faraday constant; Eox(D) and Ered(A) are the fround state oxidation and
reduction potentials of the electron donor and acceptor (the fluorescence donor can be
either the electron donor or the electron acceptor), respectively; E0,0 is the zero
vibrational electronic excitation energy of the fluorophore, calculated as the average
energy of the absorption and emission; and C is a term for Coulombic interactions that
are typically assumed to be negligible in aqueous solutions. In the case of fluorescence
quenching by a thioamide, the fluorophore is typically the electron acceptor, and the
thioamide is the electron donor. With an oxidation potential of 1.21 V (vs. S.H.E.),
thioamides were found to quench a number of near UV and visible wavelength
fluorophores (Figure 1-12), including commonly used dyes such as Alexa Fluor 488
(ΔGET = - 0.86 eV) and BODIPY FL (ΔGET = - 0.37 eV)114,115. As a proof-of-concept
example, we synthesized short peptides that were dually labeled with a fluorophore and a
thioamide, and showed that they were effective substrates for proteases such as calpain
both in vitro and in cell lysate116. Work is underway in our group to further pursue this
strategy as a tool to construct minimally-perturbing protease sensors.
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Figure 1-12. Thioamide Quenching of Fluorescence through PET.
Graphic adapted from Goldberg et al.

114,115,116

and Petersson et al.

74

In the context of protein misfolding, we envision using thioamide as a minimalist
label for “protein motion capture” (Figure 1-13). The target protein can be labeled with
fluorophore-thioamide pairs at various positions, and then fluorescence changes can be
monitored throughout the aggregation process and in the mature fibrils. The quenching
efficiencies observed will then be converted into distances, and by combining results
from various combinations of labeling positions, we can reconstruct the conformational
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changes that underlie the misfolding process. The fact that the thioamide is a nearly
isosteric substitution of the native amide bond is extremely important to the successful
application of this strategy − we can move the thioamide across the peptide backbone in a
“positional scanning” manner while keeping the fluorophore at a relatively nonperturbing position, which would not be possible with any other organic fluorophores or
fluorescent proteins (FPs).

Figure 1-13. A Conceptual Representation of “Protein Motion Capture”.
Analogous to motion capture in movie making, proteins can be tagged with fluorophorequencher pairs at various positions, and then subject to in vitro or in vivo misfolding. The
distances between the fluorophore and the quencher can be monitored throughout the
process by fluorescence quenching; results from all labeling positions can be combined to
recapitulate the “motions”, or conformational changes, involved in the misfolding process.

Thioamide Incorporation into Small Molecules and Peptides

In order to utilize

the thioamide as a minimalist chromophore, we must first be able to introduce it into the
peptide or protein of interest. Prior to our work (as shown in Chapters 2 to 4), thioamides
could only be incorporated into small molecules by solution phase thionation, or into
short peptides by solid phase peptide synthesis (SPPS).
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To our knowledge, the first synthetic thioamide-containing compound was prepared
by Gay-Lussac in 1815 from cyanogen and hydrogen sulfide117. In modern organic
synthesis, thioamides can be prepared from a variety of precursors including amides,
aldehydes, ketones and isothiocyanates, which has been extensively reviewed by several
authors118,119. The most applicable type of transformation for our studies is the direct
conversion of an oxoamide into thioamide. The two commonly used reagents are
phosphorous pentasulfide (P2S5 or P4S10)120,121 and Lawesson’s reagent122,123 − both
reactions involve a concerted sulfur transfer in a Wittig-type intermediate (Figure 1-14).
P2S5 can be used at lower temperature than Lawesson’s reagent (which typically requires
reflux for activation), but is also more difficult to remove by flash chromatography119.

Figure 1-14. Structures and Mechanisms of Common Thionating Reagents.
Adapted from Ozturk et al.

120

and Jesberger et al.

123

While thionation by P2S5 or Lawesson’s reagent is applicable to short peptides, it will
indiscriminately convert all oxoamides into thioamides (or in some cases, result in a
mixture of peptides with various degrees of thionation)119. To site-selectively incorporate
thioamides into peptides, one would need to adopt SPPS, where a preactivated thioamide
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precursor is first synthesized and then coupled to the growing peptide chain through
carbonyl substitution reactions (Figure 1-15). Rapoport et al. pioneered the synthesis of
N-Boc (Boc = t- butyloxycarbonyl) protected thioamide precursors, where 19 out of the
20 natural amino acids (except Gly) were successfully prepared124. More recently,
Chatterjee et al. systematically evaluated the preparation of N-Fmoc (Fmoc =
fluorenylmethyloxy-carbonyl) protected thioamide precursors and their coupling
conditions, where they synthesized 12 thoiamide precursors for D- and L-amino acids and
identified CH2Cl2 as the preferred solvent for thioamide coupling in SPPS125. In our own
group, we have successfully prepared 12 thioamide precursors using a similar strategy.

Figure 1-15. General Scheme for Thioamide Incorporation through SPPS.
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1.3 Protein Semi-Synthesis Methods
Protein semi-synthesis is the chemoselective condensation of two or more peptides/
proteins fragments. It has been a tremendously useful tool in incorporating synthetic
moieties that would otherwise not be accessible through cellular expression or singlechain SPPS, for the structural and functional studies of long peptides and full-length
proteins126. In the context of thioamide-containing protein preparation, we will focus on
methods that result in an amide bond at the ligation junction in the following discussions.
Overview of other methods − including thioether ligation, oxime ligation, and azidealkyne cycloaddition – can be found in a detailed review by Verzele and Madder127.

Native Chemical Ligation (NCL)

NCL was first introduced by Kent et al.128 in

1994, and quickly become the most widely adopted protein semi-synthesis method in the
last two decades. It utilized two unprotected peptide fragments in aqueous buffer − one
with a C-terminal thioester, the other with an N-terminal Cys. The thiol side chain of Cys
first undergoes a transthioesterification with the thioester fragment, and then an S-to-N
acyl shift takes place to form a native amide bond at the junction (Figure 1-16). The mild
reaction conditions are compatible with chemically sensitive groups such as glycosylated,
phosphorylated, or ubiquitinated side chains129. The most common applications for NCL
are130: 1) accessing long peptide sequences that are not possible to construct in a singlechain SPPS; 2) incorporation of unnatural modification into peptides and proteins, that
would otherwise not be accessible through cellular expression; 3) studying the properties
and functions of peptides/proteins with natural or unnatural substitutions at specific sites,
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which would otherwise be obtained as a mixture either in cell extract or through other
derivatization methods; 4) preparation of cyclized peptides and peptide analogs through
head-to-tail NCL reactions for activity screening. Even for short peptides that can be
synthesized directly through SPPS, NCL still offers two levels of benefits: 1) for
chemically sensitive groups, one could reduce the exposure of the peptide to harsh
synthesis conditions (e.g. trifluoroacetic acid, or TFA) by synthesizing shorter fragments
that can be rapidly deprotected; 2) for peptides that are functionalized at more than one
site, one could use combinatorial synthesis for the efficient generation of peptide
libraries. A notable example of NCL applications is the total chemical synthesis of αS by
Lashuel et al. − after establishing the feasibility of αS total synthesis by NCL131, they
further elucidated the effects of site-specific αS phosphorylation132, ubiquitination133, and
nitration134 on αS aggregation by synthesizing the corresponding “post-translationally”
modified αS. Another exemplary work was from Muir et al., where they synthesized
large libraries of modified histones via NCL and studied their biological functions135.

Figure 1-16. Mechanism of Native Chemical Ligation (NCL).
136

In practice, NCL is frequently catalyzed by thiol additives. A systematic study by Kent et al.
characterized the reactivity of various thiols, and identified that aromatic thiols such as 4mercaptophenylacetic acid (MPAA) as the most effective catalyst.
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Extended NCL Strategies

Major extensions of the NCL method include tandem

ligation, expressed protein ligation (EPL) and reverse native chemical ligation. Tandem
ligation was developed by Kent et al.137 using thiazolidine (Thz) as a masked Cys. The
middle fragment of the target protein was synthesized with an N-terminal Thz and Cterminal thioester to prevent self-ligation, and then joined to the C-terminal fragment.
After the first ligation, the Thz group was deprotected using MeONH2∙HCl, and then
subjected to another round of ligation with the N-terminal fragment. The tandem ligation
can be repeated to combine more than three fragments, and is frequently used in the
synthesis of large proteins135.

Expressed protein ligation (EPL) takes advantage of naturally-existing inteins to
generate protein thioesters, and greatly expands the ligation scope − prior to EPL, ligation
sites were largely restricted to the N-terminal region, as the thioester fragment could only
be chemically synthesized130. An intein is a protein fragment that exhibits self-splicing
properties – in nature, a protein sequence can be expressed with exteins and inteins
(similar to the exons and introns of nucleic acids), after which the inteins would selfexcise, leaving just the exteins in the final protein138. The process starts with an N-to-S
acyl transfer at the N-terminal Cys of the intein fragment, followed by a transthioesterification that joins the N-terminal extein with the C-terminal extein; the final step is
the formation of a succinimide at the C-terminus of intein to release the α-nitrogen of the
C-terminal extein (Figure 1-17)139. Muir et al. first reported the use of intein-mediated
EPL in 1998; without a C-terminal extein, the intein would remain as a thioester and
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serve as a substrate for subsequent ligation to a synthetic peptide140. Additional
developments using naturally existing141 or evolved split inteins142 allowed the extension
of EPL into in vivo systems; for example, a cell surface receptor can be expressed with
one intein fragment, and then treated with a fluorescent protein fused to the other intein
fragment, to achieve selective labeling on the cell surface (in comparison, traditional
fusion protein expression will result in high background fluorescence from mis-trafficked
proteins in the cytosol)143.

Figure 1-17. Intein-Mediate Protein Splicing and Expressed Protein Ligation.
Picture courtesy of Solongo Batjargal.
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Finally, reverse native chemical ligation is a similar technique to NCL, but uses a
thioacid and a side chain alkylhalide as the ligation handles instead. In the first step, a
thioester is formed by nucleophilic substitution on the alkylhalide, which subsequently
rearranges through standard S-to-N acyl shift to generate the amide bond, leaving a Cys
at the junction. Since both ligation handles are not accessible through cellular expression,
this method is primarily used for conjugating peptides127.

Traceless Staudinger Ligation

While NCL is limited to an N-terminal Cys (or

thiol surrogates as discussed in later sections) as the nucleophile, traceless Staudinger
ligation has no inherent limit on the N-terminal residue of the C-terminal fragment.
Developed by Raines and Bertozzi144,145,146, it utilizes the well-known Staudinger reaction
where an azide reacts with a phosphine to form an iminophosphorane. In the first step, a
phosphinothioester is generated in situ from a thioester; the azide then reacts with the
phosphine moiety to generate an iminophosphorane, which then undergoes
intramolecular carbonyl substitution to form the final product (Figure 1-18). While

Figure 1-18. Traceless Staudinger Ligation.
31

chemically elegant, this method suffers from several drawbacks including facile air
oxidation of the phosphine and the necessity to generate the azide-containing fragment
through chemical synthesis.

Thioacid-Azide Ligation

A thioacid can directly react with an azide to form an

amide bond through a thiatriazoline intermediate (Figure 1-19)147. Recent studies showed
that this reaction can be performed in various organic solvents as well as in water, and
can be successfully applied to the synthesis of β-glycosylamides from glycosyl
azides148,149. While no applications in peptides have been shown, it has been proposed as
a phosphine-free alternative to traceless Staudinger ligation130. Interestingly, this reaction
can also be utilized in the synthesis of thioamides; however, the reaction conditions needs
to be carefully controlled to suppress competing oxoamide formation 150.

Figure 1-19. Mechanism of Thioacid-Azide Ligation.

α-Ketoacid–Hydroxylamine Amide-Forming (KAHA) Ligation

Bode et al.

devised another amide-bond-forming ligation method by conjugating an α-ketoacid to an
N-alkylhydroxylamine151. Mechanistic studies revealed that the reaction started with a
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nucleophilic attack of the N-alkylhydroxylamine nitrogen on the α-ketoacid α-carbonyl,
followed by a transfer of its hydroxyl (or benzylhydroxy) group on to the carbonyl
carbon. The formation of the amide bond was then achieved through collapse of the
tetrahedral intermediate with release of a CO2 (Figure 1-20)152. KAHA reactions can be
classified into two types – Type I utilizes an unsubstituted hydroxylamine and is
conducted in organic solvents, while Type II uses an O-benzyl hydroxylamine and can be
performed under aqueous conditions151. Recent studies from the Bode group also showed
the feasibility of using 5-oxaproline and oxazetidine as the source of the hydroxylamine,
which would result in a homoserine or serine, respectively, at the ligation site153,154.
Similar to the traceless Staudinger ligation, this method has limited application in fulllength proteins because the ligation handles need to be chemically incorporated.

Figure 1-20. Mechanism for α-Ketoacid–Hydroxylamine Amide-Forming (KAHA) Ligtaion.
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1.4 Methods for Peptide Thioester Synthesis
Thioester Synthesis by PyBOP Activation

Thioesters are typically synthesized by

carbonyl substitution reactions from a more reactive precursor, such as an activated
amide, ester or anhydride155. In peptide chemistry, this can be achieved through
activating the C-terminal carboxylic acid in situ with benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), and then performing nucleophilic
substitution with a free thiol (Figure 1-21).156 Due to the harsh reaction conditions, the
reaction needs to be conducted on a fully protected peptide – in particular, all carboxylic
acid moieties and nucleophiles must be fully protected to avoid side reactions. In a
typical procedure, a peptide is synthesized on 2-chlorotritylchloride resin and then
cleaved under mild acidic conditions with 10% acetic acid or 1% TFA to preserve all the
protecting groups. The resulting protected peptide is very hydrophobic and poorly
soluble, which greatly limits the reaction efficiency and hinders its application to long
sequences. In addition, this activation method frequently results in epimerization – the
activation group also serves as a good leaving group for intramolecular cyclization,
which subsequently tautomerizes and results in steric scrambling of the α-carbon.
Although PyBOP has been identified as the least epimerizing reagent (as compared to
other coupling reagents such as HBTU, HCTU)157, it still exhibits 5% epimerization in
short peptides, which can be exacerbated with longer reaction time or difficult sequences.

SPPS Methods using Unmasked Thioesters

Early on-resin syntheses of peptide

thioesters was achieved using Boc-based SPPS, where successive cycles of coupling and
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Figure 1-21. Peptide Thioester Synthesis by PyBOP Activation.
Adapted from Nagalingam et al.

157

and von Eggelkraut-Gottanka et al.

156

TFA Boc removal were used to elongate the peptide. The thioester moiety is sufficiently
stable under acid conditions to allow the direct elongation of peptide on a thioester
linkage (Figure 1-22A)158. However, the requirement of harsh hydrofluoric acid
cleavages at the end of the synthesis precludes its application to chemically sensitive
groups such as thioamides. On the other hand, thioesters are not stable under the basic
conditions used in Fmoc-based SPPS, particularly in the presence of nucleophilic bases
such as piperidine used in the Fmoc deprotection steps. Recently, Rademann et al.
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attempted to use a tertiary thiol linker, hypothesizing that the steric constraints around the
thioester bond would reduce the rate of its degradation (Figure 1-22B)159. With a t1/2 of
6.5 days for the thioester in this method, it was proven successful on model peptides, but
did not fully resolve the degradation issue.

Figure 1-22. SPPS Methods using Unmasked Thioester Linkages.
Adapted from Kent et al.

158

and Radmann et al.

“Safety-Catch” Type Linkers

159

The “safety-catch” method was first introduced by

Pessi et al. for their strategy of anchoring the growing peptide chain to the resin via a
non-cleavable linkage such as a sulfonamide, and then activating the linkage at the end of
synthesis to form a good leaving group, which can subsequently undergo thiolysis to
yield a thioester 160. Various types of linkers have been developed under this principle as
summarized in Figure 1-23. In Pessi et al., a sulfonamide linkage was used, which was
subsequently alkylated by trimethylsilyldiazomethane or iodoacetonitrile to yield an Nalkyl-peptidylsulfonamide as a good leaving group for thiolysis160. Jensen et al. used an
orthogonally protected Glu residue, which was selectively deprotected at the end of
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synthesis and cyclized to the adjacent amide using harsh PyBrOP activation161. Dawson
et al. introduced 3,4-diaminobenzoic acid (Dbz)162 – only the meta-amine was acylated
for peptide elongation under standard SPPS conditions; the para-amine was suppressed
due to the electron-withdrawing effect of the amide group on the aromatic ring. Upon
completion of SPPS, the para-amine was acylated by p-nitrocholoroformate, leading to a
spontaneous ring closure to form an N-acyl benzimidazolinone that was labile towards
thiolysis. Two mdified versions of Dbz were also prepared – one by Mahto et al., where
the para-amine was protected by an allyl orthogonal protecting group that can be
selectively removed prior to the final acylation163, the other by Dawson et al. where
methylation was used to lower the para-amine nucleophilicity164. Finally, Ficht et al.
took a slightly different approach and utilized side-chain anchoring instead of post-SPPS
thiolysis. Rather than being anchored to the resin through the peptide C-terminus, the
desired peptide was attached to the resin through a Glu side chain. At the end of
synthesis, the C-terminal carboxylic acid was selectively deprotected, thioesterified by
PyBOP, and then globally cleaved to yield the peptide thioester165,166. While it is possible
to attach additional amino acids/thioesters to the C-terminus, a Glu residue is still needed
either as the C-terminal residue or one residue away from the C-terminus.

All these strategies are clever in by-passing the thioester stability problem, but they
invariably suffer from low yields due to reactive site accessibility167 – since the activation
is performed at the end of SPPS, reagents have to diffuse through a “crowded” resin
decorated with protected peptide in order to reach the C-terminus. Due to the harsh
conditions used for linker activation, these methods also require the N-terminus to be
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acetylated to prevent side reactions, which is not always desirable since the N-terminal
acetylation of proteins has been shown to affect their properties168. In the context of
thioamide incorporation, since the harsh linker activation chemistry will take place after
installation of the nucleophilic thioamide moiety into the peptide, these methods are not
as desirable as the latent thioester strategies that will be discussed next.

Figure 1-23. Selected “Safety Catch” Type Linkers.

N-to-S Latent Thioester Linkers

Taking inspiration from intein-mediated

thioester formation in nature, various groups have designed linkers that utilize an amide
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bond as the resin anchor, which is then activated in situ through a spontaneous or assisted
N-to-S acyl transfer for conversion into a thioester (Figure 1-24A). Due to the reversible
nature of N-to-S acyl shift, various auxiliaries are frequently necessary to promote the
formation of thioester (Figure 1-25).

Figure 1-24. General Mechanism for N-to-S and O-to-S Latent Thioester Linkers.
Protecting groups are designated as “PG” or grey triangles.

Aimoto et al. developed a 2-mercapto-4,5-dimethoxybenzyl (Dmmb) auxiliary, where
the tertiary amide nitrogen served as the leaving group, and an adjacent aromatic thiol
was the attacking thiol169. It has been applied in several systems, where the longest
thioester made was a 41 residue thioester170. The same group also developed a Cys-Pro
ester (CPE) linker, where the N-to-S acyl shift is promoted by the irreversible formation
of a diketopiperazine (DKP) moiety171,172,173. Hojo et al. designed a mercaptoprolylprolyl ester motif and successfully synthesized a 25 residue thioester; the method was
originally designed to promote DKP formation, but was found to proceed through a
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simple N-to-S acyl shift instead174. As a follow-up, they were able to remove the second
Pro, and obtained comparable N-to-S acyl shift efficiency; notably, they also
demonstrated the compatibility of this particular linker with microwave assisted
synthesis174. Nakahara et al. showed the use of a simple N-alkylated Cys as a latent
thioester, and identified that an ethyl substitution was most effective in promoting the
thioester formation (34%)175. Otaka et al. identified acyl oxazolidinone as a potential
linker176, and later optimized it into an N-substituted aniline linker, where the aniline
served as an even better leaving group177,178. Using the second method, a short nine
reisude phosphopeptide was synthesized in 67% yield177.

Melnyk et al. explored bis(2-sulfanylethyl)amido (SEA) as a tunable linker, where
the N-to-S acyl shift can be turned off and on simply by the oxidation or reduction of the
di-thiol moiety179. Offer et al. showed the utility of α-methylcysteine in accelerating the
N-to-S acyl shift; the extra methyl group on the Cys α-carbon favored the necessary
cyclic transition state through a Thorpe-Ingold effect180, enriching the population of the
molecule that was in the Burgi-Dunitz trajectory181. Liu et al. further synthesized alkene
analogs of Cys, and showed that it was also a viable linker182. Recently, Aucagne et al.
constructed a self-catalyzing linker with a side chain hydroxyl group that mimicked the
natural intein; this linker was also shown to be compatible with microwave assisted
SPPS183. Finally, Macmillan et al. demonstrated the similar application of selenocysteine
in the N-to-Se acyl shift, which was more effective at lower temperature due to the higher
reactivity of the selenol184. For our initial study in thioamide-containing peptide thioester
synthesis, we chose the CPE linker171 because of its synthetic accessibility.
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Figure 1-25. Overview of N-to-S Latent Thioester Linkers.
An N-to-Se linker from Macmillan et al.

184

O-to-S Latent Thioester Linkers

is also included for comparison.

Similar to their N-to-S counterparts, O-to-S

latent thioester linkers utilize an ester bond to anchor the growing peptide to the resin,
which is activated in situ through O-to-S acyl transfer (Figure 1-24B). The ester bond is
less stable than the amide bond in N-to-S linkers; therefore, O-to-S linkers are less robust
for long sequences that require repeated exposure to nucleophilic base in SPPS, but are
also faster in generating an active thioester through O-to-S acyl shift.
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Figure 1-26. Overview of O-to-S Latent Thioester Linkers.

There are four O-to-S scaffolds introduced to date, namely α-hydroxycysteine, βmercaptoethanol, thioglycerol and hydroxythiophenol (Figure 1-26). Botti et al. first
synthesized the α-hydroxycysteine linker by hydroxylation of cysteine on resin, and
successfully ligated two model peptide fragments using this method185; while it was a
great proof-of-concept demonstration, the method required a water-compatible PEGbased resin, which was fragile and difficult to handle for routine SPPS. Muir et al.
subsequently improved the synthesis and introduced a protected precursor (which we
termed TBS-ChB-OH), where the thiol was capped with a t-butylthio group and the αhydroxyl was protected by a silyl group186. Liu et al. used a different route and prepared
trityl protected α-hydroxycysteine monomer through ring opening of an epoxide187. The
β-mercaptoethanol scaffold was explored by Hoeg-Jensen et al., where it was introduced
as its dimer, dithiodiethanol, and activated in situ with reducing agents188. The
thioglycerol moiety was identified by Liu et al. after screening a variety of O-to-S linkers
for rate of NCL over hydrolysis189. The hydroxythiophenol scaffold was introduced by
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Danishefsky et al., where it was conjugated to the last residue in its protected form, and
then attached to the rest of a 5-residue peptide through solution phase coupling190. While
this linker was not directly conjugated to the resin in this particular case, one could easily
foresee its adaptation to SPPS by introducing a carboxylic handle on the phenyl ring as a
resin anchor. For our initial trial, we chose to adapt the α-hydroxycysteine scaffold with
the protected precursor approach by Muir et al.186

Hydrazide as a Thioester Precursor

In 2011, Liu et al. introduced a different

approach to synthesizing latent thioesters by using a hydrazide linkage191. The hydrazide
linkage can be conveniently introduced by treating 2-chlorotrityl chloride resin with
hydrazine, after which the peptide can be elongated using standard SPPS procedures.
After isolating the purified hydrazide peptide, it is activated in situ through NaNO2
treatment and immediately thiolyzed to generate an active thioester (Figure 1-27). This
method has been shown to be compatible with the majority of natural amino acids (except
Asn, Asp, and Gln) as the C-terminal reisdue, and has been successfully applied to the
semi-synthesis of αS192.

Figure 1-27. Hydrazides as Thioester Precursors.
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1.5 Traceless Ligation Methods
Masking Methods

The residual Cys after NCL can be further derivatized into

analogs of Lys, Glu and Gln through nucleophilic substitution (Figure 1-28). Treatment
of Cys with aziridine or 2-bromoethylamine results in S-alkylation to form an isosteric
Lys analog.193 Similarly, treatment with iodoacetamide194 or iodoacetic acid195 yielded a
Gln or Glu analog, respectively, with thioether insertion in the side chains. While these
methods are straight-forward to implement (i.e. they do not require synthetic ligation
handles), they result in modified side chains with thioether linkages, and are not truly
“traceless”. One of the first synthetic ligation handles to result in a native amino acid is
homocysteine (Hcs), which yields a native Met upon alkylation with methyl iodide or
methyl p-nitrobenzenesulfonate196. Interestingly, Roelfes and Hilvert applied the same
strategy to selenohomocysteine, and successfully generated a selenomethionine in a
peptide hormone analog through NCL followed by alkylation197.

Figure 1-28. Masking Methods for Traceless Ligation.

Desulfurization Methods

An on-going paradigm shift in NCL is the introduction

of thiol-bearing amino acid analogs as ligation handles198. The thiol serves as the
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nucleophile for NCL, which is removed after ligation to generate a native amino acid.
The first desulfurization was reported by Dawson et al. in 2001 for the conversion of Cys
into Ala using Raney nickel199. Using this approach, they were able to synthesize a 110amino acid ribonuclease, barnase. However, the Raney nickel method per se is not
translatable to other amino acids due to the lack of selectivity (for example, hydrogenation of the Trp indole and demethythiolation of Met are two known complications
with Raney nickel)198. In 2007, Danishefsky et al. used radical initiated desulfurization
by a water soluble organic initiator VA-044 as an alternative approach.200 In the same
year, Crich et al. synthesized the first β-thiol amino acid analog, β-mercaptophenylalanine, and successfully demonstrated its desulfurization201. Since then, a number of
thiol analogs have been introduced for 12 out of all 20 natural amino acids (Figure 1-29).

In 2008, Danishefky et al. and Seitz et al. independently prepared two types of valine
analogs, γ-mercaptovaline202 and β-mercaptovaline203. Two types of Lys analogs were
also synthesized by two different groups, namely γ-mercaptolysine by Liu et al. in
2007204, and δ-mercaptolysine by Brik et al. in 2009205. Interestingly, these Lys analogs
were designed with orthogonal protecting groups for the side chain amine so that they can
be used for multiple ligations to elongate the backbone and introduce ubiquitin on the
side chain − the N-terminal amine was first ligated to one thioester fragment, after which
the side chain amine was revealed through selective deprotection and then conjugated to
another thioester; finally the thiol auxiliary was removed through desulfurization to yield
a native Lys at the branching site. In 2010, three additional analogs were introduced by
the Danishefsky group, namely β-mercaptoleucine206, γ-mercaptothreonine207, and γ45

mercaptoproline208. In 2012, Brik et al. followed up with a report on the synthesis of γmercaptoglutamine209. Most recently, the Payne group has made much contribution to the
analog repertoire by adding five additional analogs, namely β-mercaptoarginine210, βmercaptoglutamic acid211, β-mercaptoaspartic acid212, β-mercaptoasparagine213, and a Trp
analog with thiol on its indole ring214. With the success of these 14 analogs for 12 amino
acids, the β- and γ-thiol strategy can conceivably be extended to 19 out of all 20 amino
acids (except for Gly that does not have a β-carbon, which would require an α-thiol and
four-membered ring transition state in NCL), which is corroborated by a computational
study on the desulfurization reaction215.

Figure 1-29. Summary of Thiol Analogs of Natural Amino Acids.
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Deselenization Methods

Similar to thiols, selenols may undergo radical initiated

deselenization reactions, which can be utilized in traceless NCL methods with β-selenol
amino acid analogs. The selenium-carbon bond is weaker than the sulfur-carbon bond
due to less effective orbital overlap, which makes the deselenization reaction easier. In
the first demonstration of traceless NCL through deselenization, Dawson et al. showed
that deselenization could be initiated by spontaneous homolytic bond cleavage of a
diselenide or hemiselenide, which then proceeded to severe the C−Se bond with the
assistance of tris(2-carboxyethyl)phosphine (TCEP)216. Under these mild conditions, Cys
residues in the peptide sequence remained intact, allowing the traceless ligation of
peptides and proteins that contain native Cys residues in their sequence. In addition to the
naturally existing selenocysteine, there are two synthetic selenol amino acids analogs
reported thus far (Figure 1-30), namely γ-selenoproline by Danishefsky et al.217 and βselenophenyl-alanine by Payne et al.218. Due to the reactive nature of the selenol, peptides
containing these analogs were typically isolated as dimers with intermolecular Se−Se
bond, and then activated in situ by reduction219.

Figure 1-30. Post-ligation Deselenization of Selenocysteine (Sec) and Selenol Analogs.

A unique property of selenols is that they can be directly converted into hydroxyls
under oxidative conditions220. This allows the post-ligation conversion of Sec into Ser,
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adding one additional amino acid as potential ligation sites. The first demonstration of its
application to peptide ligation was recently conducted by Payne et al., where they
constructed a glycol-peptide by Sec ligation and subsequent conversion to Ser221. A
recent mechanistic study also confirmed the “dual personality” of selenol – when treated
with TCEP under anaerobic conditions, Sec was predominantly converted into Ala; when
oxygen or ozone was supplemented, however, the alaninyl radical could be quenched by
oxygen instead, generating Ser-containing peptide as the major product (Figure 1-31)222.

Figure 1-31. Proposed Mechanism of Oxidative Conversion of Sec into Ser.
Graphics adapted from Metanis et al.
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1.6 Selenocysteine
Properties of Selenocysteine

Similar to the relationship between thioamides and

oxoamides, selenocysteine (Sec) is nearly isosteric to Cys, but exhibits very different
properties (Table 1-3)223. With an additional shell of electrons, selenium is slightly larger
than sulfur (1.90 Å vs. 1.85 Å);75 the C−Se bond is slightly longer (1.96 Å vs. 1.80 Å)224
and weaker (bond dissociation energy 56 kcal mol-1 vs. 65 kcal mol-1)77 than the C−S
bond. The Sec side chain pKa is much lower than that of Cys (5.2 vs. 8.3)225 – at
physiological pH, the majority of selenol will exist in the ionized form of selenoate. The
diselenide/hemeselenide exchange reaction is also faster226 – the reaction rate constant of
RS−SR exchange with thiol is 3.6 M-1 s-1, while that of RS−SeR is three times faster at 11
M-1 s-1; the corresponding reaction for RSe−SeR is 105 faster at 1.3 × 105 M-1 s-1. Finally,
although selenium and sulfur have similar electronegativity (2.58 vs. 2.55)80, diselenides
are much easier to reduce than disulfides (Ered -0.233 V vs. -0.488 V)227.

Table 1-3. Selected Properties of Cysteine and Selenocysteine.
Cys
(X = S)

Sec
(X = Se)

Van der Waals radius of X (Å)

1.85

1.90

C−X bond length (Å)

1.80

1.96

C−X bond dissociation energy (kcal∙mol-1)

65

56

−XH pKa

8.3

5.2

RS−XR exchange rate constant (M-1 S-1)

3.6

11

-0.488

-0.233

Property

Ered for RX–XR (V vs. S.H.E.)
* S.H.E. = Standard hydrogen electrode
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With these properties, Sec is a much more reactive amino acid than Cys; as
exemplified in the mutagenesis study of thioredoxin reductase, when the native Cys-Sec
catalytic motif of the enzyme was replaced with a Cys-Cys motif, a 20-fold reduction in
catalytic efficiency was observed (kcat/Km 1.3 × 107 vs. 6.0 × 105 M-1 s-1)228. While the
majority of the reactions that Sec participates in are analogous to those of Cys, Sec
undergoes a unique reaction that is termed “glutathione peroxidase (GPx) like activity” –
when a selenol is oxidized into hydroxyselenol, it can be reversed simply by the addition
of a thiol (Figure 1-32)220. This reactivity has been observed both in selenol-containing
small molecules and in Sec-containing enzymes229; when handling Sec-containing
peptides, we typically add excess thiol to protect the selenol side chain against oxidation.

Figure 1-32. Glutathione Peroxidase (GPx) Like Activity of Selenols.
Graphics adapted from Derek et al.
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Selected Applications of Selenocysteine

Selenocysteine is a useful tool in protein

mechanistic studies and in biotechnology230. First of all, Sec is a unique reaction handle
both for NCL and for other conjugation chemistry. Its reactivity in NCL was rigorously
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characterized by Raines et al. in 2001, where they discovered that due to the low pKa of
Sec, the ligation reaction can be conducted at pH ranges between 5 and 8, as compared to
pH 7−8 for Cys NCL231. They also found that the reaction rates were generally 3 times
faster, with a second order reaction rate of 9.5 × 102 M-1s-1 for Sec as compared 3.7 x 102
M-1 s-1 for Cys at neutral pH. Sec has been incorporated into a variety of target proteins
through NCL, including into full-length proteins by EPL232. A most representative
example is the semi-synthetic azurin studies by van der Donk et al.,233 where they
incorporated Sec as a replacement of the native Cys112 through EPL, and used it as a
probe to elucidate the active site copper coordination geometry.

With its distinct redox properties compared to natural amino acids, Sec can also be
used as a site-specific label to study oxidative folding234,227. Moroder et al. used Sec to
elucidate the structure of apamin, an 18 residue bee venom toxin235. With four Cys in its
sequence, apamin can adopt a variety of conformations with different disulfide bond
combinations; the authors systematically replaced Cys pairs with Sec pairs to isolate each
conformation (Sec will preferentially form diselenide with another Sec before forming a
hemiselenide with Cys), and solved the NMR structure of each disulfide/diselenide
combination. In another example, Bulaj et al. replaced a disulfide bonded Cys pair with a
diselenide bonded Sec pair in a background of six Cys on conotoxin; the other four Cys
then correctly folded into a single, functional conformation rather than forming a mixture
of various disulfides due to the templating effect of the first diselenide236.
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Another widely explored application of Sec is 77Se NMR spectroscopy. Selenium has
six stable natural isotopes, the most abundant of which are the NMR inactive
80

Se. The NMR active

78

Se and

77

Se has a natural abundance of 7.63%, and can be enriched for

NMR spectroscopy220. Early studies used

77

Se-6,6’-diselenobis(3-nitrobenzoic acid), the

selenium version of Ellman’s reagent, to covalently label Cys residues of the desired
proteins237,238. Hilvert et al. prepared semi-synthetic 77Se-enriched subtilisin, and directly
observed the formation of selenide (−Se-), hydroxyselenol (−Se−OH) and selenoic acid
(−SeOOH) as intermediates of its catalytic cycle239. Recently, Rozovsky et al. developed
a metabolic replacement method, where a target Cys containing protein was expressed in
77

E. coli in media with minimal sulfates and

Se selenite supplements240. Up to 80% 77Se

enrichment can be achieved with this method.

Selenocysteine Incorporation in SPPS

Sec-containing peptides can be synthesized

by SPPS from protected Sec amino acids. The most commonly used protecting groups are
phenyl, p-methoxybenzyl (Pmb), xanthyl and trityl groups.241,242 Due to the reactive
nature of selenols, cleavage from the resin is typically performed in the presence of
thiols, most commonly 2,2′-dithiobis(5-nitropyridine) (DTNP), to form a hemiselenide
bond as a side chain protection for selenol243. The hemiselenide can then be reduced in
situ by treatment with dithiothreitol (DTT).

Selenoprotein Biosynthesis

Sec is known as “the 21st amino acid” and can be co-

translationally inserted through special cellular machinery244. Sec is encoded by the stop
codon, UGA, which is repurposed for Sec using a set of special mRNA recognition
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A)

B)

Figure 1-33. Translational Machinery for Selenocysteine Incoporation.
UCA

A) Biosynthesis of Sec-tRNA ; B) Machinery for co-translational insertion of Sec and
structure of SECIS element. SerS = seryl-tRNA synthetase; PSTK = O-phosphoseryl-tRNA
kinase; PSer = phosphoserine; SecS = selenocysteine synthetase; SPS2 = selenophosphate
synthetase 2; SECIS = selenocysteine insertion sequence; SBP2 = SECIS-binding protein 2;
245
EFsec = special elongation factor. Graphics adapted from Hatfield et al.

elements, elongation factors and tRNAUCA (Figure 1-33)245. The Sec-tRNA is synthesized
from Ser-tRNA; the Ser is first phosphorylated, and then the phosphate is β-eliminated to
form dehydroalanine, which is subsequently attacked by selenophosphate to generate
selenocysteine on the tRNA246. The Sec-tRNA is then transported to the ribosome by a
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special elongation factor EFsec247. The decoding of the UGA codon is achieved through a
selenocysteine insertion sequence (SECIS) in the non-coding region near the 3’-end of
peptide coding sequence; SECIS binding protein 2 (SBP2) binds to the SECIS element
and then recruits the Sec-tRNAUCA/EFsec complex to insert the Sec into the growing
peptide chain248. The process is in competition with chain termination through release
factor (RF) binding; therefore, the UGA codon and SECIS element must be in spatial
proximity and able to bend into a certain geometry to allow the efficient binding of EFsec
and SBP2 for the incorporation of Sec249. The human proteome contains 25 naturally
existing selenoproteins, most of which are redox enzymes250,251; due to the reactive nature
of the selenol side chain, all these proteins contain a Cys near the Sec residue, to
sequester the Sec as a intramolecular hemiselenide.

Although recombinant expression of proteins with a Sec insertion has been achieved,
it is at a very early stage of development. Gladyshev et al. were able to express the Sec
mutant of a mammalian glutathione peroxidase in E coli. by grafting a UGA codon and a
SECIS element into the protein-coding plasmid, but predominantly observed Trp misincorporation (the Trp codon is UGG, which is similarly to the UGA codon) instead of
the desired Sec-containing protein252. A handful of other examples have been
reported253,254,255; in all cases, Sec incorporation was limited to the C-terminal region of
the target protein due to the spatial proximity requirement of the UGA codon and SECIS
element. To our knowledge, there has not been any demonstration on Sec incorporation
into proteins other than redox enzymes, which contain native Cys-Cys motifs that can be
mutated into Sec-Cys.
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1.7 Aminoacyl Transferase (AaT)
Structure and Biological Function of AaT

AaT is a key component of the N-end

degradation pathway in E. coli256. The N-end pathway is a cellular mechanism to regulate
protein half-life through N-terminal “destabilizing” amino acids known as “degrons”. In
E. coli, the primary degron is an Arg or Lys (these residues are rarely exposed at the Nterminus of a well-folded protein). The positively charged Arg or Lys is recognized by
AaT, which installs a secondary degron of Leu or Phe onto the N-terminus of the protein.
The L/F-R/K motif is then recognized by a “carrier protein” ClpS, which transports the
tagged protein to a proteolytic complex, ClpA/P, for degradation (Figure 1-34).

Figure 1-34. Aminoacyl Transferase (AaT) and E. coli N-End Degradation Pathway.
Adapted from Bukau et al.

256

Picture courtesy of Anne M. Wagner.
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The first observation of AaT activity was made in 1965 by Kaji et al., where the
incorporation of radiolabeled leucine and phenylalanine was observed in cell extracts of
E. coli257. The AaT enzyme was later isolated in 1970 by Leibowitz and Soffer258. They
also characterized the basic functional properties of AaT, including the equal preference
for its natural substrates Leu and Phe, the requirement of a monovalent cation source
such as KCl, and the optimal pH of 8. Subsequent research established that the substrates
of AaT are protein N-termini nearing a Lys or Arg, and linked its biological function to
the N-end degradation pathway259,260. A crystal structure was solved in 2007 by Suto et
al.261; it revealed two distinct binding pockets – a hydrophobic amino acid binding pocket
that consists of Met144, Met158, Leu170 and Ile185, and a negatively charged Lys/Arg
binding pocket that is formed by Tyr42, Tyr120, Glu156 and Gln188 (Figure 1-35). The
catalytic mechanism seems to be a simple “induced fit” model262; Gln188 was proposed
to be catalytic in initial studies261, but was later proved to be unnecessary for the catalytic
process as an Ala mutation can be made at this site without loss of activity262.

Figure 1-35. Crystal Structure of E. coli Aminoacyl Transferase (AaT).
Adatped from Suto et al. (PDB 2Z3N)

261

. Binding pockets highlighted in orange and purple.
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AaT as a Protein N-Terminal Modification Tool

In 1996, Abramochkin et al.

determined that the aminoacyl-tRNA anticodon was not necessary for AaT recognition
using mutant tRNAs263. It was later confirmed in the crystal structure that only the last
adenosine on the acceptor stem was involved in AaT binding261. Pioneering studies by
Sisido and Tirrell established the feasibility of using AaT for protein N-terminal
modification. Tirrell et al. took a fully enzymatic approach, where mutant synthetases
were used to charge their corresponding tRNAs with unnatural amino acids; the
aminoacyl-tRNAs were then subjected to activity screening with AaT264. Sisido et al.
showed that truncated nucleotides with from 2 to 20 bases were also tolerated as AaT
substrates265,266,267. In our own group, we were able to further minimize the substrate to
aminoacylated adenosine donors268, and used this method to identify novel AaT
substrates such as disulfide protected homocysteines (Figure 1-36)269. Known substrates
of AaT from these studies are summarized in Figure 1-37.

Figure 1-36. Aminoacyl Transferase as a Tool to Incorporate Homocysteine.
Graphics adapted from Tanaka et al.
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Figure 1-37. Known Substrates of Aminoacyl Transferase.
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1.8 Summary
Protein misfolding is the molecular basis of various human diseases, including AD,
PD and Type 2 diabetes. However, little information is known about either the structural
details of the misfolded species or the conformational changes that are involved in the
misfolding process, which greatly restricts our ability to develop effective therapies for
these diseases. We propose to study the misfolding phenomenon using thioamides as
minimalist fluorescence quenchers. Previous work in our group has established the
photophysics of fluorescence quenching by thioamides. In the current work, we will
explore methods to incorporate thioamides into full-length proteins, a prerequisite for
using fluorophore/thioamide dually labeled proteins for misfolding studies.
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Chapter 2 . Latent Peptide Thioester Strategies for Incorporation of Thioamides
into Full-length Proteins via Native Chemical Ligation

The CbPGo linker and full-length αS studies in this chapter was originally published in the Journal of the
American Chemical Society. It is adapted here with permission from the publisher:

Reprinted and adapted with permission from Batjargal, S.; Wang, Y. J.; Goldberg, J. M.; Wissner, R. F.;
Petersson, E. J., Native Chemical Ligation of Thioamide-Containing Peptides: Development and
Application to the Synthesis of Labeled Alpha-Synuclein for Misfolding Studies. J. Am. Chem. Soc. 2012,
134, 9172-9182. Copyright 2012 American Chemical Society.
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2.1 Introduction
Having demonstrated the utility of the thioamide as a minimalist fluorescence
quencher in previous work from our group115, we were faced with a major chemistry
challenge: as a backbone modification, thioamides can only be installed onto small
molecules through solution phase thionation, or short peptides by Fmoc-based (Fmoc =
fluorenylmethyloxycarbonyl) solid phase peptide synthesis (Figure 2-1). To the best of
our knowledge, the longest thioamide-containing peptides previously synthesized were
two 35-residue peptides, one by Miwa et al.89 and one by our group115. In order to utilize
thioamide as a probe for misfolding studies, we needed to first devise a method to
incorporate it into full-length proteins reliably and site-specifically.

Figure 2-1. Thioamide Incorporation into Small Molecules and Peptides.
For small molecules and dipeptides, solution phase thionation can be used to convert an oxoamide precrusor into thioamide; this would not be applicable to peptides with more than two
residues due to the lack of site-specificity. Solid phase peptide synthesis (SPPS) using
activated thioacyl benzotriazole precursors can be used for site-specific thioamide install270
ation; however, SPPS has an inherent length limit of ~70 residues , beyond which cleavage
and purification would become extremely difficult.

There are four general strategies to incorporate synthetic moieties into proteins: posttranslational chemical derivatization271, unnatural amino acid (Uaa) mutagenesis272, in
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vitro translation from chemically synthesized tRNA273, and protein semi-synthesis130. The
first two are primarily used for side chain derivatization, and would be difficult to adapt
for backbone thioamide incorporation. With chemically synthesized tRNA, it is possible
to incorporate a dipeptide substrate (a direct thioacid linkage to tRNA would be unstable);
however, extensive synthetic efforts and directed evolution of the translational machinery
are necessary for each Xaa-Yaa dipeptide combination274, which is not desirable for our
goal of thioamide incorporation at any position. Among available strategies, protein
semi-synthesis, particularly native chemical ligation (NCL), is most promising for our
applications – a small thioamide-containing peptide fragment can be chemically synthesized via SPPS, and then joined to the rest of the target protein produced by cellular
expression, yielding a full-length target protein with a site-specific thioamide label.

Figure 2-2. Native Chemical Ligation (NCL) as a Strategy for Thioamide Incorporation.
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Native chemical ligation (NCL), as pioneered by Kent et al.128, utilizes the transthioesterification between two unprotected peptide fragments − one with a C-terminal
thioester and another with an N-terminal Cys – and generates a native amide bond after
S-to-N acyl shift (Figure 2-2). The reaction takes place under mild aqueous conditions,
and has been successfully applied to the semi-synthesis of chemically sensitive peptide
derivatives such as glycopeptides275. In our preliminary trials, we were delighted to find
that the thioamide was compatible with the NCL method; the real challenge, however,
was to synthesize the peptide fragments, particularly the thioester fragment, for ligation.

Figure 2-3. Challenges in the Synthesis of Thioamide-Containing Peptide Thioesters.

In standard SPPS methods, thioesters are synthesized using Boc-based SPPS (Boc =
t-butyloxycarbonyl), as they are not stable towards the basic conditions in Fmoc-based
SPPS; on the contrary, the thioamide is not stable towards the highly acidic conditions in
Boc-based SPPS, and requires the Fmoc method for successful incorporation (Figure
2-3). In fact, this apparent mismatch has led to the speculation that NCL of thioamidecontaining peptides was “not suitable because the presence of [thioamide] bonds is not
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compatible with the subsequent synthesis of the thioester moiety”.110 We hypothesized
that we could find a compromise by adopting Fmoc-based SPPS for the synthesis of
thioamide-containing peptides, and then identify a viable method to either generate the
thioester off-resin or synthesize it on-resin as a latent thioester that is activated in situ.

Upon a survey of the literature, we identified three main strategies for thioester
synthesis in the context of Fmoc-based SPPS (Figure 2-4). Solution phase PyBOP
activation130 is performed on the free carboxylic acid terminus of a peptide; due to the
harsh reaction conditions, it requires side chains of the peptide to be fully protected,
which greatly affects its solubility and thus lowers reaction efficiency. Nbz and other
“safety-catch” type linkers276,277 utilize non-labile amide linkages to anchor the growing
peptide to the resin; the linkers are activated at the end of the synthesis (typically by Nacylation) and converted to thioesters by thiolysis. Latent thioester linkers278,171 are
synthesized and purified as ester or amide using standard SPPS; they are only activated in
situ through O-to-S or N-to-S acyl shift to generate an active thioester in aqueous buffer.

We chose to investigate the latent thioester strategy for thioamide incorporation
because of its various advantages: 1) while the other methods require additional derivatization after thioamide installation, all harsh reactions in the latent thioester strategy are
completed at the linker synthesis stage, ensuring maximal compatibility with chemically
sensitive functional groups such as thioamide; 2) from a practical point of view, latent
thioesters are purified and stored as esters or amides until the final NCL, which are much
more stable and easier to handle than an actual thioester.
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Figure 2-4. Thioesterification Strategies for Fmoc-based SPPS.
Due to the diversity of “safety-catch” type linkers, Nbz linker is shown here as an example.
Triangles indicate side chain protecting groups on peptides. TFA = trifluoroacetic acid; PG =
protecting group SPPS = solid phase peptide synthesis; Nbz = N-acyl-benzimidazolinone.

The two main sub-types of latent thioester linkers are O-to-S and N-to-S linkers. As
the names suggest, O-to-S linkers are joined to the peptide through an ester bond and are
subsequently activated by O-to-S acyl shift, while N-to-S linkers are the amide bond
counterparts. Rather than choosing one type over the other, we decided to explore both
strategies because they have complementary advantages: 1) due to the higher stability of
amide bond as compared to ester bond, N-to-S linkers are more stable than O-to-S linkers
in synthesis and handling, but would also be slower in in situ thioester formation; 2) for
the same reason, O-to-S acyl shifts are typically conducted in mildly acidic conditions
(pH 6.8 ~ 7.0) to avoid ester hydrolysis, whereas N-to-S acyl shifts can be conducted at
much higher pH (7.4 ~ 8.4) to accelerate the reaction. Exploring both types gave us
65

access to a wide range of reactivity and reactions conditions, which would be beneficial
in fine-tuning synthetic procedures for different target proteins.

Figure 2-5. ChB Latent Thioester Linker utilizing O-to-S Acyl Shift.

The O-to-S linker we chose to adapt for the thioamide is ChB, an α-hydroxyl analog
of Cys, as developed by Botti et al.278 (Figure 2-5). It was initially synthesized by onresin hydroxylation of Cys, and subsequently refined by Muir et al. into a monomer
building block that can be directly incorporated by SPPS186. The N-to-S linker we chose
was CPGo, a Cys-Pro-Gla motif, as developed by Aimoto et al.171 (Figure 2-6). Pro is a
well-known substrate for diketopiperazine (DKP) formation; glycolic acid promotes this
cyclization by serving as a good leaving group, which in turn shifts the N-to-S acyl shift
equilibrium towards the thioester. In our design of CbPGo, we would added a tBuS−
protecting group on Cys to avoid complications from dimerization and aggregation.

Figure 2-6. CPGo Latent Thioester Linker utilizing N-to-S Acyl Shift.
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2.2 Results and Discussion
We began by exploring the O-to-S latent thioester linker ChB. It can be synthesized
in its protected form TBS-ChB-OH (6) in five steps from 1-thioglycerol (Figure 2-7)
based on a route developed by Muir et al.186, where successive oxidations were used to
obtain the carboxylic acid functionality. (We note that all synthetic routes from Cys or
cystine proved unfruitful as summarized in Figure 2-15.) The precursor can then be used
as a building block for incorporation by SPPS – 6 is first coupled onto Rink amide resin,
and deprotected to reveal the hydroxyl group; the next amino acid is installed using in
situ carbodiimide activation, after which the rest of the sequence can be assembled using
standard SPPS (Figure 2-8).

To test the compatibility of the ChB thioester linker with a thioamide, we synthesized
model peptide 7 with thioleucine (LeuS) in the sequence. As expected, the latent ester
strategy was a sufficiently small deviation from standard SPPS that 7 could be readily
synthesized and purified without complications. When subjected to a test ligation with Nterminal Cys peptide 8, the latent thioester was rapidly converted into the desired product
9c within 10 min (Figure 2-9). Intermediates 9a and 9b could be observed early in the
reaction, which corresponded to the O-linked and S-linked isomers as latent or active
thioesters. The UV-Vis absorption profile of 9c clearly demonstrated the presence of two
7-methoxycoumarin chromophores and the integrity of thioamide, giving us confidence
that the ChB linker is compatible with the synthesis of thioamide-containing thioesters.
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We next investigated the N-to-S latent thioester linker CbPGo. The synthesis was
much more straight-forward, where the only precursor necessary was an Fmoc-Xaa-CsbOH dipeptide (10) to pre-load the C-terminal residue in order to avoid spontaneous
diketo-piperazine (DKP) ester formation171 (Figure 2-18). 10 can be readily derivatized
from Fmoc-protected amino acids in one step by isobutylchloroformate (IBCF)

Figure 2-7. Synthesis of TBS-ChB-OH Precursor.
Conditions: a) tBuSH, I2, EtOH, 89%; b) TBS-Cl, imidazole, DMAP, DMF, 99%; c) 1:1:5
TFA/H2O/THF, 0 ˚C, 61%; d) Dess-Martin periodinane, CH2Cl2, 65%; e) NaClO2, NaH2PO4, 2methyl-2-butene, 4:9 H2O/tBuOH, 31%. TBS = t-butyldimethylsilyl; DMAP = 4-dimethylaminopyridine; DMF = N,N-dimethylformamide; TFA = trifluoroacetic acid; THF = tetrahydrofuran.

Figure 2-8. Synthesis Scheme for Thioamide-Containing Peptide-ChB Thioester.
We note that the symmetric anhydride intermediate from carbodiimide acitivation method was
necessary for successful ester bond; uronium reagents such as HBTU were much less
effective. TBAF = tetra-n-butylammonium fluoride; Fmoc-AA-OH = Fmoc protected amino
acid building block; DCC = dicyclohexylcarbodiimide.
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(9a)

(9b)
(8)
(9c)

9c

7

9b
9a

8

7

9c

Figure 2-9. Ligation of Thioamide-Containing Peptide-ChB Thioester with CA-Mcm-NH2.
A) Schematic representation of the test reaction. B) HPLC chromatograms monitored at 325
nm. Ligation was conducted using 1:10 Peptide-ChB 7/Cys-Peptide 8 for a 10 min reaction;
intermediates were isolated using 1:1 Peptide-ChB 7/Cys-Peptide 8 for a 30 sec reaction.
+
Excess 8 eluted at 18.5 min; it is omitted in these graphics for clarity. MALDI MS: [7+H] ,
+
+
expected 939.37, found 939.23; [9a+H] , expected 851.34, found 851.22; [9b+H] , expected
+
851.34, found 851.21, [9c+H] , expected 1166.46, found 1166.30. 9a was positive towards
Ellman’s reagent, while 9b was negative. C) UV-Vis absorption profiles of reactants and
product, showing the integrity of thioamide and two Mcm chromophores in the product.
Conditions: 0.5 mM 7, 0.5 or 5 mM 8, 20 mM TCEP, 200 mM Na2HPO4, pH 6.8.
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activation, a common amide bond formation method that is compatible with all 20 natural
amino acids124. To construct the CbPGo linker, we devised an efficient synthesis from
bromoacetic acid (Figure 2-10) – after its coupling onto the resin, an SN2 reaction was
used to form the Pro-Gla ester bond, and then 10 was installed by PyBOP; standard SPPS
was then used to complete subsequent synthesis and purification.

(10)

b

Figure 2-10. Synthesis Scheme for Thioamide-Containing Peptide-C PGo Thioester.
We note that BrCH2COOH loading must be conducted at neutral to acidic conditions without
catalytic DMAP to avoid glycolic acid polymer formation. Synthesis of Fmoc-Xaa-Csb-OH 10
is detailed in Materials and Methods. DCC = dicyclohexylcarbodiimide; DMAP = 4-dimethylaminopyridine; DIPEA = N,N-diisopropylethylamine.

Model peptide 11, analogous to peptide 7, was synthesized and evaluated in a test
ligation with Cys (Figure 2-11). Upon treatment with reducing agent tris(2-carboxyethyl)
phosphine (TCEP), 11 was rapidly reduced to the Cys form 11a in 10 min; the
subsequent N-to-S acyl shift took place gradually and approached completion after 6 h.
The reaction rate was much slower than that of the latent ChB thioester, presumably due
to the higher stability of the amide bond in the N-to-S acyl shift than the ester bond in the
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(11a)

(12)

11

11

11a

11a
12

12
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b

Figure 2-11. Ligation Thioamide-Containing Peptide-C PGo Thioester with Cys.
A) Schematic representation of the test reaction. B) HPLC chromatogram monitored at 325
+
nm, and UV-Vis absorption spectra of isolated peptides. MALDI MS: [11 + H] , expected
+
+
1093.34, found 1093.46; [11a + H] , expected 1005.41, found 1005.37; [12 + H] , expected
851.34, found 851.16. Star sign indicates thioamide absorption at 272 nm. See Materials and
b
Methods for DKP intermediate characterization. Conditions: 1 mM peptide-C PGo 11, 10 mM
Cys, 50 mM TCEP, 200 mM Na2HPO4, pH 8.4.
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O-to-S acyl shift. Using a large excess of Cys, we were able to achieve a pseudo firstorder reaction with respect to 11, from which a second-order reaction constant (1.53 ±
0.06) × 10-2 M-1∙s-1 was obtained,with an empirical half-life of 75 ± 1 min (Figure 2-12).
As a further validation, we showed that the thioamide was fully intact in the final
product, and that DKP thioester intermediate could be observed at a very low substrate
concentration in the absence of Cys (Figure 2-19). Lastly, we showed that both ChB and
CbPGo latent thioesters were tolerant of denaturants – ligation rates were slower, but
otherwise no additional complications were observed (Figure 2-17, Figure 2-20).

Reduced 11a
Product 12
Side Products
All Products

b

Figure 2-12. Triplicated Ligation Kinetics between C PGo Thioester and Cys.
Side products were defined as all products other than the desired product 12. See Material
and Methods for detailed descriptions of quantification and data fitting methods.

Having validated both ChB and CbPGo latent thioester strategies in the context of
thioamide incorporation, we were eager to find out if these methods would be applicable
to a full-length protein. Our chosen target was α-synuclein (αS), a 140 residue protein
that is implicated in Parkinson’s disease (PD)
72

279

. αS is a small pre-synaptic protein that

is ubiquitously expressed in the brain; upon conformational changes, it aggregates into
oligomers and fibrils, leading to neuronal death and thus the degenerative symptoms in
PD. By incorporating a Trp/thioamide fluorophore-quencher pair into αS, we would be
able to track the relative movements of the two labels during aggregation using
fluorescence spectroscopy, and then reconstruct the conformational changes involved.

We chose the CbPGo linker for this particular application because of its ease of
synthesis. Using an improved procedure, we synthesized Ac-αS1-8VS3-CbPGo 13 and
ligated it to the other fragment αS9-140C9 that was expressed in E. coli. The ligation
proceeded smoothly, yielding full-length Ac-αSVS3C9 as the desired product (Figure
2-13). The integrity of thioamide can be confirmed by trypsin digest, as well as UV-Vis
absorption (Figure 2-23). To generate the Trp/thioamide dually labeled protein, αSC9W94
was use as the C-terminal fragment instead, which also proceeded without complications
to yield Ac-αSVS3C9W94 (Figure 2-22).

As a proof-of-concept experiment to demonstrate the utility of thioamide in protein
misfolding studies, we subjected our semi-synthetic doubly labeled Ac-αSVS3C9W94 to in
vitro aggregation and monitored the Trp fluorescence change over time (Figure 2-14).
There is no native Trp in the αS sequence, therefore selective excitation of Trp can be
achieved with 295 nm incident light. To account for the environmental effects on Trp
emission, all fluorescence data were compared to an oxoamide control, where αSW94
with no thioamide in its sequence was aggregated side by side with the thioamide-labeled

73

b

Figure 2-13. Synthesis of Thioamide-Containing Full-length αS using C PGo Linker.
C-Terminal fragment of αS9-140 with an N-terminal His tag, an S9C mutation, and IEGR
cleavage sequence was expressed and purified on Ni-NTA resin. After Factor Xa cleavage to
S
b
generate an N-terminal Cys (αS9-140C9), the protein fragment is ligated Ac-αS1-8V 3-C PGo
latent thioester. Top Right: PAGE gel analysis of ligation. Far Right: MALDI-TOF MS of full
S
S
length (calcd m/z 14,536) or trypsinized Ac-αSV 3C9 (Ac-αS1-5V 3, calcd m/z 828.4). No
desulfurized oxopeptide (calcd m/z 812.4) was observed. With Solongo Batjargal.
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samples. To isolate intramolecular misfolding events, we carried out our aggregation
using 1:30 doubly labeled Ac-αSVS3C9W94 in WT αS, so that statistically there should not
be intermolecular Trp/thioamide interactions within 30 Å (the contact quenching distance
for Trp/thioamide pair280). Finally, with a residual Cys in our semi-synthetic construct,
we conducted our aggregation in the presence of β-mercaptoethanol (BME) to prevent
disulfide bond formation that may interfere with the aggregation process.

We were excited to find that as aggregation proceeded, Trp fluorescence quenching
was clearly observed, which corresponded to compaction between the Trp and thioamide
labels as one would expect in oligomer and fibril formation. Comparing to aggregation
progress as monitored by thioflavin T (ThT) fluorescence, Trp fluorescence quenching
took place before the rise of ThT fluorescence (ThT preferentially binds to fibrils 54),
indicating that our Trp/thioamide dual labeling method revealed conformational changes
at the early oligomer formation stage (< 24 h), which had been a difficult target in prior
efforts281. While an extensive data set from various labeling positions is certainly
necessary to draw definitive conclusions about the exact conformations involved, these
studies clearly demonstrated the feasibility of thioamide incorporation into full-length
proteins via NCL, as well as their great potential as minimalist probes in studying the
misfolding of pathogenic proteins.
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Figure 2-14. Monitoring αS Misfolding Using Thioamide Fluorescence Quenching.
S

Monomeric Ac-αS1-140V 3C9W 94 was mixed in a 1:30 ratio with WT αS, and shaken at 37 °C
for several days. Samples were taken at defined intervals and Trp fluorescence were
measured at 295 nm. Thioflavin T (ThT) was used as a secondary assay to confirm fibril
formation. See Materials and Methods for detailed description. With Rebecca F. Wissner.
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2.3 Conclusion
We have established two efficient thioesterification methods for the incorporation of
thioamide into full-length proteins by NCL. ChB, an O-to-S latent thioester linker,
functions at mildly acidic pH and exhibits rapid reaction kinetics, while CbPGo, an N-to-S
latent thioester, utilizes mildly basic reaction conditions and is more stable toward
purification and storage. Both methods are fully compatible with thioamide, giving a
wide range of conditions for protein-specific optimization.

As a proof-of-concept example, we successfully extended the thioesterification and
NCL method to synthesizing a thioamide-labeled variant of αS, a protein implicated in
Parkinson’s disease. We demonstrated the utility of the thioamide as a minimalist
fluorescence quencher probe in an aggregation study with a Trp/thioamide dually labeled
αS construct; conformational compaction was observed at the oligomer stage determined
by Trp fluorescence quenching by the thioamide. Our semi-synthesis method has enabled
the site-specific incorporation of thioamide into full-length proteins, greatly expanding its
potential applications as a minimalist probe in protein misfolding studies.
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2.4 Materials and Methods
General Information

Fmoc protected amino acids and peptide synthesis reagents

were purchased from EMD Millipore (Billerica, MA). All other reagents and solvents
were purchased from Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO)
unless otherwise specified. High resolution electrospray ionization mass spectra (ESIHRMS) were collected with a Waters LCT Premier XE liquid chromatograph/mass
spectrometer (Milford, MA). Low resolution electrospray ionization mass spectra (ESILRMS) were obtained on a Waters Acquity Ultra Performance LC connected to a single
quadrupole detector (SQD) mass spectrometer. UV-Vis absorption spectra were acquired
on a Hewlett-Packard 8452A diode array spectrophotometer (Agilent Technologies,
Santa Clara, CA). Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker
DRX 500 MHz instrument (Billerica, MA). Matrix assisted laser desorption/ionization
with time-of-flight detector (MALDI-TOF) mass spectra were acquired on a Bruker
Ultraflex III instrument (Billerica, MA). Analytical HPLC was performed on an Agilent
1100 Series HPLC system equipped with a photodiode array detector (Santa Clara, CA).
Preparative HPLC was performed on a Varian Prostar HPLC (Agilent Technologies,
Santa Clara, CA). HPLC columns were purchased from W. R. Grace & Compnay
(Columbia, MD). Fluorescence spectra were collected with a Varian Cary Eclipse
fluorescence spectrophotometer with a Peltier multicell holder (Agilent Technologies,
Santa Clara, CA). Protein purification was conducted on a BioCad Sprint fast protein
liquid chromatography (FPLC) system (Agilent Technologies, Santa Clara, CA).
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Synthesis of 3-(t-Butyldisulfanyl)propane-1,2-diol (2)

3-Mercaptopropane-1,2-

diol (1, 960 µL, 90% aq., 10 mmol, 1 equiv) was mixed with 2-methylpropane-2-thiol
(tBuSH, 3.4 mL, 30 mmol, 3 equiv), and chilled to 0 °C on ice. A solution of iodine
(2.7918 g, 11 mmol, 1.1 equiv) in ethanol (50 mL) was added dropwise over 2 h, until the
reaction changed from colorless to red. The reaction was allowed to proceed for another 2
h on ice, and then quenched with saturated NaS2O3 (1 mL). The crude mixture was
concentrated by rotary evaporation, and then purified by flash chromatography in 2:3
ethyl acetate/petroleum ether. The product was isolated as a yellow oil (1.7391 g, 8.9
mmol, 89% yield). Rf 0.23 in 2:3 ethyl acetate/petroleum ether; 1H NMR (500 MHz,
CDCl3): δ 2.78 (m, 1H), 3.52 (dd, J = 11.3, 4.7 Hz, 1H), 3.48 (dd, J = 11.3, 5.7 Hz, 1H),
2.85 (dd, J = 13.2, 5.4 Hz, 1H), 2.73 (dd, J = 13.4, 7.4 Hz, 1 H), 1.29 (s, 9H). ESI+LRMS calculated for C6H13O2S2+ 181.04, found [M − CH3]+ 181.10.

Synthesis of 1,2-Bis-(t-butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propane (3)
2 (1.0144 g, 5.2 mmol, 1 equiv), imidazole (2.1105 g, 31 mmol, 6 equiv) and 4-dimethylaminopyridine (DMAP, 0.0379 g, 0.3 mmol, 0.06 equiv) were dissolved in anhydrous
N,N-dimethylformamide (DMF, 15 mL) on ice under argon. tert-Butyl-dimethylsilyl
chloride (TBSCl, 2.3359 g, 16 mmol, 3 equiv) was added, and the reaction was allowed
to proceed overnight (≥ 12 hr). Upon completion, the reaction was quenched with 0.5 N
NaOH (10 mL), and extracted with ethyl acetate (30 mL × 3). The organic layers were
concentrated by rotary evaporation and purified by flash chromatography in 1:19 ethyl
acetate/hexanes. The product was isolated as a clear oil (2.1758 g, 5.1 mmol, 99% yield).
Rf 0.74 in 1:19 ethyl acetate/hexanes; 1H NMR (500 MHz, CDCl3): δ 3.87 (m, 1H), 3.58
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(dd, J = 10.0, 5.1 Hz, 1H), 3.51 (dd, J = 10.1, 6.3 Hz, 1H), 2.97 (dd, J = 13.1, 5.0 Hz,
1H), 2.71 (dd, J = 13.1, 6.7 Hz, 1H), 1.31 (s, 9H), 0.87 (s, 18H), 0.04 (m, 12H); ESI+LRMS calculated for C19H44O2S2Si2Na+ 447.22, found [M + Na]+ 447.27.

Synthesis of 2-((t-Butyldimethylsilyl)oxy)-3-(t-butyldisulfanyl)propan-1-ol (4) 3
(0.8676 g, 2 mmol, 1 equiv) was dissolved in tetrahydrofuran (THF, 9 mL) on ice, and
then a solution of trifluoroacetic acid (TFA, 1.8 mL, 24 mmol, 12 equiv) in water (1.8
mL) was added dropwise. The reaction was allowed to proceed for 3 h on ice until all
reactant was consumed, and then quenched with saturated NaHCO3 (30 mL) and
extracted with ethyl acetate (30 mL × 3). The organic layers were concentrated by rotary
evaporation and purified by flash chromatography in 1:15 ethyl acetate/hexanes. The
product was isolated as a clear oil (0.3889 g, 1.3 mmol, 61% yield). Rf 0.25 in 1:15 ethyl
acetate /hexanes; 1H NMR (500 MHz, CDCl3): δ 3.95 (m, 1H), 3.68 (dd, J = 11.3, 3.8 Hz,
1H), 3.60 (dd, J = 11.3, 4.2 Hz, 1H), 2.85 (dd, J = 13.4, 7.2 Hz, 1H), 2.77 (dd, J = 13.4,
5.7 Hz, 1H), 1.85 (s, 1H), 1.31 (s, 9H), 0.88 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H). ESI+LRMS m/z calculated for C13H30O2S2SiNa+ [M + Na]+ 333.14, found 333.10.

Synthesis of 2-((t-butyldimethylsilyl)oxy)-3-(t-butyldisulfanyl)propanal (5) DessMartin periodane was freshly prepared according to Ireland et al.282 4 (1.8736 g, 6 mmol,
1 equiv) was dissolved in CH2Cl2 (40 mL) under argon. Dess-Martin periodane (3.8379
g, 9 mmol, 1.5 equiv) was slowly added, and then the reaction was allowed to proceed for
3 h at room temperature. Upon completion, the reaction mixture was diluted with CH2Cl2
(50 mL) and ethyl acetate (50 mL), filtered, concentrated by rotary evaporation, and then
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purified by flash chromatography in 1:19 ethyl acetate/hexanes. The product was isolated
as a pale yellow oil (1.2183 g, 4.0 mmol, 65% yield). R f 0.27 in 1:19 ethyl acetate/
hexanes; 1H NMR (500 mHz, CDCl3): δ 9.65 (d, J = 1.1 Hz, 1H), 4.23 (ddd, J = 7.9, 4,4,
1,1 Hz, 1H), 2.99 (dd, J = 13.3, 4.4 Hz, 1H), 2.81 (dd, J = 13.4, 7.9 Hz, 1H), 1.32 (s, 9H),
0.92 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H). ESI--LRMS calculated for C13H27O2S2Si- 307.13,
found [M − H]+ 307.21.

Synthesis of 2-((t-butyldimethylsilyl)oxy)-3-(t-butyldisulfanyl)propanoic acid (6)
5 (0.2479 g, 0.8 mmol, 1 equiv) was dissolved in 2-methyl-2-propanol (tBuOH, 4 mL) on
ice. 2-Methyl-2-butene (4.8 mL, 45 mmol, 58 equiv) was added, followed by a solution
of NaClO2 (0.2110 g, 2.3 mmol, 3 equiv) and NaH2PO4 (0.2053 g, 1.7 mmol, 2.2 equiv)
in water (4 mL). The reaction was vigorously stirred for 2 h under nitrogen, and then
diluted with ethyl acetate (10 mL) upon completion. The crude mixture was extracted
against 0.1N HCl (10 mL × 3), concentrated by rotatory evaporation, and then purified by
flash chromatography in 1:19 methanol/CH2Cl2. The product was isolated as a clear oil
(0.0782 g, 0.24 mmol, 31% yield). Rf 0.16 in 1:19 methanol /CH2Cl2; 1H NMR (500
MHz, CDCl3): δ 9.28 (s, 1H), 4.46 (dd, 1H, J = 7.8, 3.9 Hz), 3.11 (dd, 1H, J = 13.4, 3.8
Hz), 2.91 (dd, 1H, J = 13.4, 7.7 Hz), 1.31 (s, 9H), 0.91 (s, 9H), 0.14 (s, 3H), 0.12 (s, 3H).
ESI−-HRMS calculated for C13H27O3S2Si− 323.1171, found [M − H]− 323.1168.

L-Cystine and L-Cysteine Routes towards TBS-ChB-OH

Various routes using L-

cystine or protected Cys as starting material were proven unsuccessful at various stages
of synthesis, due to solubility or reactivity limitations.
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Figure 2-15. Attempted Synthesis towards TBS-ChB-OH from Cys

Synthesis of α-N-Fmoc-L-thioleucine-benzotriazolide (S1)

S-tBu

or Cystine.

Thioleucine (LeuS or

LS) precursor was synthesized using a similar procedure as previously described in J. Am.
Chem. Soc. 2012, 134, 6088−6091. 1H NMR (500 MHz, CDCl3): δ 8.78 (d, J = 8.3 Hz,
1H), 8.15 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 7.3 Hz, 2H), 7.69 (d, J = 7.5 Hz, 1H), 7.65 (t, J
= 9.1 Hz, 2H), 7.55 (t, J = 7.6 Hz, 1H), 7.40 (t, J = 7.3 Hz, 2H), 7.33 (t, J = 7.2 Hz, 2H),
6.39 (t, J = 8.8 Hz, 1H), 5.78 (d, J = 9.6 Hz, 1H), 4.49 (d, J = 7.0 Hz, 1H), 4.41 (t, J = 7.2
Hz, 1H), 4.25 (t, J = 6.5 Hz, 1H), 1.92 (s, 1H), 1.85 (t, J = 10.1 Hz, 1H), 1.15 (d, J = 6.2
Hz, 3 H), 0.98 (d, J = 6.4 Hz, 3H). ESI+-LRMS calculated for C27H26N4O2SNa+ 493.17,
found [M + Na]+ 493.26.
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Synthesis of α-N-Fmoc-L-thiovaline-benzotriazolide (S2)

Thiovaline (ValS or

VS) precursor was synthesized by Solongo Batjargal using a similar procedure as detailed
in J. Am. Chem. Soc. 2012, 134, 9172−9182.

Peptide Synthesis and Purification

Peptides were synthesized using standard

Fmoc solid phase peptide synthesis (SPPS) procedure on either Rink Amide or 2chlorotrityl chloride resin (100 - 200 mesh; 0.6 mmol substitution/g). For ChB and CbPGo
latent thioesters, the linkers were first installed, and then the remaining sequences were
completed using the standard procedure. For coupling, 5 equiv of amino acid and 5 equiv
of HBTU were dissolved in DMF, and then added to the resin. 10 equiv of N,Ndiisopropylethylamine (DIPEA) was then added, and the mixture was stirred for 30 min.
For deprotection, 20% piperidine in DMF was stirred with the resin for 20 min.
Thioleucine (LeuS or LS) and thiovaline (ValS or VS) were introduced as activated
benzotriazole precursors283,115; 3 equiv of the precursor was dissolved in DMF, and
stirred with the resin for 1 h in the presence of 10 equiv DIPEA. For N-terminally
acetylated

peptides,

an

acetylation

cocktail

of

1:1:8

acetic

anhydride/N-

methylmorpholine/DMF was stirred with the resin twice, each for 10 min, after the last
deprotection. Upon completion of SPPS, resins were rinsed thoroughly with CH2Cl2 and
dried under vacuum.

For cleavage, resins were treated with a cleavage cocktail (38:1:1 trifluoroacetic
acid/triisopropylsilane/H2O unless otherwise specified) for 30 min. The solution was then
collected by filtration, and dried by rotary evaporation. For purification, the crude
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residues were brought up in 1:10 CH3CN/H2O, and then purified by reverse phase HPLC
with acidified (with 0.1% trifluoroacetic acid) CH3CN/H2O gradients. Individual
fractions were charac-terized by MALDI-TOF MS, and dried by lyophilization. When
necessary, the isolated products were subjected to multiple rounds of purification until
99.5% pure by MALDI-TOF MS and analytical HPLC. Solvent radients, retention times
and MALDI-TOF MS results are listed in Table 2-1 through Table 2-3.

Table 2-1. Peptide Purification Methods and Retention Time.
Gradient

Retention
Time

Ac-GLSKXAG-ChB-NH2 (7)

1

20.9 min

Vydac C18 semi-prep

CAX-NH2 (8)

2

18.5 min

Vydac C18 semi-prep

1

19.2 min

Vydac C18 semi-prep

Ac-MDV FMKGL-C PGo (13)

5

21.0 min

Vydac C18 semi-prep

αS9-140C9 (14)

6

24.4 min

Vydac C4 prep

Peptide

S

b

Ac-GL KXAG-C PGo (11)
S

b

Column

* X = 7-methoxycoumarinylalanine; LS = thioleucine; VS = thiovaline.
Table 2-2. HPLC Gradients for Peptide Purification and Characterization.
Time
(min)

%B

No.

1

0:00
5:00
10:00
30:00
35:00
40:00
45:00

2
2
30
50
100
100
2

4

0:00
5:00
10:00
25:00
30:00
35:00
40:00

2
2
20
50
100
100
2

No.

Time
(min)

%B

No.

Time
(min)

%B

2

0:00
5:00
10:00
25:00
30:00
35:00
40:00

2
2
15
30
100
100
2

3

0:00
6:00
30:00
40:00
45:00
50:00

2
2
50
100
100
2

5

0:00
5:00
10:00
25:00
30:00
35:00
40:00

2
2
40
55
100
100
2

6

0:00
5:00
15:00
30:00
35:00
40:00
45:00

5
5
35
50
100
100
2

* Solvent A: 0.1% trifluoroacetic acid in water; Solvent B: 0.1% trifluoroacetic acid in acetonitrile
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Table 2-3. MALDI-TOF MS Characterization of Purified Peptides.
Peptide

[M + H]+

[M + Na]+

Calc’d

Found

Calc’d

Found

Ac-GLSKXAG-ChB-NH2 (7)

939.37

939.23

961.36

961.20

CAX-NH2 (8)

437.14

436.99

459.13

458.96

Ac-GL KXAG-C PGo (11)

1093.44

1093.36

1115.43

1115.34

Ac-MDVSFMKGL-CbPGo (13)

1357.58

1357.38

1379.56

1379.50

αS9-140C9 (14)

13552.2

13552.8

-

-

S

b

* X = 7-methoxycoumarinylalanine; LS = thioleucine; VS = thiovaline.

Synthesis of Peptide-ChB Latent Thioester (7)

Rink amide resin (25 µmol, 0.6

mmol/g substitution, 1 equiv) was swollen in dimethylformaide (DMF) for 1 h, and then
deprotected twice with 2 mL of 20% piperdine in DMF for 20 min each. For ChB
installation, TBS-ChB-OH (6, 0.0089 g, 27.5 μmol, 1.1 equiv) and PyBOP (0.0143 g,
27.5 μmol, 1.1 equiv) were dissolved in 2 mL of DMF, and then added to the resin.
DIPEA (43.5 μL, 250 μmol, 10 equiv) was added, and then the reaction was allowed to
proceed for 90 min with stirring. Upon completion, the resin was thoroughly rinsed with
DMF and CH2Cl2, and then stirred in tetrahydrofuran (THF) for 1 h for equilibration. For
TBS deprotection, 2 mL of 1.0 M tetra-n-butylammonium (TBAF) in THF was added.
The reaction was allowed to proceed for 4 h, and then thoroughly rinsed with THF.

For coupling of the next residue Gly, Fmoc-Gly-OH (0.0516 g, 125 μmol. 5 equiv)
and dicyclohexylcarbodiimide (DCC, 0.0129 g, 62.5 μmol, 2.5 equiv) were dissolved in 2
mL of THF, and then pre-activated for 30 min. Dicyclohexylurea (DCU) side product
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was removed by filtration, and then the clear solution was added to the resin. Catalytic
amount of 4-dimethylaminopyridine (DMAP, 0.0003 g, 2.5 µmol, 0.1 equiv) was added,
and then the reaction was allowed to proceed for 45 min. Upon completion, the resin was
thoroughly rinsed with THF, and then stirred in DMF for 1 h for equilibration. The rest of
the sequence was elongated using standard SPPS protocol, cleaved with 3:7 trifluoroacetic acid/CH2Cl2 (3 mL), and purified by reverse phase HPLC (Table 2-1 to Table 2-3).

Test Ligation of Peptide-ChB Latent Thioester

A ligation buffer (20 mM TCEP,

200 mM Na2HPO4, pH 6.8) was freshly prepared and degassed by argon purging. 7 (10
nmol, ε325 = 12,000 M-1 cm-1, 1 equiv) and 8 (100 nmol, ε325 = 12,000 M-1 cm-1, 10 equiv)
was each dissolved in 10 µL of ligation buffer and then combined. The reaction was
allowed to proceed at 37 ˚C for various amount of time under argon atmosphere. Upon
completion, 5 µL of the reaction mixture was removed, diluted into 795 uL of H2O, and
analyzed by reverse phase HPLC on a Luna C8 analytical column using gradient 3.
Fractions were collected for MALDI-TOF MS analysis, and UV-Vis absorption profiles
were extracted from data acquired by photodiode array detector on analytical HPLC.

9a

9b

(9a)

(9b)

Figure 2-16. UV-Vis Absorption Spectra for Intermediate 9a and 9b.
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Denaturant Tolerance of ChB Ligation

Reactions were conducted similarly to the

standard ChB ligation procedure, except that a ligation buffer containing 6 M Gdn∙HCl
was used. The presence of denaturant resulted in slower reaction kinetics, but otherwise
no additional complications were observed.

9a

9c

9b

Figure 2-17. Denaturant Tolerance of ChB Ligation between 7 and 8.

Synthesis of Peptide-CbPGo Latent Thioester (11)

Ac-GLSKXAG-CbPGo 11 (X =

7-methoxycoumarinylalanine) was synthesized on Rink amide resin (100 μmol, 0.6
mmol/g). The resin was deprotected with 20% piperidine in dimethylformamide (DMF),
thoroughly rinsed, and then dried on vacuum. Bromoacetic acid (0.0695 g, 500 μmol, 5
equiv) was pre-activated with dicyclohexylcarbodiimide (DCC, 0.0516 g, 250 μmol, 2.5
equiv) for 30 min in anhydrous DMF (6 mL); dicyclohexylurea (DCU) side product was
removed by filtration, and then the clear solution was added to the resin. The reaction
was allowed to proceed with stirring for 30 min, and then thoroughly rinsed with DMF.
Subsequently, Fmoc-Pro-OH (0.1687 g, 500 μmol, 5 equiv) was dissolved in anhydrous
DMF (6 mL) with diisopropylethylamine (DIPEA, 174.3 μL, 1 mmol, 10 equiv), and
coupled to the resin for 30 min.
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The next two residues were introduced as a dipeptide, to avoid premature diketopiperazine (DKP) formation on resin (Figure 2-18). To accomplish this, Fmoc-GlyCys(tButhio)-OH was synthesized on 2-chlorotrityl resin at 125 μmol scale using
standard SPPS, and cleaved with 1:1:8 acetic acid/trifluoroethanol/CH2Cl2. The crude
product (0.0537 g, 110 μmol, 1.1 equiv) was dissolved in anhydrous DMF (6 mL) with
PyBOP (0.0572 g, 110 μmol, 1.1 equiv) and DIPEA (174.3 μL, 1 mmol, 10 equiv), and
then coupled to the resin for 1 h. The rest of the peptide was elongated and acetylated
with standard SPPS. For cleavage, the resin was treated with 30:70 trifluoroacetic
acid/CH2Cl2 (6 mL) for 30 min, dried by rotary evaporation, and then purified by reverse
phase HPLC (Table 2-1 through Table 2-3).

Figure 2-18. Necessity of Fmoc-Xaa-Csb-OH in Preventing DKP Formation in SPPS.

Ligation between Peptide-CbPGo and Cys

A 2x ligation buffer (100 mM TCEP,

400 mM Na2HPO4, pH 8.4) was freshly prepared and degassed by argon purging. AcGLSKXAG-CbPGo 11 (100 nmol, ε325 = 12,000 M-1 cm-1) was dissolved in argon-purged
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water (30 μL), and mixed with 20 μL of 5x Cys stock (50 mM in argon-purged water).
50 μL of 2x ligation buffer was added, and then the reaction was allowed to proceed at 37
˚C for 10 h. At appropriate time points, a 4 μL sample was removed from the reaction
mixture, quenched with 796 μL of 0.1% trifluoroacetic in water, and analyzed by reverse
phase HPLC on a Luna C8 analytical column using gradient 4. Fractions were collected
for MALDI-TOF MS analysis, and UV-Viv absorption profiles were extracted from data
acquired by photodiode array detector on analytical HPLC.

Kinetic Characterization of CbPGo Ligation

To obtain a kinetic profile of CbPGo

ligation, HPLC chromatograms of samples taken at various time points were integrated
for areas under the curve based on absorbance at 325 nm (λmax for Mcm, 7-methoxycoumarinylalanine). Peak identities were assigned based on MALDI MS, and then LC area
percentages (LCAP) were calculated using equation S1:
LCAP = Area of individual peak at 325 nm / Area of all peaks at 325 nm

(S1)

For data fitting, LCAP for each peak was averaged from three independent trials, and
plotted against the time point at which they were obtained. Since all Mcm-containing
peptides originate from the reactant peptide 11, their total concentration will stay the
same as initial concentration of 11 (1 mM) and their individual concentrations (in terms
of molarity) will also be proportional to their LCAPs. With Cys in large excess (10 equiv)
and the rapid conversion of CbPGo to its reduced form, the reaction can be assumed as a
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pseudo-first-order reaction of the reduced reactant 11a. Therefore, LCAPs were fitted to a
single exponential decay function S2 using Microcal Origin 6.0 Pro ((Northampton, MA).
LCAP = LCAP0 + A ∙ exp [ -t / τ ]

(S2)

The fitting parameters were then converted into pseudo first order rate constant k1’,
second order rate constant k2, and half-life t1/2 using equations S3 through S5.
k1’ = 1 / τ

(S3)

k2 = k1 / [Cys]

(S4)

t1/2 = τ · ln2

(S5)

With an R-value of 0.9998, the experimental pseudo first order rate constant k1’ was
calculated to be (1.53 ± 0.06) × 10-4 s-1, corresponding to a second order rate constant k2
of (1.53 ± 0.06) × 10-2 s-1 and a reaction half-life t1/2 of (75 ± 1) min.

Diketopiperazine (DKP) Thioester Intermediate

The DKP thioester intermediate

S3 could be observed when 0.1 mM peptide-CbPGo 11 was incubated with ligation buffer
in the absence of Cys (Figure 2-19). Briefly, 11 (10 nmol, ε325 = 12,000 M-1 cm-1) was
dissolved in 50 μL of argon-purged water, and then 50 μL of 2x argon-purged ligation
buffer stock (100 mM TCEP, 400 mM Na2HPO4, pH 8.4) was added. The reaction was
allowed to proceed at 37 ˚C for 45 min, and then quenched with 900 μL of 0.1%
trifluoroacetic acid in water and analyzed by reverse phase HPLC on a Vydac C18
analytical column using gradient 4. Fractions were collected for MALDI-TOF MS.
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Denaturant Tolerance of CbPGo Ligation

Three Cys stocks (10 mM Cys, 20 mM

TCEP, 200 mM Na2HPO4, pH 8.0) were prepared with various additives: A) none; B) 6
M Gdn·HCl; C) 6 M Gdn·HCl and 50 mM 4-mercaptophenylacetic acid (MPAA). For
each condition, 11 (20 nmol, ε325 = 12,000 M-1 cm-1) was dissolved in the corresponding
Cys stock (20 μL), and allowed to react at 37 ˚C for 2 h. Upon completion, the reaction
was diluted into 780 μL of 0.1% trifluoroacetic acid in water, and analyzed by reverse
phase HPLC (Figure 2-20). The results showed that the presence of Gdn·HCl led to
slower kinetics, whereas the addition of MPAA could partially “rescue” the reactivity.

(S3)

(S4)

(S5)

S5

S4
S3

b

Figure 2-19. Diketopiperazine (DKP) Intermediate in C PGo Ligation.
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12

11a

11a
12

12

11a

b

Figure 2-20. Effects of Denaturant and Thiol Additive on C PGo Ligation.

Synthesis of Fmoc-Leu-Cys(S-tBu)-OH (S6)

Fmoc-Leu-OH (1.0602 g, 3 mmol,

1.5 equiv) was dissolved in 20 mL of tetrahydrofuran (THF), and chilled to 0 °C on ice.
N-Methylmorpholine (NMM, 769 µL, 7 mmol, 3.5 equiv) and isobutyl chloroformate
(IBCF, 290 µL, 2.2 mmol, 1.1 equiv) were added, and then the reaction was stirred for 15
min on ice. S-t-butylmercapto-L-cysteine (0.4186 g, 2 mmol, 1 equiv) was added, and the
reaction was allowed to proceed at room temperature overnight (≥ 14 hr) under an argon
atmosphere. Upon completion, solvent was removed by rotary evaporation. The residue
was brought up in 40 mL of ethyl acetate, and extracted against 40 mL each of 1 M HCl
and brine. The crude product was purified by flash chromatography in 40:60 ethyl
acetate/petroleum ether with 0.1% acetic acid. A white foam was yielded as the final
product (0.7643 g, 1.29 mmol, 70% yield). Rf 0.5 in 4:6 ethyl acetate/petroleum ether
with 0.1% acetic acid. 1H NMR (500 MHz, CDCl3): δ 10.38 (s, 1H), 7.73 (d, J = 7.1 Hz,
2H), 7.59 (t, J = 6.8 Hz, 2H), 7.41 (d, J = 7.0 Hz, 1H), 7.38 (t, J = 7.2 Hz, 2H), 7.29 (t, J
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= 7.2 Hz, 2H), 5.95 (d, J = 8.3 Hz, 1H), 4.86 (m, 1H), 4.45 (m, 1H), 4.38 (m, 2H), 4.21 (t,
J = 6.5 Hz, 1H), 3.28 (dd, J = 13.4, 3.9 Hz, 1H), 3.17 (dd, J = 13.3, 6.0 Hz, 1H), 1.69 (m,
2H), 1.59 (m, 2H), 1.26 (s, 9H), 0.94 (m, 6H).

13

C NMR (500 MHz, CDCl3): δ 173.10,

156.72, 144.09, 143.86, 141.48, 127.93, 126.33, 125.41, 120.17, 68.90, 67.56, 53.60,
52.71, 48.37, 47.29, 41.89, 41.54, 30.02, 29.96, 28.08, 24.87, 23.15, 22.34, 22.29. ESI+HRMS: calculated for C28H37N2O5S2+ 545.2144, found [M + H]+ 545.2150.

Synthesis of Ac-αS1-8VS3-CbPGo (13)

Rink amide resin (100 µmol, 0.6 mmol/g

substitution) was swollen in anhydrous DMF for 1 h, and then deprotected twice with 6
mL of 20% piperidine in anhydrous DMF, each for 20 min. BrCH2COOH (0.0695 g, 500
µmol, 5 equiv) was dissolved in 6 mL of anhydrous DMF, and pre-activated with
diisopropylcarbodiimide (DIC, 78 μL, 500 µmol, 5 equiv) for 20 min. The mixture was
then transferred to the resin, and the coupling reaction was allowed to proceed for 45
min. For Pro installation, Fmoc-Pro-OH (0.1687 g, 500 µmol, 5 equiv) was dissolved in 6
mL of anhydrous DMF and transferred to the resin. DIPEA (174 μL, 1 mmol, 10 equiv)
was added, and then the reaction was allowed to proceed for 4 h. A second coupling was
repeated with fresh Fmoc-Pro-OH/DIEPA/DMF overnight (≥ 8 h). The resin was then
deprotected with 6 mL of 20% piperidine in anhydrous DMF for 20 min.

To install the next two amino acids as dipeptide, Fmoc-Leu-Cys(S-tBu)-OH (0.1634
g, 300 µmol, 3 equiv) was dissolved in 6 mL of anhydrous DMF, and pre-activated with
PyBOP (0.1561 g, 300 µmol, 3 equiv) and DIPEA (174 μL, 1 mmol, 10 equiv) for 3 min.
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The mixture was then transferred to the resin, and the coupling reaction was allowed to
proceed for 4 h. The rest of the sequence was assembled using standard SPPS procedure.

For cleavage, the resin was treated with 6 mL of 1:1:2:20 1,2-ethanedithiol/triisopropylsilane/thioanisole/trifluoracetic acid for 30 min. The solution was then collected by
filtration, concentrated by rotary evaporation, and then precipitated with 10 mL of cold
diethyl ether. The pellets were collected by centrifugation at 4 krpm for 20 min, and then
brought up in 50:50 H2O/CH3CN for reverse phase HPLC purification.

Over-expression and Purification of αS9-140C9 or αS9-140C9W94

Expression and

purification were performed by Solongo Batjargal as detailed in J. Am. Chem. Soc. 2012,
134, 9172−9182. Briefly, a plasmid encoding for HTag-αS9−140C9 or HTag-αS9−140C9W94
were transformed into E. coli BL21 DE3 cells, and over-expressed with isopropyl-β-Dthiogalactopyranoside (IPTG) induction. After lysis of the cells, target protein was pulled
down by Ni-NTA resin, and treated with Factor Xa to remove the HTag. The crude was
then dialyzed against water, and further purified by reverse phase HPLC on a Vydac C4
prep column using gradient 6 (Tables Table 2-1 through Table 2-3).

Ligation between Ac-αS1-8VS3-CbPGo and αS9-140C9 or αS9-140C9W94

Latent

thioester Ac-αS1-8VS3-CbPGo 13 (90 nmol, 1.5 equiv) and expressed protein fragment αS9140C9

or αS9-140C9W94 (60 nmol, 1 equiv) were dissolved in 60 μL of freshly degassed

ligation buffer (6 M Gdn·HCl, 200 mM Na2HPO4, 20 mM TCEP, 1% v/v thiophenol, and
1% v/v benzylmercaptan, pH 8.0). The reaction was allowed to proceed for 24 h at 37 °C,
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and then quenched with 940 µL of 0.1% trifluoroacetic acid in water. The crude was
dialyzed against water, and purified by reverse phase HPLC. Fractions were collected,
characterized by MALDI-TOF MS, and then lyophilized until further use.

S

Figure 2-21. HPLC Chromatogram of Ligation between αS1-8V 3-CbPGo and αS9-140C9.
S

b

Peaks a, b,and c correspond to hydrolyzed Ac-αS1-8V 3-C PGo, αS9-140C9, and the ligation
S
product, Ac-αS1-140V 3C9. UV absorbance monitored at 215 and 277 nm.

S

Figure 2-22. HPLC Chromatogram of Ligation between αS1-8V 3-CbPGo and αS9-140C9W 94.
b

Peaks a, b, and c correspond to hydrolyzed Ac-αS1-8VS3-C PGo, αS9-140C9W 94, and ligation
product, Ac-αS1-140VS3C9W 94. UV absorbance monitored at 215 and 270 nm. The large peak
at 20 min is excess thiophenol additive.
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Trypsin Digest Analysis of Ac-αSVS3C9

Ligated Ac-αSVS3C9 15 (20 μg) was

dissolved in 18 μL of digestion buffer (25 mM NH4HCO3, pH 7.5), and treated with 2 μL
of sequencing-grade modified trypsin (0.1 μg/μL). The digestion was allowed to proceed
at 37 °C for 4 h, and then analyzed by MALDI-TOF MS.

UV-Vis Absorption Spectroscopy Analysis

αS9-140C9 contains four Tyr with a

molar absorption of 5,340 M-1 cm-1 at 273 nm; Ac-αSVS3C9 contains four Tyr and one
thioamide with a molar absorption of 15,368 M-1 cm-1 at 273 nm. Therefore, the molar
absorption ratio (Ac-αSVS3C9: αS9-140C9) at 273 nm is 2.88. The absorption spectra of the
two proteins were normalized by assuming that the molar absorption of Ac-αSVS3C9 (140
residues) at 218 nm is 1.07 times that of αS9-140C9 (131 residues). The experimental
absorbance ratio (Ac-αSVS3C9: αS9-140C9) at 273 nm is 2.84, indicating 2.84/2.88 = 99 %
thioamide incorporation.

Normalized Intensity
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Figure 2-23. Normalized UV-Vis Absorption Spectra of αS Ligation.
S

αS9-140C9 (green line), αSV 3C9 red line), and difference spectrum (blue line).
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Aggregation of Ac-αS1-140VS5C9W94

Aggregation experiments were performed

according to literature precedence.284,285 First, 350 μL samples for aggregation assays
were prepared (97 μM WT αS with 3 μM αSW94 or 3 μM Ac-αSVS3C9W94) in phosphatebuffered saline (pH 7.0) containing 1 mM β-mercaptoethanol. Aggregation was seeded
by the addition of approximately 10% (wt/wt) pre-formed WT αS fibrils. The samples
were incubated at 37 °C for 4−6 days with continuous shaking at 1,100 rpm. Periodically,
40 μL aliquots were removed to monitor changes in Trp fluorescence and ThT binding.

For fluorescence spectroscopy, the 40 μL aliquots were diluted to 120 μL with
phosphate buffered saline prior to loading the sample into quartz cuvettes. To selectively
monitor changes in Trp fluorescence in the presence of tyrosine, the excitation
wavelength was 295 nm and emission data was collected from 315 to 385 nm. ThT
binding was determined by directly adding 1 mL of ThT solution (20 μM in phosphate
buffered saline) to the cuvette after monitoring Trp fluorescence. The samples were
incubated within the cuvettes for two minutes prior to collecting ThT fluorescence data.
The excitation wavelength was 446 nm and emission data was collected from 460 to 600
nm. For all experiments, the temperature was 37 °C, the excitation and emission slit
widths were 5 nm, the scan rate was 120 nm/min with an averaging time of 0.5 s, and the
data interval 1.0 nm. Examples of primary spectra are shown below.
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Figure 2-24. Examples Fluorescence Spectra from αS Aggregation Experiments.
Left: Trp fluorescence, excited at 295 nm. Right: ThT fluorescence, excited at 436 nm. In both
cases, red, green, and blue indicate data at 0, 8, and 72 h respectively. Solid lines: 1:30
S
αSW 94/WT mix. Broken lines 1:30 Ac-αSV 3C9W 94/WT mix. With Rebecca F. Wissner.

PAGE Gel Analysis of Aggregation Experiments

Immediately following the

assembly of the aggregation reaction, a 10 μL aliquot from each sample was removed for
PAGE gel analysis and stored at - 80 °C. After 96 hours of aggregation, an additional 10
μL aliquot was removed from each sample. Each aliquot was diluted to 30 μL with
MilliQ water and centrifuged for 45 min at 13,200 rpm to determine the loss of soluble
protein post-aggregation. 15 μL of the resultant supernatant was removed from the
centrifuged samples and run on an 18% SDS-PAGE gel. The gel was stained with
Coomassie blue and scanned.
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Figure 2-25. PAGE Gel Analysis of Aggregation Experiments.
Gel band intensity of soluble fraction before aggregation (Pre) and after 4 days of aggregation (Post) shows a loss of soluble monomer due to fibrillization. With Rebecca F. Wissner.
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Chapter 3 . Chemoselective Desulfurization and Deselenization for Traceless
Incorporation of Thioamides into Peptides and Proteins
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3.1 Introduction
While traditional native chemical ligation (NCL), as developed by Kent 128, was
proven successful in incorporating thioamides into peptides and proteins, one inherent
limitation of this method is the necessity of a Cys at the ligation site (Figure 3-1A). This
greatly restricts the scope of thioamide incorporation – Cys is among the least abundant
amino acids (2.4% frequency in the human proteome286) and does not exist in the native
sequences of many protein targets, including α-synuclein, a Parkinson’s disease protein
of interest to our laboratory For these systems, thioamide incorporation via NCL would
leave an artifact of residual Cys in the ligated product, undermining the utility of the
thioamide as a minimalist probe and introducing complications during biophysical
studies. In fact, it has been clearly demonstrated that Cys mutations in αS can alter its
aggregation and cellular toxicity.287

To circumvent the Cys limitation in NCL, various groups have developed traceless
methods by either masking or “erasing” the side chain thiol. Masking techniques utilize
alkyl halides to convert Cys into Lys/Glu/Gln analogs, or homocysteine (Hcs) into Met
after ligation130 (Figure 3-1C). The former is not truly traceless since it results in a
thioether linkage (and an extra methylene group as in the case of Glu/Gln) that is
chemically and electrostatically different from the native residue. Hcs methylation does
yield a native Met, and has previously been utilized by our group for the synthesis of
thioamide-containing proteins269,288, granting access to another 2.1% of potential ligation
sites (Met abundance out of all 20 natural amino acids).286
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Figure 3-1. Comparison of Traditional and Traceless Native Chemical Ligation (NCL).
A) Traditional NCL utilizes an N-terminal Cys as the nucleophile, and leaves a residual Cys
in the ligated product. B) Traceless NCL via desulfurization/deselenization requires a Cys or
β-thiol/selenol analog as the nucleophile; the thiol/selenol is chemically removed after NCL.
C) Traceless NCL via masking uses either Cys or homocysteine (Hcs) as the nucleophile; the
thiol is subsequently masked into a functionalized thioether to mimic the natural side chain.
* Conditions are different for Ser as compared to all other amino acids.

The true paradigm shift, though, would come from adopting recently developed
desulfurization /deselenization methods, where the N-terminal residue is decorated with a
thiol or selenol at its β- or γ-carbon as the NCL handle, and then chemically “erased”
after ligation to become the native amino acid218,202 (Figure 3-1B). These methods are
extremely versatile – with nearly identical reaction conditions, it has thus far been
concretely demonstrated on 12 amino acids219 and theoretically possible for 19 out the 20
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amino acids (except for Gly which does not have a β-carbon). In addition, the β-selenol
analogs offer a second level of selectivity against native Cys residues, where the mild
deselenization conditions using tris(2-carboxyethyl)phosphine (TCEP) are fully
compatible with side chain thiols.216 However, it is unclear whether such methods would
be amenable to the incorporation of thioamides into peptides and proteins, particularly in
the case of desulfurization. Since both the thioamide and Cys contain a sulfur atom,
characterizing and fine-tuning the chemoselectivity would seem quite challenging.

Upon a closer examination at the reactions utilized – namely desulfurization by
Raney nickel, desulfurization by VA-044, and deselenization by TCEP – we hypothesize
that Raney nickel would be too harsh but the latter two should be feasible for thioamidecontaining peptides and proteins. Raney nickel is well-established for its broad substrate
scope where thiols, thioethers and thionoesters (thiocarbonyl esters) are all effectively
desulfurized, largely because of the high nickel-sulfur affinity.289 The only wellcharacterized precedence of Raney nickel/thioamide reactions was published by
Kornfield, where he reported a reductive desulfurization into amine (Figure 3-2).290,291
Although the exact reaction conditions would be different in our traceless NCL (for
example, it will be conducted in aqueous solution instead of organic solvents), one would
assume that Raney nickel could lead to complications with thioamides.

On the other hand, radical initiated desulfurization and deselenization do not depend
on metal-sulfur affinity, therefore as long as thioamide could tolerates an environment
with certain concentrations of radicals, it is possible to conduct traceless ligation while
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leaving the thioamide intact. Based on our prior knowledge that thioamide can function
as an acceptor for photoinduced electron transfer (PET)115,114 − where a single electron is
transferred from thioamide to a paired fluorophore, generating a transient thioamide
radical cation in the process (Figure 3-3) − we believed that the thioamide could be stable
towards ambient radicals in desulfurization/deselenization reactions. If our hypothesis
was valid, we would greatly expand the scope of potential ligation sites and remove the
possibility of complications from thiol side chains in biophysical assays.

Figure 3-2. Raney Nickel Desulfurization of Cys and Thioamide.
A) Mechanism for Cys desulfurization. B) Proposed mechanism for reductive thioamide
desulfurization as reported by Kornfield. * Raney nickel is denoted as Ni(H) to represent that
the reagent contains H2 as part of the formulation; it is generally understood that the
hydrogen in the resulting C−H bond comes from the Raney nickel reagent.

Figure 3-3. Transient Thioamide Radical Cation in Photo-induced Electron Transfer (PET).
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3.2 Results and Discussion
We began by establishing the compatibility of the thioamide with various desulfurization/deselenization methods. First, we tested Raney nickel desulfurization on model
peptide 1. Upon treatment with Raney nickel, peptide 1 is fully consumed; surprisingly,
instead of a secondary amine from reductive desulfurization290, cleavage at the thioamide
bond was observed, yielding peptide 1a with an N-terminal amine at the cleavage site
(Figure 3-4). We reasoned that since the reaction was conducted in an aqueous solution
(instead of organic solvents as in the previous study), water could serve as an excellent
nucleophile to attack the thiocarbonyl group that is activated by nickel-sulfur binding
(Figure 3-5). While Raney nickel has been a useful reagent in other contexts, it is evident
that such method would not be a viable option for the incorporation of thioamides.

We next sought to explore the compatibility of the thioamide with radical initiated
desulfurization/deselenization. We chose to start with TCEP induced deselenization, to
take advantage of our prior knowledge that the thioamide per se is stable towards
TCEP.283 Without attempting to synthesize a complex Sec-containing peptide in this
initial trial, we designed a one-pot ligation-deselenization reaction, where a thioamidecontaining CPGo thioester 2a (CPGo = Cys-Pro-Gla latent thioester; see Chapter 2) was
ligated to selenocystine, and then treated with TCEP for deselenization. We were
delighted to find that both the ligation and deselenization proceeded smoothly and
chemoselectively, where peptide 2d was generated as the final product (Figure 3-6). 2d
exhibited the characteristic thioamide π-π* absorption at 272 nm, giving us confidence
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(1)

(1a)

(1b)

1

1a

1b

1

1a

1b

Figure 3-4. Non-Selective Desulfurization of Cys and Thioamide by Raney Nickel.
A) Schematic representation of the test reaction. B) HPLC chromatogram monitored at 325
+
nm, and MALDI-TOF mass spectra for major peak in each chromatogram; [1 + H] : expected
+
+
1262.96, found 1262.56; [1a + H] : expected 988.53, found 988.46; [1b + H] : expected
1230.63, found 1230.62. C) UV-Vis absorption spectra of isolated peptides. The star sign
indicates thioamide absorption at 272 nm, which was absent in 1a. Conditions: 0.1 mM
peptide 1, 0.1% w/v Raney nickel, 100 mM Na2HPO4, 10 mM TCEP, pH 5.8, 12 h. TCEP =
tris(2-carboxyethyl)phosphine; Mcm = 7-methoxycoumarinylalanine.
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Figure 3-5. Proposed Mechanism for Raney Nickel Induced Thioamide Bond Cleavage.

that the thioamide remained intact throughout the process. It is interesting to note that due
to the unique activity of selenol292,293, two ligation intermediates were isolated − namely
homodimer 2b via a Sec diselenide bond and monomer 2c that was sequestered at Sec
through a hemiselenide bond to a −SPh group from ambient thiophenol used in the
ligation – instead of free selenol. In subsequent deselenization, both species were reduced
into selenol upon treatment with dithiothreitol (DTT) and converted into Ala.

The positive results from selective deselenization prompted us to further investigate
the possibility of selective desulfurization with VA-044 as radical initiator This is a more
challenging method for two reasons: 1) there is a smaller energy difference between a
C=S double bond (standard bond enthalpy 137 kcal∙mol-1) and C−S single bond (65
kcal∙mol-1), than with a C−Se single bond (56 kcal∙mol-1)77, requiring the method to be
more stringently discriminating against the thioamide; 2) mechanistically, deselenization
of Sec does not require ambient radicals and is simply initiated by spontaneous cleavage
of the Se−X (X = Se, S, H) bond, whereas desulfurization of Cys requires high
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Figure 3-6. Selective Deselenization of Sec in the Presence of Thioamide.
A) Schematic representation of the test reaction; a reduced version of CPG o instead of the
b
tBuS-protected C PGo was used to eliminate the need for TCEP as a reducing reagent in
ligation. B) HPLC chromatogram monitored at 325 nm, and UV-Vis absorption spectra of
isolated peptides. The star sign indicates thioamide absorption at 272 nm; 2c also contained
a peak around 260 nm that is characteristic of −SPh group. Ligation Conditions: 0.2 mM
peptide 2a, 2 mM selenocystine, sat. PhSH, 200 mM Na2HPO4, pH 8.0, 12 h. Deselenization
Conditions: 0.2 mM ligated peptide (without purification), 20 mM TCEP, 20 mM DTT, 200 mM
+
Na2HPO4, pH 8.0, overnight. MALDI MS: [2a + H] , expected 1005.42, found 1005.35; [2b +
+
+
H] , expected 1795.55, found 1795.41; [2c + H] , expected 1007.29, found 1007.25; [2d +
+
H] , expected 819.37, found 819.19. TCEP = tris(2-carboxyethyl) phosphine; DTT =
dithiothreitol; Mcm = 7-methoxycoumarinylalanine.
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2c

concentrations of ambient radicals that are initiated by VA-044 and propagated by thiol
additives to sever the C−S bond (Figure 3-7).

Figure 3-7. Proposed Mechanisms for TCEP Deselenization and VA-044 Desulfurization.

We carried out our initial test on peptide 3, using an intermediate VA-044
concentration and short reaction time to minimize potential thioamide complications. We
were excited to find that Cys can be selectively desulfurized in the presence of a
thioamide, generating 3a as the major product in 80% yield in 10 min (Figure 3-8). The
nearly identical UV-Vis absorption profiles of isolated product as compared to the
reactant demonstrated that the thioamide remained intact in Cys desulfurization
(normalized A272

nm

= 0.48 for both product and reactant). These results gave us

confidence that the thioamide was indeed compatible with the radical initiated
desulfurization/deselenization methods. Given that β-thiol analogs are much easier to
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handle than β-selenol compounds in terms of synthetic efforts and air-sensitivity, we
decided to pursue VA-044 desulfurization as the primary method for traceless NCL
incorporation of thioamides, and reserve TCEP deselenization for situations where
additional selectivity against Cys is needed.

(3)

(3a)

3

3a

3a’

3
*

3a
*

*

3a’

Figure 3-8. Selective Desulfurization of Cys in the Presence of Thioamide.
A) Schematic representation of the test reaction. B) HPLC chromatogram monitored at 325
nm. 3a’ denotes a genuine product standard synthesized via solid phase peptide synthesis
+
(SPPS) for comparison. MALDI-TOF MS: [3 + H] , expected 1482.62, found 1482.66; [3a +
+
+
H] , expected 1450.64, found 1450.70; [3a’ + H] , expected 1450.64, found 1450.74. C) UVVis absorption of isolated peptides. Star indicates thioamide absorption. Conditions: 0.1 mM
peptide 3, 10 mM VA-044, 40 mM TCEP, 200 mM Na2HPO4, 10% tBuSH (v/v) pH 7.0.

110

To optimize the VA-044 desulfurization reaction, we systematically varied individual
components of the reaction to identify their optimal concentration. We found that high
TCEP concentration was necessary to avoid disulfide bond formation (Figure 3-22),
which was likely an off-pathway product from collisional quenching of thiol radicals
(Figure 3-9). A high concentration of TCEP serves the dual function of ensuring the
prompt scavenging of thiol radical for on-pathway desulfurization, and reducing the
disulfide bonded side product to reverse the off-pathway reaction. We also found that the
reaction was tolerant to a wide range of VA-044 concentrations, and no complications
were observed with as high as 1000 equivalents of VA-044 (Figure 3-23). We reasoned
that since the majority of reactive radicals were propagated from the thiol additive
present at 10% (v/v), the reaction was relatively insensitive to VA-044 excess as long as
it was above a critical concentration (empirically 10 equivalents for this test reaction). In
addition, we showed that dissolved oxygen – which may function as collisional radical
quencher – was well-tolerated (Figure 3-24). Only minor alterations in reaction kinetics
were observed with no additional complications, eliminating the need to keep the reaction
buffer degassed and making it easier for other research groups to adopt our methodology.

Figure 3-9. Proposed Mechanism for Off-Pathway Disulfide Bond Formation.
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Upon a closer examination of the robustness of chemoselectivity against the
thioamide, we observed that after prolonged exposure to the radical environment, a
thioamide-to-oxoamide conversion side product 3b gradually accumulated over time
(Figure 3-26). Although 3b only represented a 6% side reaction after 2 h, it became
significant after 18 h (17% side product formation). We hypothesize that this is due to the
amide-to-imine equilibrium, where the stable C=S bond is converted to a labile C−S bond
as part of the transformation (Figure 3-10). Since this equilibrium is intrinsic to the
thioamide bond, we turned to “suicide scavengers” in order to suppress the side reaction.

Figure 3-10. Proposed Mechanism for Radical Initiated Thioamide Desulfurization.

After screening a few thiocarbonyl-containing small molecules as candidates, we
identified thioacetamide as the most effective “suicide scavenger”. Its utility as a
desulfurization chaperon can be clearly demonstrated on model peptide 3a’ (we use a
prime symbol to denote the genuine peptide standards in order to distinguish them from
species identified in desulfurization reactions) – when we treated 3a’ with VA-044 in the
absence of thioamide, side product 3b was generated at 16% by 18 h; in the presence of
thioacetamide, 3a’ was fully stable for the same time frame (Figure 3-11B). When we
applied this additive to the Cys/thioamide peptide 3, the protective effect was equally
profound – by suppressing thioamide side reaction, the yield of desired product 3a was
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(3a)

(3b)
3a’ + VA-044

3a
3b

3a

3 + VA-044

3b

3a

3a

3b’
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*
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Figure 3-11. Thioacetamide as Chaperon to Suppress Thioamide Side Reaction.
A) Schematic representation of the test reaction. B) Treatment of control peptide 3a’ with
VA-044 in the absence and presence of thioacetamide. HPLC chromatograms monitored at
+
+
325 nm. MALDI-TOF MS: [3a + H] , expected 1450.64, found 1450.74; [3b + H] , expected
1434.67, found 1434.87. C) Desulfurization of peptide 3 in absence and presence of
+
+
thioacetamide. MALDI-TOF MS: [3a + H] , found 1450.46; [3b + H] , found 1434.44. D) UVVis absorption spectra of isolated 3b compared to a genuine standard 3b’. 3a’, 3b’ denotes
the genuine standards synthesized by solid phase peptide synthesis. Star sign indicates the
absence of thioamide absorption at 272 nm. Conditions: 0.1 mM peptide 3a’ or 3, 10 mM VA044, 40 mM TCEP, 200 mM Na2HPO4, 10% tBuSH (v/v) pH 7.0, 18 h.
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improved from 58% to 88% after an 18 h reaction (Figure 3-11C). It is worth noting that
the residual peak at 21.8 min represented a 2% Cys-to-Ser conversion side reaction rather
than thioamide-to-oxoamide conversion, which is rigo-rously characterized in Materials
and Methods (Figure 3-30). As a further validation, we demonstrated that the supperssion was effective over a wide range of thioacetamide concentrations (Figure 3-27), and
that the oxygen and denaturant tolerance of VA-044 desulfurization was unaltered by the
addition of thioacetamide (Figure 3-28).

Having established a robust method for selective Cys desulfurization on thioamidecontaining peptides, we next sought to investigate its application in traceless native
chemical ligation (NCL) – joining two peptide fragments using Cys as a ligation handle,
and subsequently “erasing” it into an Ala after ligation. There are two general ways to
achieve ligation-desulfurization – with or without an intermediate purification step on the
ligated Cys peptide. The latter is obviously advantageous in terms of purification efforts,
but chemically more challenging as it requires all reagents used in ligation to be compatible with desulfurization. A particular reagent of concern is the aromatic thiol, typically
thiophenol (PhSH) or 4-mercaptophenylacetic acid (MPAA), that is a common additive
to accelerate ligation by converting alkyl thioesters into reactive aryl thioesters 136, but
also a radical quencher that would sequester the reactivity of tBuS∙ radicals294 (Figure
3-12).
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Figure 3-12. Effects of Aromatic Thiols on One-Pot Ligation Desulfurization.

To solve this problem, we attempted using CF3CH2SH as a non-aromatic substitute
for aromatic thiols as advocated in a prior study from Payne’s group;294 unfortunately,
this method did not yield successful ligation in our test reactions, presumably due to the
high volatility of CF3CH2SH (boiling point 34 °C). Upon a closer examination of
properties of the various thiols295, we hypothesized – contrary to previous claims by other
groups294 – that PhSH can be effectively removed by lyophilization if the pH was kept
sufficiently low to maintain it in the thiol-free form (Figure 3-13). The thiol-free residue
can then be brought up in fresh buffer and desulfurized, without the need of additional
purification steps for PhSH removal.

Figure 3-13. Schematic Representation of Thiol/Thiolate Equilibrium of PhSH.
See Materials and Methods for theoretical calculations of residual PhSH concentrations from
a saturated PhSH solution after lyophilization at different pH.
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Using thioester 4a and Cys-containing peptide 4b, we demonstrated that one-pot
ligation-desulfurization can be successfully performed in the presence of aromatic thiol
PhSH, by adopting the simple procedure of acidification and lyophilization (Figure 3-14).
Both ligation product 4c and desulfurization product 4d perfectly matched the genuine
peptide standards − 3 and 3a’, respectively − in MALDI-TOF MS, UV-Vis absorption
and HPLC retention time. Notably, the presence of 7-methoxycoumarin and thioamide
chromophores deriving from the two fragments was clearly exemplified. With thioacetamide present as a desulfurization chaperon, no thioamide-to-oxoamide conversion
was observed.

With an effective strategy for one-pot ligation-desulfurization, one constraint still
remains − VA-044 initiated desulfurization would indiscriminately desulfurize all Cys in
the sequence, limiting its application to proteins without endogenous Cys. To remove this
constraint, we turned to selective deselenization, where Sec can be selectively converted
into Ala by TCEP while leaving Cys intact216. Having previously demonstrated the
compatibility of the thioamide with deselenization (see Figure 3-6), we synthesized a
Sec/Cys/thioamide-containing peptide 5, and subjected it to the standard deselenization
procedure. Much to our surprise, while the thioamide was unaffected throughout the
reaction, both selective deselenization on Sec and non-selective desulfurization on Cys
took place, giving a mixture of 55% Ala/Cys product 5a and 12% Ala/Ala product 5b
(Figure 3-15).

116

A)
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(4a)

(4c)

(4d)
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4a

4b

4c

4c

4d

Figure 3-14. One-Pot Ligation-Desulfurization of Thioamide-Containing Peptides.
A) Schematic representation of the test reaction. B) HPLC chromatograms monitored at 325
nm (4b at 272 nm) and UV-Vis absorption spectra of major peak in each chromatogram.
+
+
MALDI-TOF MS: [4c + H] , expected 1482.62, found 1482.47; [4d + H] , expected 1450.64,
found 1450.82. Star sign indicates thioamide absorption at 272 nm. Ligation: 1 mM thioester
4a, 1 mM peptide 4b, 40 mM TCEP, 200 mM Na2HPO4, pH 7.0, overnight. Desulfurization:
0.1 mM reaction crude 4c, 10 mM VA-044, 40 mM TCEP, 200 mM Na2HPO4, 10% tBuSH
(v/v) pH 7.0, 2 h. See Figure 3-8 for genuine standards 3 and 3a’. See Materials and
Methods for residual PhSH characterization.
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Figure 3-15. Selective Deselenization of Sec in the Presence of Cys and Thioamide.
A) Schematic representation of the test reaction. B) HPLC chromatograms monitored at 325
+
+
nm. MALDI-TOF MS: [5 + H] , expected 1148.37, found 1148.56; [5a + H] , expected
+
1070.48, found 1070.74; [5b + H] , expected 1038.50, found 1038.73. C) UV-Vis absorption
spectra of reactant and isolated products. Star sign indicates thioamide absorption at 272 nm.
Conditions: 0.1 mM peptide 5, 40 mM TCEP, 40 mM DTT, with or without 10 mM MPAA, 200
mM Na2HPO4, pH 7.0, 18 h. TCEP = tris(2-carboxyethyl) phosphine; DTT = dithiothreitol;
MPAA = 4-mercaptophenylacetic acid; Mcm = 7-methoxycoumarinylalanine.
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After examining the reaction mechanism, we realized that the side reaction originates
from homolytic cleavage of Se−S bond as the first step of the deselenization reaction,
which also generates a sulfur radical that can proceed with desulfurization (Figure 3-16).
Since these intramolecular Se−S bonds formed spontaneously during peptide synthesis
and purification (in fact, we used hemiselenide protected Boc-Sec(S-iPr)-OH as the
building block, but could only isolate the intramolelar hemiselenide 5 as product), we
would need to develop a strategy to suppress the sulfur radical. Knowing that an aromatic
thiol is tolerated in one-pot ligation-deselenization (see Figure 3-6) but not in
desulfurization294,296, we hypothesized that aromatic thiol may be able to selectively
quench R−S∙ radicals but not R−Se∙ radicals, which is theoretically favorable based on a
comparison of the bond dissociation energy of Se−H bond (66 kcal mol-1) and S−H bond
(87 kcal mol-1)297 (Figure 3-17). If this is true, we should be able to selectively suppress
desulfurization side reaction using aromatic thiols, while allowing desired deselenization
to proceed without complications. Indeed, using MPAA as an aromatic thiol additive, we
were able to effectively suppress desulfurization, giving the desired product 5a in 62%
yield (Figure 3-15). While more in-depth mechanistic studies are certainly necessary to
fully characterize the reactivity of the various radicals involved, we have provided an
effective empirical method for the synthesis of thioamide-containing proteins that also
contain native Cys residues.
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Figure 3-16. Proposed Mechanism for Non-Selective Desulfurization.

Figure 3-17. Thermodynamics Prediction of Sulfur and Selenium Radical Quenching.
296

Bond dissociation energy for aromatic thiols differs by substitution , so a range is given
instead of a single value; this difference does not alter the overall predicted trends.

Finally, to demonstrate the possibility of expanding traceless NCL into non-Cys/Sec
residues, we performed a proof-of-concept desulfurization reaction with a Pen-containing
peptide 6 (Pen = penicillamine). Pen is the β-thiol analog of Val; similar to Cys, it can be
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used as a ligation handle and subsequently “erased” into the native Val202. We chose Pen
because it is a most sterically demanding member among all β-thiol analogs; the ambient
radicals will need to access a quantanery carbon center than is one bond away from the
peptide backbone in order to intiate desulfurization. Upon treatment with VA-044 in the
presence of thioacetamide, 6 was converted to desired 6a in 73% yield, with its thioamide
intact (Figure 3-18). This clearly showed the feasibility of β-thiol and β-selenol analogs
for thioamide incorporation via traceless NCL, lifting the last restriction on semisynthesis of thioamide-containing peptides and proteins.

(6)

(6a)

6

6a

6

6a

Figure 3-18. Selective Deselenization of Sec in the Presence of Cys and Thioamide.
A) Schematic representation of the test reaction. B) HPLC chromatograms monitored at 325
+
nm, and UV-Vis absorption of isolated peptides. MALDI-TOF MS: [6 + H] , expected 1482.62,
+
found 1482.56; [6a + H] , expected 1450.64, found 1450.82. Retention time: 22.4 min for 6,
and 22.7 min for 6a; the difference is small but reproducible; identities of the peptides were
confirmed by mass spectrometry. Star sign indicates thioamide absorption at 272 nm.
Conditions: 0.1 mM peptide 6, 10 mM VA-044, 40 mM TCEP, 200 mM Na2HPO4, 10% tBuSH
(v/v), pH 7.0, 18 h. TCEP = tris(2-carboxyethyl) phosphine; Mcm = 7-methoxycoumarinylalanine. With D. Miklos Szantai-Kis.
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3.3 Conclusion
We have devised a method for the traceless incorporation of thioamide into peptides
and proteins using chemoselective desulfurization/deselenization in combination with
native chemical ligation (NCL). We demonstrated that Cys can be selectively converted
into Ala using VA-044 as a radical initiator in the presence of a backbone thioamide, and
discovered that a small molecule, thioacetamide, can be used as an additive to improve
the robustness of this chemoselectivity. We also showed that by acidifying the ligation
mixture, PhSH can be effectively removed by lyophilization, enabling one-pot ligationdesulfurization that had not previously been achieved. For sequences with additional
native Cys, we showed the utility of selective deselenization, where Sec was converted
into Ala in the presence of Cys and thioamides, and identified aromatic thiols as additives
to enhance the chemo-selectivity. To expand into ligation sites other than Cys/Sec, we
demonstrated selective desulfurization of β-thiol analogs, using conversion of
penicillamine into Val as a proof-of-concept example. In conclusion, we have greatly
expanded the scope of thioamide incorporation − it is now possible to achieve NCL at
nearly any amino acid site in a target protein, which should greatly advance the adoption
of the thioamide as a minimalist probe.

3.4 Future Directions
With the methodology for thioamide incorporation in place, we are now capable of
performing “positional scanning” experiments, where a combinatorial library of target
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proteins can be generated, with thioamide and fluorophores at various positions.
Specifically, there are 15 good ligation sites in α-synuclein, where the junction is between
a small amino acid Gly or Ala and an “erasable” Ala or Val handle (Figure 3-19). This
would not only enable us to incorporate a thioamide at the N- or C-terminal region, but
also allow us to perform a tandem ligation to incorporate thioamide directly into the fibril
core (residues 65 to 95) without worrying about the perturbation of residual Cys.

1
MDVFM

6
KGLSK

35
41
G|VLYV GSKTK

11
16
21
26
31
AKEG|V VA|A|AE KTKQG |VAEA|A GKTKE
46
51
EG|VVH G|VATV

56
AEKTK

61
EQVTN

66
VGG|AV

71
76
81
86
91
VTG|VT A|VAQK TVEG|A GSIA|A |ATGFV

96
KKDQL

101
GKNEE

105
111
G|APQE GILED

131
EGYQD

136
YEPEA

116
MPVDP

121
DNEAY

126
EMPSE

Figure 3-19. α-Synuclein Sequence and Potential Traceless NCL Sites.

Of particular interest would be tandem ligation between αS1-66, αS67-89 and αS90-140.
We can synthesize the middle fragment αS67-89 using standard SPPS, with thioamides at
any Val, Ala, Glu, Gln or Lys sites. The C-terminal fragment αS90-140 would contain a
fluorophore at F94 position, which has been previously shown to be at a rigid position
just outside the fibril core47. By generating fibrils using these doubly labeled proteins, we
can extrapolate thioamide-fluorophore distances from fluorescence spectroscopy both in
the mature fibril and during the aggregation process, and start to decode the biophysical
process that is the very basis of Parkinson’s disease.
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3.5 Materials and Methods
General Information

VA-044 was purchased from Wako Pure Chemical Industries

(Osaka, Japan). Fmoc protected amino acids and peptide synthesis reagents were
purchased from EMD Millipore (Billerica, MA). All other reagents and solvents were
purchased from Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO)
unless otherwise specified. High resolution electrospray ionization mass spectra (ESIHRMS) were collected with a Waters LCT Premier XE liquid chromatograph/mass
spectrometer (Milford, MA). Low resolution electrospray ionization mass spectra (ESILRMS) were obtained on a Waters Acquity Ultra Performance LC connected to a single
quadrupole detector (SQD) mass spectrometer. UV-Vis absorption spectra were acquired
on a Hewlett-Packard 8452A diode array spectrophotometer (Agilent Technologies,
Santa Clara, CA). Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker
DRX 500 MHz instrument (Billerica, MA). Matrix assisted laser desorption/ionization
with time-of-flight detector (MALDI-TOF) mass spectra were acquired on a Bruker
Ultraflex III instrument (Billerica, MA). Analytical HPLC was performed on an Agilent
1100 Series HPLC system (Santa Clara, CA). Preparative HPLC was performed on a
Varian Prostar HPLC system (Agilent Technologies, Santa Clara, CA). HPLC columns
were purchased from W. R. Grace & Compnay (Columbia, MD).

Figure 3-20. Synthesis Scheme of Thioalanine Precursors for Thioamide Incorporation.
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Synthesis of N-Boc-1,2-phenylenediamine (S1)

1,2-Phenylenediamine (5.9478 g,

55 mmol, 1.1 equiv) was dissolved in anhydrous tetrahydrofuran (THF, 50 mL). A
solution of of di-tert-butyldicarbonate (Boc2O, 10.9125 g, 50 mmol, 1 equiv) in
anhydrous THF (50 mL) was added dropwise over 4 h on ice. Upon completion, the
reaction was quenched by slow addition of H2O (100 mL), and extracted with ethyl
acetate (100 mL×3). The organic layers were combined, dried by rotary evaporation, and
then purified by flash chromatography with 2:8 ethyl acetate/petroleum ether. A white
flake was isolated as the final product (6.9823 g, 33.5 mmol, 67% yield). Rf 0.18 in 2:8
ethyl acetate/petroleum ether. 1H-NMR (500 MHz, CDCl3): δ 7.27 (d, J = 7.6 Hz, 1H),
6.99 (t, J = 8.3 Hz, 1H), 6.77 (t, J = 7.6 Hz, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.60 (s, 1H),
3.76 (s, 2H), 1.54 (s, 9H).

13

C-NMR (500 MHz, CDCl3): δ 154.16, 140.23, 126.17,

124.82, 119.44, 117.53, 80.48, 28.48. ESI+-HRMS: calculated for C11H17N2O2+: 209.12;
found [M + H]+: 209.14.

Synthesis of α-N-Fmoc-L-alanine-(N-Boc)-2-aminoanilide (S2).

In an argon

atmosphere, Fmoc-Ala-OH (1.5567 g, 5mmol, 1 equiv) was dissolved in 50 mL of dry
tetrahydrofuran (THF) and chilled in a 1:3 NaCl : ice bath (-10 °C). With stirring, Nmethylmorpholine (NMM, 1.10 mL, 10 mmol, 2 equiv) and isobutylchloroformate
(IBCF, 0.65 mL, 5 mmol, 1 equiv) were slowly added. The reaction was stirred at -10°C
for 15 min, and N-Boc-1,2-phenylenediamine (S1, 1.0413g, 5 mmol, 1 equiv) was added.
The reaction was allowed to proceed at -10°C for 2 h, and then at room temperature
overnight (≥ 14 h). Upon completion, the solvent was removed by rotary evaporation.
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The residue was brought up in 40 mL of ethyl acetate, and extracted against 40 mL each
of 1 M Na2HPO4, brine, 5% NaHCO3, and brine. The aqueous layers were combined and
extracted against 100 mL of ethyl acetate. The organic layers were combined, dried by
rotary evaporation, and purified by flash chromatography in ethyl acetate/petroleum ether
(35:65 v/v). A pale yellow solid was yielded as the final product (1.7944 g, 3.6 mmol,
77% yield).

Rf 0.23 in 35:65 ethyl acetate/petroleum ether.

1

H-NMR (500 MHz,

CDCl3): δ 8.73 (s, 1H), 7.70 (d, J = 7.6 Hz, 2H), 7.52 (t, J = 8.0 Hz, 2H), 7.48 (d, J = 7.4
Hz, 1H), 7.33 (t, J = 8.0 Hz, 2H), 7.31 (m, 1H), 7.22 (m, 2H), 7.12 (s, 1H), 7.10 (t, J =
7.5 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 5.87 (d, J = 7.1 Hz, 1H), 4.38 (m, 1H), 4.35 (t, J =
6.4 Hz, 2H), 4.14 (t, J = 6.7 Hz, 1H), 1.44 (s, 9H), 1.41 (d, J = 7.1 Hz, 3H).

13

C-NMR

(500 MHz, CDCl3): δ 171.83, 156.25, 154.11, 143.72, 141.28, 131.39, 128.81, 127.79,
127.11, 126.57, 125.40, 125.08, 124.20, 80.75, 68.62, 51.08, 47.09, 28.32, 22.11. ESI+HRMS: calculated for C29H31N3O5Na+: 524.2161; found [M + Na]+: 524.2148.

Synthesis of α-N-Fmoc-L-thioalanine-(N-Boc)-2-aminoanilide (S3). In an argon
atmosphere, S2 (1.6593 g, 3.3 mmol, 1 equiv) and Lawesson’s reagent (1.0036 g, 2.5
mmol, 0.75 equiv) were refluxed in 30 mL of CH2Cl2 for 18 h. Upon completion, the
solvent was removed by rotary evaporation. The crude product was purified by flash
chromatography in ethyl acetate/petroleum ether (35:65 v/v) to yield a pale yellow foam
(1.5214 g, 2.9 mmol, 89% yield). Rf 0.43 in 35:65 ethyl acetate/petroleum ether.

1

H-

NMR (500 MHz, CDCl3): δ 10.09 (s, 1H), 7.69 (d, J = 7.3 Hz, 2H), 7.61 (d, J = 7.4 Hz,
1H), 7.51 (d, J = 7.6 Hz,1H), 7.49 (d, J = 7.1 Hz,1H), 7.33 (t, J = 7.4 Hz, 2H), 7.30 (m,
1H), 7.23 (m, 2H), 7.22 (m, 1H), 7.05 (t, J = 7.6 Hz, 1H), 6.91 (s, 1H), 6.04 (d, J = 6.4
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Hz, 1H), 4.67 (m, 1H), 4.31 (d, J = 6.1 Hz, 2H), 4.14 (t, J = 7.0 Hz, 1H), 1.50 (d, J = 6.6
Hz, 3H), 1.42 (s, 9H).

13

C-NMR (500 MHz, CDCl3): δ 205.90, 155.94, 153.83, 143.61,

143.56, 141,22, 141.20, 132.95, 129.64, 128.49, 127.78, 127.14, 125.11, 125.07, 124.65,
123.59, 120.01, 81.07, 67.27, 55.58, 46.99, 28.26, 22.42. ESI+-HRMS: calculated for
C29H31N3O4SNa+: 540.1933; found [M + Na]+: 540.1914.

Synthesis of α-N-Fmoc-L-thioalanine-benzotriazolide (S4) In argon atmosphere,
S3 (1.0861 g, 2.1 mmol, 1 equiv) was dissolved in 10 mL of CH2Cl2 and chilled to 0 ˚C
on ice. 10 mL of an ice cold TFA/CH2Cl2 (50:50 v/v) solution was slowly added, and the
reaction was allowed to proceed at 0 ˚C for 2 h. Upon completion, the solvent was
removed by rotary evaporation. The residue was dissolved in glacial AcOH (9.5 mL) and
water (0.5 mL), and then chilled to 0 ˚C on ice. With stirring, NaNO2 (0.2202 g, 3.2
mmol, 1.5 equiv) was added in small portions over 5 min. The reaction was allowed to
proceed at 0 ˚C for 30 min, and then quenched with 30 mL of ice cold water. The
precipitate was collected by filtration, dried on vacuum for 30 min, and then purified by
flash chromatography in ethyl acetate/petroleum ether (35:65 v/v). A yellow foam was
yielded as the final product (0.6286 g, 1.5 mmol, 69% yield). Rf 0.54 in 35:65 ethyl
acetate/petroleum ether.

1

H-NMR (500 MHz, CDCl3): δ 8.75 (d, J = 8.3 Hz, 1H), 8.12

(d, J = 8.0 Hz, 1H), 7.74 (d, J = 7.1 Hz, 2H), 7.64 (m, 2H), 7.61 (m, 1H), 7.52 (t, J = 7.4
Hz, 1H), 7.38 (t, J = 6.7 Hz, 1H), 7.30 (t, J = 6.8 Hz, 1H), 6.31 (m, 1H), 5.91 (d, J = 8.8
Hz, 1H), 4.47 (dd, J = 10.3, 7.0 Hz, 1H), 4.34 (dd, J = 10.3, 7.0 Hz, 1H), 4.22 (t, J = 6.6
Hz, 1H), 1.66 (d, J = 6.6 Hz, 3H).

13

C-NMR (500 MHz, CDCl3): δ 210.01, 155.61,

147.18, 144.03, 143.88, 141.41, 132.46, 131.68, 127.83, 127.32, 127.20, 125.32, 125.22,
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120.92, 120.11, 116.31, 67.16, 57.27, 47.33, 23.10.

ESI+-HRMS: calculated for

C24H20N4O2SNa+: 451.1205; found [M + Na]+: 451.1195.

Figure 3-21. Crystal Structure of Thioalanine Precursor.
Crystal was grown in 35:65 ethyl acetate/petroleum ether; data were acquired on a Bruker
Kappa APEX II Duo CCD diffractometer (Billerica, MA). Graphics were generated using
Schrödinger PyMOL (Cambridge, MA). C=S bond length observed: 1.6 Å.

Peptide Synthesis and Purification

Peptides were synthesized using standard

Fmoc solid phase peptide synthesis (SPPS) procedure on either Rink Amide or 2chlorotrityl chloride resin (100 - 200 mesh; 0.6 mmol substitution/g). For coupling, 5
equiv of amino acid and 5 equiv of HBTU were dissolved in dimethylforamide (DMF),
pre-activated for 1 min in the presence of 10 equiv of N,N-diisopropylethylamine
(DIPEA), and then stirred with the resin for 30 min at room temperature. For
deprotection, 20% piperidine in DMF was stirred with the resin for 20 min. Thioalanine
(denoted AlaS or AS) was introduced through activated benzotriazole precursors (S4); 2
equiv of the precursor was dissolved in dry CH2Cl2, and stirred with the resin for 45 min
in the presence of 2 equiv DIPEA. For N-terminally acetylated peptides, an acetylation
cocktail of 1:1:8 acetic anhydride/N-methylmorpholine/DMF was stirred with the resin
twice, each for 10 min, after the last deprotection. Upon completion of SPPS, resins were
rinsed thoroughly with CH2Cl2 and dried under vacuum.
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For cleavage, resins were treated with a cleavage cocktail (12:1:1:26 trifluoroacetic
acid/triisopropylsilane/H2O/CH2Cl2) for 30 min. The solution was then collected by
filtration, and dried by rotary evaporation. For purification, the crude residues were
brought up in 1:10 CH3CN/H2O, and then purified by reverse phase HPLC with acidified
(with 0.1% trifluoroacetic acid) CH3CN/H2O gradients. Individual fractions were characterized by MALDI-TOF MS, and dried by lyophilization. When necessary, the isolated
products were subjected to multiple rounds of purification until 99.5% pure by MALDITOF MS and analytical HPLC. Solvent radients, retention times and MALDI-TOF MS
results are listed in Table 3-1 through Table 3-3.

Table 3-1. Peptide Purification Methods and Retention Time.
Gradient

Retention
Time

Ac-LASAKAGCAKXAG-NH2 (1)

1

23.1 min

Vydac C18 Semi-prep

Ac-LASAKAGAAKXAG-NH2 (1b)

1

22.3 min

Vydac C18 Semi-prep

Ac-GL KXAG-CPGo (2a)

4

22.0 min

YMC-Pack Pro C8 Semi-prep

Ac-XTTEAVDACTASAK-NH2 (3)

5

16.0 min

Vydac C18 Semi-prep

Ac-XTTEAVDAATA AK-NH2 (3a’)

6

21.6 min

Vydac C18 Semi-prep

Ac-XTTEAVDAATAAK-NH2 (3b’)

6

19.9 min

Vydac C18 Semi-prep

Ac-XTTEAVDASTA AK-NH2 (S7’)

6

19.7 min

Vydac C18 Semi-prep

Ac-XTTEAVDACTAAK-NH2 (S8’)

6

21.2 min

Vydac C18 Semi-prep

Ac-XTTEAVDA-SC2H4COOCH3 (4a)

7

17.6 min

YMC-Pack Pro C8 Semi-prep

CTASAK-NH2 (4b)

8

12.8 min

Vydac C18 Semi-prep

9

24.5 min

YMC-Pack Pro C8 Semi-prep

10

34.6 min

Vydac C18 Prep

Peptide

S

S

S

S

UTA ACVFKX-NH2

Se−S

(5)**

Ac-XTTEAYDAATASAK-NH2 (6)

Column

* X = 7-methoxycoumarinylalanine; Y = penicillamine; U = selenocysteine; Go = glycolic acid.
** The “Se-S” superscript denotes that 5 was isolated as an intramolecular hemiselenide species.
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Table 3-2. HPLC Gradients for Peptide Purification and Characterization.
Time
(min)

%B

No.

1

0:00
5:00
10:00
25:00
30:00
35:00
40:00

2
2
15
30
100
100
2

4

0:00
10:00
15:00
30:00
35:00
40:00
45:00

7

10

No.

Time
(min)

%B

No.

Time
(min)

%B

2

0:00
5:00
10:00
25:00
30:00
35:00
40:00

2
2
20
50
100
100
2

3

0:00
8:00
10:00
30:00
35:00
40:00
45:00

2
2
10
50
100
100
2

2
2
20
50
100
100
2

5

0:00
5:00
10:00
25:00
30:00
35:00
40:00

2
2
25
40
100
100
2

6

0:00
5:00
10:00
25:00
30:00
35:00
40:00

2
2
20
35
100
100
2

0:00
5:00
10:00
30:00
35:00
40:00
45:00

2
2
25
45
100
100
2

8

0:00
5:00
10:00
20:00
25:00
30:00
35:00

2
2
10
20
100
100
2

9

0:00
5:00
10:00
40:00
45:00
50:00
55:00

2
2
20
50
100
100
2

0:00
5:00
15:00
45:00
50:00
55:00
60:00
60:00

5
5
22
28
100
100
5
5

* Solvent A: 0.1% trifluoroacetic acid in water; Solvent B: 0.1% trifluoroacetic acid in acetonitrile

Table 3-3. MALDI-TOF MS Characterization of Purified Peptides.
Peptide

[M + H]+

[M + Na]+

Calc’d

Found

Calc’d

Found

1262.59

1262.63

1282.58

1284.62

Ac-LA AKAGAAKXAG-NH2 (1b)

1230.62

1230.78

1252.61

1252.77

Ac-GLSKXAG-CPGo (2a)

1005.41

1005.35

1027.40

1027.33

1482.62

1482.42

1504.61

1504.41

Ac-LASAKAGCAKXAG-NH2 (1)
S

S

Ac-XTTEAVDACTA AK-NH2 (3)
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Table 3-3 (cont’d). MALDI-TOF MS Characterization of Purified Peptides.
[M + H]+

Peptide

[M + Na]+

Calc’d

Found

Calc’d

Found

Ac-LASAKAGCAKXAG-NH2 (1)

1262.59

1262.63

1282.58

1284.62

Ac-LASAKAGAAKXAG-NH2 (1b)

1230.62

1230.78

1252.61

1252.77

Ac-GL KXAG-CPGo (2a)

1005.41

1005.35

1027.40

1027.33

Ac-XTTEAVDACTASAK-NH2 (3)

1482.62

1482.42

1504.61

1504.41

Ac-XTTEAVDAATA AK-NH2 (3a’)

1450.64

1450.80

1472.63

1472.79

Ac-XTTEAVDAATAAK-NH2 (3b’)

1434.67

1434.81

1456.66

1456.80

Ac-XTTEAVDASTA AK-NH2 (S7’)

1466.64

1466.74

1488.63

1466.72

Ac-XTTEAVDACTAAK-NH2 (S8’)

1466.64

1466.80

1488.63

1466.81

Ac-XTTEAVDA-SC2H4COOCH3 (4a)

1095.41

-

1117.40

1117.45

CTASAK-NH2 (4b)

508.23

508.37

530.22

530.34

1148.37

1148.46

1170.36

1170.44

1482.62

1482.56

1504.61

1504.55

S

S

S

S

UTA ACVFKX-NH2

Se−S

(5)**

Ac-XTTEAYDAATASAK-NH2 (6)

* X = 7-methoxycoumarinylalanine; Y = penicillamine; U = selenocysteine; Go = glycolic acid.
** 5 was isolated as an intramolecular hemiselenide species.

Raney Nickel Desulfurization

Peptide 1 (10 nmol, ε325 = 12,000 M-1 cm-1) was

dissolved in desulfurization buffer (100 µL, 100 mM Na2HPO4, 10 mM TCEP, pH 5.8),
and then Raney nickel (0.1 mg) was added. The reaction was allowed to proceed at room
temperature for 12 h, and then supernatant was recovered by centrifugation at 13.2 krpm
for 20 min. The crude was analyzed by analytical RP-HPLC on a Luna C8 analytical
column using gradient 2. Individual fractions were collected manually, and then analyzed
by MALDI-TOF and UV-Vis absorption spectroscopy.

Synthesis of Reduced Ac-GLSKXAG-CPGo (2a)

Ac-GLSKXAG-CbPGo (S5) with

a side chain tBuS− protecting group was synthesized as we described previously283. To
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generate the reduced 2a, S5 (200 nmol, ε325 = 12,000 M-1 cm-1) was mixed with 100 µL
of reduction buffer (40 mM TCEP, 200 mM Na2HPO4, pH 6.8) and 20 µL of CH3CN.
The reaction was allowed to proceed at 37 ˚C for 1 h. Upon completion, CH3CN (80 μL)
was added, and the supernatant was recovered by centrifugation at 13.2 krpm for 20 min.
The crude was diluted into H2O (800 μL), and then purified by reverse phase HPLC
(Table 3-1). Isolated product was characterized by MALDI MS (Table 3-3), quantified by
UV-Vis absorption, split into 20 nmol aliquots, and then lyophilized until further use. X =
7-methoxycoumarinylalanine; Go = glycolic acid.

One-Pot Ligation Deselenization with Selenocystine

A phosphate buffer stock

(200 mM Na2HPO4, pH 8.0) and a 5 M NaOH solution were freshly degassed using the
freeze-pump-thaw method. 2% (v/v) PhSH was added to the buffer stock, and pH was
quickly adjusted back to 8.0 using the degassed 5 M NaOH solution under an argon
atmosphere. A 1.1x L-selenocystine stock (2.2 mM) was prepared by dissolving L-selenocystine (0.0007 g, 2.2 µmol) in the above buffer (1 mL). To thioester 2a (20 nmol, ε325 =
12,000 M-1 cm-1), 10 µL of CH3CN and 90 uL of the 1.1x L-selenocytine stock (final
concentration 2 mM, 10 equiv) was added. The reaction was allowed to proceed at 37 °C
for 12 h under an argon atmosphere.

For deselenization, a 50 µL aliquot of the ligation reaction was removed, and directly
added to 50 µL of 2x deselenization buffer stock (40 mM TCEP, 40 mM DTT, 200 mM
Na2HPO4, pH 8.0) that had been freshly degassed by freeze-pump-thaw method. The
reaction was allowed to proceed at 37 °C overnight (≥ 14 h) under an argon atmosphere.
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Upon completion, both ligation and deselenization crudes were diluted with argon-purged
H2O, and then analyzed by reverse phase HPLC on a Luna C8 column using gradient 2.
Individual fractions were recovered, and analyzed by MALDI-TOF MS and UV-Vis
absorption spectroscopy.

VA-044 Desulfurization of Cys/Thioamide-Containing Peptide

Peptide 3 (10

nmol, ε325 = 12,000 M-1 cm-1) was dissolved in 80 µL of argon-purged 1.25x buffer stock
(50 mM TCEP, 125 mM Na2HPO4, pH 7.0). 10 µL of tBuSH was added, followed by 10
µL of freshly prepared 10x VA-044 stock (100 mM in argon-purged water). The reaction
was allowed to proceed at 37 °C for 10 min under argon atmosphere, and then quickly
quenched by chilling to 0 °C on ice. Excess tBuSH was removed by a stream of argon,
and then the crude mixture was diluted into H2O for analysis by reverse phase HPLC on a
Luna C8 analytical column using gradient 3. Fractions were collected, and then analyzed
by MALDI-TOF MS and UV-Vis absorption spectroscopy. Yield was quantified by
integrating peak areas in HPLC chromatogram.

TCEP Dosage Dependence

The reactions were conducted similarly to the standard

procedure, except that 1.25x buffer stocks of various TCEP concentration were used, and
that a 2 h reaction time was adopted. At low TCEP concentrations, side product S6 was
observed, with a disulfide bond between Cys and ambient tBuSH (Figure 3-22). The side
product was not observed at high TCEP concentrations.
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(S6)

S6
3a

3a
S6

3a

Figure 3-22. TCEP Dosage Dependence and Generation of Disulfide Bonded Side Product.
+

MALDI-TOF MS: [S6 + H] , expected 1570.65, found 1570.74.

VA-044 Dosage Dependence

Reactions were conducted similarly to the standard

procedure, except that 10x VA-044 stocks at various concentrations were used for 2 h or
18 h (Figure 3-23). Above 0.1 mM, no distinction was observed at the range of VA-044
concentrations tested. At very low VA-044 concentration, however, the reaction was
significantly slower and messier − at 2 h, while all other conditions showed complete
reaction, minimal product formation was observed at 0.01 mM VA-044. At 18 h, the
reaction was still not complete, with additional side peaks in the chromagram.
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3a

3a

3a

3a

3
3a

3a
3

Figure 3-23. VA-044 Dosage Dependence on Chemoselective Cys Desulfurization.

Oxygen Tolerance

Reactions were conducted similarly to the standard procedure,

except that an undegassed buffer stock was used with 5 min or 10 min reaction time.
While both reactions completed within 10 min, the undegassed condition resulted in a
slightly slower kinetics – 80% complete (as measured by reactant consumed) by 5 min as
compared to 89% complete for the degassed condition (Figure 3-24).
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3a

3a
3

3a
3

Figure 3-24. Oxygen Tolerance on Chemoselective Cys Desulfurization.

Denaturant Tolerance

Reactions were conducted similarly to the standard proce-

dure, except that a 1.25x buffer stock with denaturant was used with 2 h reaction time.
No difference was found as compared to denaturant free conditions (Figure 3-25).

3a

3a

Figure 3-25. Denaturant Tolerance on Chemoselective Cys Desulfurization.
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Prolonged Reaction with Cys/Thioamide-Containing Peptide

Reactions were

conducted similarly to the standard procedure, except that longer reaction times were
adopted. Side products, particularly 3b, accumulated over time (Figure 3-26).

3a

3a

3a
3b

Figure 3-26. Accumulation of Non-Selectively Desulfurized Side Product over Time.

Thioacetamide Dosage Dependence

Reactions were conducted similarly to the

standard procedure, except that buffers with various concentrations of thioacetamide
were used with 18 h reaction time. Suppression of thioamide-to-oxoamide conversion
was effective over the wide range of concentrations tested; at very high concentration,
thioacetamide may quench ambient radicals, leading to slower kinetics (Figure 3-27).

Oxygen and Denaturant Tolerance in the Presence of Thioacetamide

Reactions

were conducted similarly to the control reactions without thioacetamide for 18 h. No
distinction was found with the addition of thioacetamide (Figure 3-28).
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3a

3a

3a

Figure 3-27. Thioacetamide Dosage Dependence on Thioamide Protection.

3a

3a

3a

Figure 3-28. Oxygen and Denaturant Tolerance in the Presence of Thioacetamide.

Characterization of Cys-to-Ser Conversion Side Products We were surprised to
find a residual peak at 21.8 min even in the presence of thioacetamide, which should
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suppress thioamide-to-oxoamide conversion and abolish side product 3b. Upon a closer
examination of the MALDI-TOF MS and UV-Vis absorption spectra (Figure 3-30), we
realized that the residual peak represents a separate side product S7 where a Cys-to-Ser
conversion took place with thioamide intact. The conversion could result from quenching
of alkyl radical by water or dissolved oxygen in the reaction solution (Figure 3-29); in
fact, a similar conversion had been reported for oxygen-related complications in Sec
deselenization.221,222 We believe both water and oxygen contribute to the Cys side
reaction observed here – a 2% conversion still took place in argon purged buffer, as
compared to 3% in non-degassed buffer.

Figure 3-29. Proposed Mechanism for the Cys-to-Ser Conversion Side Reaction.

To prove the identity of the residual peak, we synthesized three control peptides −
Ala/oxoamide peptide 3b’, Ser/thioamide peptide S7’, and Cys/ oxoamide peptide S8’
(prime symbol denotes the genuine peptide standards to distinguish them from species
identified in desulfurization reactions). We showed that 3b’ and S7’ both eluted at 21.8
min under the gradient used, but had vastly different UV-Vis absorption profiles. While
S8’ shares the same expected mass with S7’, it eluted at a different retention time, and of
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(3b)
(S7)
(S8)

3b

[3b+H]+
[3b+Na]+

[S7+H]+

[S7+Na]+

S7

3b’

3b’

S7’

S7’

S8’

S8’

Figure 3-30. Characterization of Cys-to-Ser Conversion Side Reaction.
A) Sequence of all side products involved. B) MALDI-TOF mass spectra and UV-Vis
absorption spectra for the 21.8 min peak isolated from reactions with or without
thioacetamide. The retention times may be similar, but peak identities were vastly different.
C) HPLC chromatrogram monitored at 325 nm and UV-Vis absorption spectra for genuine
peptide standards synthesized by solid phase peptide synthesis (SPPS). Only S7’ matches
the profile observed in reaction with thioacetamide as additive. Mcm = 7methoxycoumarinylalanine.
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course, did not exhibit thioamide absorption at 272 nm (Figure 3-30). Therefore, we
conclude that the 2% residual peak corresponded to Cys-to-Ser conversion side product
S7, and that thioamide-to-oxoamide conversion was fully suppressed by thioacetamide.

Synthesis of Ac-Mcm-TTEAVDA-SC2H4COOCH3 Thioester (4a)

Protected

precursor Ac-Mcm-TtBuTtBuEOtBuAVDOtBuA-OH (S9) was synthesized on 2-chlorotrityl
chloride resin using standard solid phase peptide synthesis (SPPS) procedure, and cleaved
with 1:1:8 acetic acid/trifluoroethanol/CH2Cl2. Lyophilized crude S9 (20 µmol, 1 equiv)
was mixed with dimethylformamide (DMF, 1 mL), tetrahydrofuran (THF, 1 mL), N,Ndiisopropylethylamine (DIPEA, 34.8 µL, 200 µmol, 10 equiv) and methyl 3-mercaptopropionate (43.3 µL, 400 µmol, 20 equiv). PyBOP (0.0520 g, 100 µmol, 5 equiv) was
added, and then the reaction was allowed to proceed at room temperature for 4 h. Upon
completion, the reaction was quenched with 0.1% trifluoroacetic acid in water (10 mL).
The precipitate was collected by centrifugation at 13.2 krpm for 20 min, and then cleaved
with 3 mL of 1:1:38 triisopropylsilane/methyl 3-mercaptopropionate/trifluoroacetic acid
for 30 min. The crude mixture was dried by rotary evaporation, and then brought up in
50:50 acetonitrile/water for purification by reverse phase HPLC. The purified product
was quantified by UV-Vis absorption (ε325 = 12,000 M-1 cm-1) and lyophilized. Mcm = 7methoxycoumarinylalanine.

Theoretical Prediction of PhS- Concentration at Various pH

Knowing that the

pKa of thiophenol is 6.6 and that its solubility is 0.08% (7.3 mM), we can theoretically
predict the concentration of PhS- at any given pH by solving the acid-base equilibrium.
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Assuming that the protonated form PhSH can be fully removed by lyophilization (typical
vacuum: 0.024 mBar << vapor pressure of PhSH: 1.8 mBar), the concentration of PhS would provide a good estimation for residual aromatic thiol/thiolate after lyophilization.
pKa = −log

[H + ] ∙ [PhS − ]
= 6.6
[PhSH]

[PhS − ] + [PhSH] = 0.726 M
⇒ [PhS − ] =

0.726 × 10−6.6
[H + ] + 10−6.6

When lyophilization is conducted at pH 7, as much as 5.2 mM of 7.3 mM total PhSH
would remain in the PhS- form, which would overwhelm the 0.1 mM peptide. When
lyophilization is carried out at pH 1, however, the residual PhS- concentration is only 18
nM, an insignificant amount with respect to the 0.1 mM peptide.

One-Pot Ligation-Desulfurization

A phosphate buffer stock (40 mM TCEP, 100

mM Na2HPO4, pH 7.0) was freshly prepared and degassed by argon purging. 2% PhSH
(v/v) was added, and then pH was quickly adjusted back to 7.0 under argon atmosphere.
Thioester 4a and peptide 4b (50 nmol each) were each dissolved in 25 µL of the above
buffer, and then combined. The reaction was allowed to proceed at 37 °C overnight.

For desulfurization, 10 µL of the ligation crude was removed, acidified with 100 µL
of 1% trifluoroacetic acid in water, and then quickly frozen and lyophilized. The crude
residue was brought up in 80 µL of freshly degassed 1.25x desulfurization buffer (50 mM
TCEP, 125 mM Na2HPO4, pH 7.0), and then tBuSH and VA-044 were added to proceed
with the standard desulfurization procedure. Upon completion, all crude reaction samples
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were diluted into H2O, and analyzed by reverse phase HPLC on a Luna C8 analytical
column using gradient 3. Individual fractions were collected, and then analyzed by
MALDI-TOF MS and UV-Vis absorption spectroscopy.

Figure 3-31. Synthetic Scheme for Sec-Containing Peptides.

Synthesis of N,N’-di-Boc-L-selenocystine (S10)

L-Selenocystine (0.1670 g, 0.5

mmol, 1 equiv) was dissolved in argon-purged H2O (4 mL) and 1,4-dioxane (4 mL), and
chilled to 0 °C on ice. Trimethylamine (900 μL, 6 mmol, 12 equiv) was added, followed
by Boc anhydride (0.2728 g, 1 mmol, 2 equiv). The reaction was allowed to proceed on
ice for 2 h, and then at room temperature overnight (≥ 12 hr) under argon atmosphere.
Upon completion, the reaction was diluted with H2O (18 mL), acidified with 3 M
hydrochloric acid (3 mL), and then quickly extracted with ethyl acetate (30 mL × 3). The
organic layers were combined, concentrated by rotary evaporation, and then purified by
flash chromatography in 0.1% acetic acid in ethyl acetate. A pale yellow foam was
isolated as the product (0.2383 g, 0.45 mmol, 89% yield). Rf 0.15 in ethyl acetate with
0.1% acetic acid. 1H-NMR (500 MHz, CDCl3): δ 8.93 (s, 2H), 5.65 (d, J = 6.9 Hz, 1H),
4.57 (m, 2H), 3.48 (m, 2H), 3.40 (dd, J = 12.7, 5.6 Hz, 2 H), 1.44 (s, broad, 18 H). 13CNMR (500 MHz, CDCl3): δ 174.95, 155.84, 81.18, 54.01, 33.34, 28.66. ESI--HRMS:
calculated for C16H27N2O8Se2-, 535.0098; found [M - H]- 535.0095.
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Synthesis of Boc-Sec(S-iPr)-OH (S11)

S10 (0.1681 g, 0.31 mmol, 1 equiv) was

dissolved in argon-purged tetrahydrofuran (THF, 5 mL). Triethylamine (439 μL, 3.2
mmol, 10 equiv) was added, followed by 2-propanethiol (599 μL, 6.3 mmol, 20 equiv).
The reaction was allowed to proceed at room temperature for 3 h under argon
atmosphere. Upon completion, the reaction mixture was dried by rotary evaporation. The
residue was brought up in H2O (10 mL), acidified with 3 M hydrochloric acid (1 mL),
and quickly extracted with ethyl acetate (10 mL × 3). Organic layers were combined,
concentrated by rotary evaporation, and then purified by flash chromatography in 5:5
ethyl acetate/ petroleum ether with 0.1% acetic acid. A white foam was isolated as the
final product (0.2005 g, 0.59 mmol, 93% yield). Rf in 0.27 in 5:5 ethyl acetate/petroleum
ether with 0.1% acetic acid. 1H-NMR (500 MHz, CDCl3): δ 5.43 (d, J = 6.9 Hz, 1H), 4.63
(dd, J = 11.3, 6.9 Hz, 1H), 3.33 (dd, J = 12.5, 4.2 Hz, 1H), 3.24 (dd, J = 12.1, 6.5 Hz,
1H), 3.03 (septet, J = 6.7 Hz, 1H), 1.46 (s, 9H), 1.32 (d, J = 6.6 Hz, 6H). ESI+-HRMS:
calculated for C11H21NO4SSeNa 366.0254, found [M + Na]+ 366.0252.

Synthesis of Sec-Containing Peptide

Peptide 5 was synthesized using standard

solid phase peptide synthesis (SPPS) procedure on Rink amide resin. Sec was introduced
as Boc-Sec(S-iPr)-OH (S11) using standard HBTU activation method. The peptide was
cleaved with 12:1:1:26 trifluoroacetic acid/2-propanethiol/triisopropylsilane/CH2Cl2, and
then purified by reverse phase HPLC. 5 was isolated as the primary product, with an
intramolecular hemiselenide bond between Sec and Cys.
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Deselenization of Sec/Cys/Thioamide-Containing Peptide

Deselenization buffer

(40 mM TCEP, 40 mM DTT, 200 mM phosphate, pH 7.0) was freshly prepared and
degassed by the freeze-pump-thaw method. Peptide 6 (10 nmol, ε325 = 12,000 M-1 cm-1)
was dissolved in 100 µL of the above buffer, and then the reaction was allowed to
proceed at 37 ˚C for 18 h. Upon completion, the reaction was chilled to 0 ˚C on ice, and
then 100 µL of argon-purged CH3CN was added. The supernatant was recovered by
centrifugation at 13.2 krpm for 20 min, diluted into argon-purged H2O (650 μL), and then
analyzed by reserve phase HPLC on a Luna C8 analytical column using gradient 3.
Fractions were collected and analyzed for MALDI-TOF MS and UV-Vis absorption.

4-Mercaptophenylacetic Acid (MPAA) as Deselenization Additive

Reaction was

conducted similarly to the standard procedure, except that a buffer stock containing 10
mM MPAA was used. MPAA was chosen over PhSH for its low volatility.

Synthesis of Pen-Containing Peptide

Fmoc-Pen(Trt)-OH was purchased from

Sigma-Aldrich (St. Louis, MO), and incorporated into peptide 6 sequence using standard
solid phase peptide synthesis (SPPS) procedure.

Desulfurization of Pen/Thioamide-Containing Peptide

Reaction was conducted

using standard desulfurization procedure with thioacetamide. Briefly, Peptide 6 (10 nmol,
ε325 = 12,000 M-1 cm-1) was dissolved in 80 µL of argon-purged 1.25x buffer stock (50
mM TCEP, 125 mM thioacetamide, 125 mM Na2HPO4, pH 7.0). tBuSH and VA-044
stock were then added, and the reaction was allowed to proceed at 37 °C for 18 h. The
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crude was analyzed by reverse phase HPLC on a Luna C8 analytical column using
gradient 3, and characterized by MALDI-TOF MS and UV-Vis absorption spectroscopy.
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Chapter 4 . Chemoenzymatic Incorporation of Selenocysteine onto the Protein Nterminus by Aminoacyl Transferase (AaT)
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4.1 Introduction
Having established a robust method for thioamide incorporation through traceless
native chemical ligation (NCL), we have one last challenge to address – the installation
of “erasable” ligation handles onto expressed protein fragments. For short peptides,
ligation handles such as selenocysteine (Sec) and β-thiol/selenol amino acid analogs can
be conveniently introduced by solid phase peptide synthesis (SPPS). However, SPPS has
an inherent length limit (typically 70 aa)270, beyond which synthesis and purification
would become prohibitively difficult. Therefore, when an expressed protein C-terminal
fragment is required for ligation sites that are far from the C-terminus, a new approach
for Sec/analog attachment must be developed.

The conventional way to generate N-terminal Xaa protein fragments is through fusion
protein expression. As demonstrated in our preparation of αS9-140C9,283 a construct with
an N-terminal purification tag and a protease recognition sequence can be expressed,
after which the N-terminal Cys is revealed by proteolysis (Figure 4-1A). To apply this
method to N-terminal Sec/analog fragments, however, we would also need to adopt
unnatural amino acid (Uaa) mutagenesis272 for translational insertion of Sec/analog into
the

fusion

protein.

This

would

be

overwhelmingly complex

in

terms

of

validation/optimization efforts – at the bare minimum, we will need to evolve an
orthogonal synthetase-tRNACUA pair for the analogs, ensure that all analogs are
metabolically stable and nontoxic for cellular expression, and identify a protease that
would tolerate a β-branched side chain at the cleavage site. If the unnatural side chains
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are not readily tolerated by the ribosome, we would also need to evolve a modified
ribosome for ligation handle incorporation.

Figure 4-1. Methods for Sec and β-Thiol Analog Installation onto Expressed Proteins.
A) Fusion protein expression with unnatural amino acid (Uaa) mutagenesis. A TAG codon is
introduced into the fusion protein construct at the desired site of ligation; a specifically
evolved synthetase (RS) charges tRNACUA with an unnatural amino acid, and “reads through”
the TAG codon which would otherwise be interpreted as a “stop” codon. B) Post-translational
enzymatic modification. Target protein is produced by regular cellular expression, and then
N-terminally modified by an appropriate enzyme to install the Sec/analog.

In contrast, post-translational enzymatic modifications present a much simpler and
arguably more versatile option (Figure 4-1B). Rather than evolving an entire cellular
expression machinery for these ligation handles, we just need to identify (or evolve) an
appropriate enzyme that could transfer synthetic moieties like Sec and β-thiol analogs
site-specifically onto the N-termini of expressed proteins. If viable, this strategy would
have two major advantages: 1) with minimal deviation from regular recombinant protein
production procedure, very little optimization is necessary for target protein expression
and handling; 2) conducting the modification ex vivo with a single enzyme gives us
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nearly full control over key variables, where we can quickly screen substrates, optimize
reaction conditions and evolve the enzyme for incorporation of our desired analogs.

A naturally-existing enzyme that performs exactly this type of modifications is E. coli
aminoacyl transferase (AaT), a component of the prokaryotic N-end degradation pathway
(Figure 4-2). AaT recognizes an N-terminal Lys or Arg on an expressed protein, and then
attaches a Leu or Phe onto the N-terminus from a tRNA donor258. In E. coli, this serves as
a means to tag proteins for degradation; the L/F-K/R motifs are recognized by an
“adapter protein” ClpS, which then transports the tagged proteins to a proteolytic
complex for degradation. 256 From a protein engineering perspective, this unique Nterminal amide bond formation capability presents an excellent opportunity for selective

Figure 4-2. Aminoacyl Transferase (AaT) as a Protein Engineering Tool.
A) Biological function of AaT in the E. coli N-end degradation pathway. AaT transfers a Leu or
Phe onto the exposed Arg or Lys on the protein N-terminus, which results in an N-terminal
L/F-R/K motif that is recognized as a degradation signal. B) AaT as a protein engineering
tool. When AaT is used in isolate without the other components of the N-end degradation
pathway, the enzyme can be repursposed for transfer of natural or unnatural amino acids
onto the protein N-terminus.

150

protein N-terminal modification − when used in isolation (i.e. in the absence of other
components of N-end degradation pathway), AaT can be adapted as a tool to incorporate
a variety of natural or synthetic amino acids site-specifically onto the protein N-terminus.

AaT was discovered in the 1960s from E. coli cell lysate for its ability to transfer Leu
or Phe onto proteins257,258. It was later established that the AaT modification was specific
to the protein N-terminus259, and that the anticodon of the tRNA was unneccesary for the
AaT recognition of aminoacylated tRNA as its substrate263. In early protein engineering
studies

264,265,267

, AaT has been used by Sisido and Tirrell for the proof-of-concept

incorporation of unnatural amino acids such as acridone and fluorinated leucine. In our
own group, we were able to greatly simplify the substrate synthesis and screening process
by adopting a minimal adenosine donor (Figure 4-3)268 – while full-length aminoacyltRNA is the natural substrate, only the last adenosine on the acceptor stem is essential for
AaT recognition and activity261. This allows us to take an efficient “chemoenzymatic”
approach, where adenosine donors of unnatural amino acids are chemically synthesized
through simple organic transformations, and then directly screened for activity as AaT
substrates without being limited by the RS specificity in the tRNA-charging step. Using
this approach, we were able to identify novel AaT substrates such as benzo-phenone or
disulfide protected amino acids in our previous work268,269.
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Figure 4-3. Aminoacyl Adenosine Donors as Minimal AaT Substrates.
Top: Fully Enzymatic Approach. Desired amino acid is charged onto a tRNA by its corresponding synthetase (RS), which is then utilized by AaT as a substrate. Bottom: Chemoenzymatic Approach. An amino acid/adenosine conjugate is directly used as donor for AaT
268
mediated protein N-terminal modification. Adapted from Wagner et al.

By examining the known substrate scope and crystal structures of AaT,261, 264-265, 267269

we hypothesized that the AaT-mediated N-terminal modification strategy would be

applicable to hemiselenide protected selenocysteine (Sec) using wildtype AaT without
additional directed evolution. AaT is a somewhat “promiscuous” enzyme; it has equal
preference between its natural substrates Leu and Phe, and has been shown to tolerate a
variety of unnatural substrates in reconstituted ex vivo systems (Figure 4-4). In the crystal
structure with a Phe-adenosine substrate bound, there is a small void space next to the εcarbon of Phe that could tolerate side chain extension (Figure 4-5); with the precedence
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Figure 4-4. Selected Natural and Unnatural Substrates of AaT.
See Introduction chapter for a complete summary of known AaT substrates. We have shown
269
previously that un-protected Cys and homocysteine (Hcs) are not viable substrates .

Figure 4-5. Crystal Structure and Contact Scheme of AaT Substrate Binding Pocket.
261

Crystal structure adapted from Watanabe et al. (PDB: 2Z3K) ; residues in direct contact
with substrate Phe side chain (within 5 Å) are highlighted in purple; certain non-contact
segments are omitted for clarity. A small void space is present next to the ε-carbon (pink
dotted circle).
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of disulfide protected homocysteine and polyaromatic amino acids, we also expect good
conformational flexibility of this binding pocket for Sec(SR) side chains

It is worth noting that while the Sec amino acid can be naturally incorporated with a
special cellular machinery298, a post-translational modification approach is still necessary
for traceless ligation. The Sec amino acid is encoded by the UGA stop codon, which is
re-interpreted as a Sec codon by a special elongation factor EFsec, a selenocysteine insertion sequence (SECIS) in the 3’-untranslated region of the mRNA, and a SECIS/EFsecbinding protein SBP2245. Current attempts to recombinantly express Sec-containing
proteins had limited success, where Trp mis-incorporation (Trp codon: UGG) and low
yields due to chain termination were cited as the most common complications252. In
addition, all natural and recombinant Sec-proteins are expressed with a Sec-Xaan-Cys
motif (n = 2 ~ 4) to sequester the highly reactive selenol side chain as an intramolecular
hemiselenide with the adjacent Cys during expression and handling251,252. If we choose
the recombinant expression approach with Sec/Cys motifs, it would completely defeat the
purpose of ligation site expansion through traceless NCL by re-introducing the need for a
native Cys residue (or a non-native Cys mutation). Another approach is the metabolic
replacement of the Cys sulfur with selenium by supplying nutrients with a certain
percentage of selenites in the E. coli growth media240; this results in global replacement
of all Cys, which is also undesirable for our applcations. In comparison, the AaT posttranslational modification approach directly incorporates a single Sec with hemiselenide
protection in a site-specific manner, enabling the expansion of traceless NCL to
expressed protein fragments without the Cys complication.
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4.2 Results and Discussion
To screen hemiselenide protected Sec derivatives for activity as AaT substrates, we
first needed to chemically synthesize the corresponding “minimal” adenosine (Ade)
donors. Using a similar strategy as previously applied to other amino acids268,269, we
developed a 6-step synthesis of H-Sec(SR)-Ade donors 6 from L-selenocystine 1 (Figure
4-7). Hemi-selenides have unique thiol exchange properties – similar to the well-known
disulfide exchange, the Se−S bond is in constant equilibrium with other thiol or selenol
species in their surrounding environment, and can be readily substituted by supplying
large excess of the desired thiol (Figure 4-6)226,220. Taking advantage of this property, we
were able to greatly simplify and streamline our synthesis − an H-Sec(S-tBu)-Ade donor
6c was first prepared in bulk, and then derivatized through a simple one-step
hemiselenide exchange to generate a library of adenosine donors 6a-e. We note that these
exchange reactions are highly versatile – interconversion among the H-Sec(SR)-Ade
donors can be achieved by simply incubating one donor with excess of the desired thiol
(Figure 4-14).

Figure 4-6. Thiol Exchange Equilibrium of Hemiselenides.

To assess the chemoenzymatic activity of our Sec-adenosine donor library, we subject
these donors to an in vitro transfer assay using a model peptide LysAlaAcm 7. If the
hemiselenide protected Sec amino acids are viable substrates for AaT, we should observe
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transfer of the Sec(SR) cargo from adenosine donor onto the N-terminus of LysAlaAcm.
Indeed, the formation of Sec(SR)-LysAlaAcm products 8a-e was clearly observed for all

Figure 4-7. Synthesis of Hemiselenide-Protected Sec-Ade Donors from L-Selenocystine.
A) Synthesis scheme from L-selenocystine 1 to desired adenosine donors 6a-e. B) MALDITOF MS and UV-Vis absorption characterization using 6b as an example. Selenium isotopic
pattern can be clearly observed in final product by MALDI-TOF MS; presence of adenosine is
also evident in UV-Vis absorption. See Figure 4-12 for characterization of other products.
Conditions: a) (Boc)2O, DIPEA, 1:1 H2O/1,4-dioxane; b) tBuSH, DIPEA, THF; c) ClCH2CN,
DIPEA, THF; d) (DMT)-A, DIPEA, catalytic NBu4Ac, THF; e) TFA, tBuSH, TIPS, THF; f) RSH,
H2O. Boc = tert-butoxy carbamate; DIPEA = N,N-diisopropylethylamine, THF = tetrahydrofuran; DMT = 4,4'-dimethoxytrityl; (DMT)-A = 5’-O-DMT-adenosine; NBu4Ac = tetrabutylammonium acetate; TFA = trifluoroacetic acid; TIPS = triisopropylsilane; Et = ethyl; iPr =
isopropyl; Ph = phenyl; Bz = benzyl.
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8b

8b

7

7

8c
8c

Figure 4-8. Screening of Hemiselenide Protected Sec-Ade Donors as AaT Substrates.
A) Schematic representation of the AaT activity assay for substrate screening. B) Transfer
efficiencies of various amino acids by wildetype AaT. The natural substrate Phe is also tested
as H-Phe-Ade donor for positive control. C) HPLC and MALDI-TOF MS characterization of
the transfer reactions. Chromatogram monitored at 325 nm; integrity of selenium in isolated
products can be clearly observed in the MALDI-TOF spectra. See Table 4-4 for a complete
characterization of all test reactions. Acm = 7-aminocoumarin.* Data on protected Cys were
acquired by Tomohiro Tanaka and Anne M. Wagner.
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Sec-Ade donors tested (Figure 4-8). The isopropyl protected Sec(S-iPr) and t-butyl
protected Sec(S-tBu) exhibited the highest transfer efficiencies, presumably due to the
better steric accommodation of the small, branched side chains by the AaT substrate
binding pocket (see Figure 4-5). As a further validation, we also synthesized the Cys
counterparts H-Cys(S-iPr)-Ade 6f and H-Cys(S-tBu)-Ade 6g of the two most effective
Sec-Ade donors, and observed nearly identical transfer efficiencies as the Sec substrates
6b and 6c. This gave us confidence that selenium in the hemiselenide side chains did not
interfere with our AaT-mediated chemoenzymatic transformation. Lastly, we showed that
the reaction was tolerant of ambient oxygen – nearly identical transfer efficiencies were
observed in degassed or non-degassed reaction buffers (Figure 4-15).

To demonstrate the utility of this chemoenzymatic strategy in incorporating Sec onto
the N-termini of expressed protein fragments, we generated αS6-140 9 (a truncated version
of αS with an N-terminal Lys) through cellular expression and successfully transferred
Sec(S-iPr) onto its N-terminus from adenosine donor 6b (Figure 4-9). The integrity of
Sec can be further confirmed in a subsequent deselenization test – when 10 was treated
with tris(2-carboxyethyl)phosphine (TCEP), a 155 Da mass shift was clearly observed,
corresponding to the characteristic deselenization of Sec into an Ala (Figure 4-16).
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9

9

10

Figure 4-9. Chemoenzymatic Incorporation of Sec(S-iPr) onto Express αS6-140.
A) Schematic representation of the AaT chemoenzymatic modification reaction. αS 6-140 was
prepared through cellular expression, and then subject to AaT mediated N-terminal modifi+
cation using 6b as adenosine donor. B) MALDI-TOF MS characterization. [9 + H] , expected
+
13828.95, found 13824.14; [10 + H] , expected 14053.92, found 14049.13.
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4.3 Conclusion
We have developed an efficient chemoenzymatic approach to incorporate hemiselenide protected selenocysteine (Sec) site-specifically onto the N-termini of expressed
proteins with E. coli aminoacyl transferase (AaT). Using minimal adenosine donors, we
identified that small, branched side chain protecting groups were preferred as AaT
substrates, with the isopropyl protected Sec(S-iPr) and t-butyl protected Sec(S-tBu) being
the most effective. As a proof-of-concept example, we successfully transferred Sec(S-iPr)
onto the N-terminus of an expressed protein, αS6-140, from the corresponding adenosine
donor. Combining this chemoenzymatic approach with solid phase peptide synthesis
(SPPS) for short peptides, we are now capable of generating N-terminal Sec peptide and
protein fragments of any size (given an appropriate N-terminus, see discussion below),
enabling thioamide incorporation at any desired regions in the protein sequence through
traceless native chemical ligation.
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4.4 Future Directions
To fully realize our vision of efficiently installing any traceless ligation handle at any
desired position, we need to achieve three additional milestones: 1) quantitative transfer
efficiency of the desired ligation handle; 2) ability to utilize β-thiol analogs as AaT substrates; 3) expansion of the N-terminal recognition residue to those other than Lys or Arg.

To achieve quantitative transfer efficiency, we would need to either evolve a more
efficient AaT for our desired substrates, or reinstate the fully enzymatic route for AaTmediated N-terminal modification (see Figure 4-3). We chose the second approach
because it is more feasible − by re-introducing a RS into the reaction, the charged tRNA
substrate can be continuously regenerated. It does not require either the AaT or the RS to
achieve quantitative transfer/aminoacylation efficiency; with the appropriate reaction
time, the substrate regeneration process per se is sufficient to drive the transfer reaction
to completion. The hurdle is, of course, to identify/generate a synthetase that would
recognize our desired ligation handle. As a preliminary trial, we screened S. cerevisiae
phenylalaninyl synthetase (PheRS), E. coli methioninyl synthetase (MetRS), E. coli
leucyl synthetase (LeuRS) and their rationally designed mutants, but unfortunately were
not able to identify a positive candidate. (See Materials and Methods for details.) With
the vast number of potential variables, we will next resort to directed evolution to
generate a viable synthetase.
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For the second goal of expanding AaT substrate scope to β-thiol analogs, we will
utilize directed evolution and computational design to evolve an appropriate AaT mutant.
In wildtype AaT, there are tight van der Waals contacts between the β-carbon of the
substrate and nearby residues, precluding the incorporation of β-branched substrates.
Rationally designed mutations have been attempted by other members in our group, but
did not yield much success. Work is currently underway in our group to use a
combination of surface display screening and in silico design to generate a mutant AaT
for β-branched substrates.

To expand the selection of N-terminal recognition residues, we can either mutate the
AaT peptide recognition pocket or explore other transferases with different recognition
properties. For E. coli AaT, the preference for N-terminal Arg or Lys is dictated by the
presence of a negatively charged Glu156 residue in the peptide binding pocket, with the
assistance of Tyr42, Tyr120 and Gln188 as hydrogen bonding partners261. Conceivably,
these residues can be mutated through directed evolution to alter the steric and electrostatic selectivity of the binding pocket, thus expanding the scope of N-terminal residue
recognition. Another option is to adopt other transferases – for example, arginyl transferase (ATE-1) in S. cerevisiae and H. sapiens recognizes an N-terminal Asp, Glu, and
Cys, and then transfers an Arg onto the N-terminus of these proteins299,300. Using a
similar minimal adenosine donor strategy, we can quickly characterize the substrate
promiscuity of these enzymes, and if necessary, evolve them for our desired ligation
handles.
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4.5 Materials and Methods
General Information

L-Selenocystine was purchased from Sigma-Aldrich (St.

Louis, MO). 5′-O-(4,4′-Dimethoxytrityl) adenosine ((DMT)-A) was purchased as a
custom order from ChemGenes Corporation (Wilmington, MA). Lysylalanylaminomethylcoumarin (LysAlaAcm) was purchased from Bachem (Torrence, CA). The pEG6
plasmid, containing His10-tagged E. coli AaT, was a gift from Alexander Varshavsky
(California Institute of Technology). QuikChange® site-directed mutagenesis kits were
purchased from Stratagene (La Jolla, CA). DNA oligomers were purchased from
Integrated DNA Technologies (Coralville, IA). Bradford reagent assay kits were
purchased from BioRAD (Hercules, CA). Amicon Ultra centrifugal filter units (3k Da
MWCO) were purchased from EMD Millipore (Billerica, MA). All other reagents and
solvents were purchased from Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St.
Louis, MO) unless otherwise specified.

High resolution electrospray ionization mass spectra (ESI-HRMS) were collected
with a Waters LCT Premier XE liquid chromatograph/mass spectrometer (Milford, MA).
Low resolution electrospray ionization mass spectra (ESI-LRMS) were obtained on a
Waters Acquity Ultra Performance LC connected to a single quadrupole detector (SQD)
mass spectrometer. Nuclear magnetic resonance (NMR) spectra were obtained on a
Bruker DRX 500 MHz instrument (Billerica, MA). UV-Vis absorption spectra were
acquired on a Hewlett-Packard 8452A diode array spectrophotometer (Agilent Technologies, Santa Clara, CA). Matrix assisted laser desorption/ionization with time-of-flight
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detector (MALDI-TOF) mass spectra were acquired on a Bruker Ultraflex III instrument
(Billerica, MA). Analytical HPLC was performed on an Agilent 1100 Series HPLC
system (Santa Clara, CA). Preparative HPLC was performed on a Varian Prostar HPLC
system (Agilent Technologies, Santa Clara, CA). HPLC columns were purchased from
W. R. Grace & Compnay (Columbia, MD).

Synthesis of N,N’-di-Boc-L-Selenocystine (2)

2 was synthesized by Boc protect-

tion of L-selenocystine 1 as described in Chapter 3.

Synthesis of Boc-Sec(S-tBu)-OH (3c)

Tetrahydrofuran (THF) and triethylamine

(Et3N) were freshly degassed by the freeze-pump-thaw method. 2 (0.2072 g, 0.4 mmol, 1
equiv) was dissolved in 6.5 mL of degassed THF, and then Et3N (541 μL, 4 mmol, 10
equiv) and 2-methyl-2-propanethiol (tBuSH, 1.1 mL, 10 mmol, 25 equiv) were added.
The reaction was allowed to proceed at room temperature under an argon atmosphere for
4 h. Upon completion, the reaction mixture was concentrated by rotary evaporation. The
residue was brought up in 10 mL of H2O, acidified with 1 mL of 3 M HCl, and then
extracted with ethyl acetate (10 mL × 3). The organic layers were combined and concentrated by rotary evaporation, and then purified by flash chromatography in 5:5 ethyl
acetate/petroleum ether with 0.1% acetic acid. A pale yellow crystalline solid was
isolated as the final product (0.2523 g, 0.7 mmol, 91% yield). Rf = 0.25 in 5:5 ethyl
acetate/ petroleum ether with 0.1% acetic acid. 1H-NMR (500 MHz, CDCl3): δ 11.16 (s,
1H), 5.44 (d, J = 7.1 Hz, 1H), 4.64 (d, J = 3.7 Hz, 1H), 3.30 (dd, J = 11.9, 4.1 Hz, 1H),
3.22 (dd, J = 12.1, 5.8 Hz, 1H), 1.44 (s, 9H), 1.34 (s, 9H). 13C-NMR (500 MHz, CDCl3):
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δ 175.61, 155.69, 82.52, 53.78, 46.57, 34.39, 30.84, 28.61. ESI−-HRMS: calculated for
C12H22NO4SSe−: 356.0435; found [M − H]−: 356.0442.

Synthesis of Boc-Sec(S-tBu)-OCH2CN (4c)

Tetrahydrofuran (THF) and diisopro-

pylethylamine (DIPEA) were freshly degassed by the freeze-pump-thaw method. 3c
(0.2194 g, 0.64 mmol, 1 equiv) was dissolved in degassed THF (7.7 mL), and chilled to
0 ˚C on ice. DIPEA (335 μL, 1.9 mmol, 3 equiv) was added, followed by ClCH2CN (2.0
mL, 32 mmol, 50 equiv). The reaction was allowed to proceed on ice for 2 h, and then at
room temperature overnight (≥ 12 hr) under an argon atmosphere. Upon completion, the
reaction mixture was concentrated by rotary evaporation, and then purified by flash
chromatography in 5:5 ethyl acetate/petroleum ether. The reactant was recovered in 5:5
ethyl acetate/petroleum ether with 0.1% acetic acid, and then subject to two additional
rounds of ClCH2CN activation. A pale yellow solid was isolated as the product (0.1396 g,
0.35 mmol, 57% yield). Rf = 0.74 in 5:5 ethyl acetate/ petroleum ether. 1H-NMR (500
MHz, CDCl3): δ 5.39 (d, J = 6.9 Hz, 1H), 4.79 (s, 2H), 4.72 (dd, J = 12.4, 5.7 Hz, 1H),
3.24 (dd, J = 13.2, 4.8 Hz, 1H), 3.20 (dd, J = 13.4, 5.7 Hz, 1H), 1.45 (s, 9H), 1.36 (s, 9H).
13

C-NMR (500 MHz, CDCl3): δ 170.04, 155.29, 114.15, 81.01, 53.53, 49.48, 47.00,

33.55, 30.83, 28.59. ESI+-HRMS: calculated for C14H24N2O4SSeNa+: 419.0520; found
[M + Na]+: 419.0519.

Synthesis of Boc-Sec(S-tBu)-(5’-O-DMT)Adenosine (5c)

Tetrahydrofuran (THF)

was freshly degassed by the freeze-pump-thaw method. 4c (0.1396 g, 0.35 mmol, 2
equiv) was dissolved in THF (4 mL). 5′-O-(4,4′-Dimethoxytrityl) adenosine (0.1006 g,
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0.18 mmol, 1 equiv) was added, followed by catalytic amount of tetrabutylammonium
acetate (0.0027 g, 9 µmol, 0.05 equiv). The reaction was allowed to proceed overnight (≥
12 h) under an argon atmosphere. Upon completion, the reaction was concentrated by
rotary evaporation, and then purified by flash chromatography in 1:19 methanol/ethyl
acetate. A white foam was isolated as the final product (0.1029 g, 0.11 mmol, 65% yield).
Rf = 0.42 in 1:19 methanol/ethyl acetate. 1H-NMR and 13C-NMR sepctra (500 MHz, d8THF) are shown below (Figure 4-10). ESI+-HRMS: calculated for C43H53N6O9SSe+:
909.2760; found [M + H]+: 909.2767.

Synthesis of H-Sec(S-tBu)-Ade (6c)

Tetrahydrofuran (THF), CH2Cl2 and H2O

were freshly degassed by the freeze-pump-thaw method. 5c (0.0200 g, 22 μmol, 1 equiv)
was dissolved in degassed THF (1 mL) and chilled to 0 °C on ice. Triisopropylsilane (23
μL, 110 μmol, 5 equiv) was added, followed by tBuSH (205 μL, 2.2 mmol, 100 equiv).
Trifluoroacetic acid (1 mL) was added dropwise, and then the reaction was allowed to
proceed at room temperature for 2 h under an argon atmosphere. Upon completion, the
reaction was dried by rotary evaporation. The residue was brought up in degassed CH2Cl2
(1 mL), and then extracted with degassed H2O (1 mL × 3) to recover the product. The
crude was directly purified by reverse phase HPLC using a binary solvent system of
water/acetonitrile with 0.1% trifluoroacetic acid (Table 4-1 through Table 4-3).

Synthesis of Other H-Sec(SR)-Ade Donors (6a-e) All other adenosine donors were
derivatized from 6c through thiol exchange: H2O was freshly degassed by the freezepump-thaw method. 6c (0.0056 g, 11 µmol, 1 equiv) was dissolved in 1 mL of degassed
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H-NMR

13

C-NMR
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13

Figure 4-10. H and C NMR Characterization of Boc-Sec(S-tBu)-(5’-O-DMT)Ade (5c)
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H2O. 100 µL of an appropriate thiol (ethanethiol for 6a; 2-propanethiol for 6b; thiophenol for 6d; benzyl mercaptan for 6e) was added, and the reaction was allowed to
proceed at room temperature for 2 h under an argon atmosphere. Upon completion,
excess thiol was evaporated by a stream of argon. The aqueous crude was directly
injected onto reverse phase HPLC for purification (Table 4-1 through Table 4-3).

6b’

6b

6b’

6b

Figure 4-11. iPrSH Exchange with or without Intermediate Purification.
HPLC analysis of crude reaction mixtures monitored at 260 nm on a YMC-Pack Pro C8 semiprep column using gradient 1.In one-pot deprotection/thiol exchange, 5c was deprotected,
lyophilized, and then directly subject to thiol exchange without purification of 6c. 6b’ denotes
the 2’-acylated isomer of 6b (see later sections); asterisk denotes the absence of 6c.

We note that no major difference was observed when the thiol exchange reaction was
conducted on either HPLC purified 6c, or crude 6c that had simply been lyophilized after
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TFA deprotection of 5c (Figure 4-11). Therefore, all bulk preparations of the adenosine
donors were performed in a one-pot manner without the intermediate HPLC purification
step, both to simplify the process and to avoid material loss during purification. MALDITOF MS and UV-Vis characterization of final products 6a-e are shown in Figure 4-12.

Figure 4-12. MALDI-TOF MS and UV-Vis Characterization of Adenosine Donor 6a-e.
See Figure 4-7 for characterization of 6b, and Table 4-3 for a complete list of expected and
observes m/z values. The integrity of selenium and adenosine can be clearly observed in all
products. 6d and 6e showed additional absorption around 230 nm, which is characteristic for
the side chain phenyl/benzyl substitution.

Table 4-1. Adenosine Donor Purification Methods and Retention Time.
Gradient

Retention
Time*

Column

H-Sec(S-Et)-Ade (6a)

1

16.2 / 18.2 min

YMC-Pack Pro C8 Semi-prep

H-Sec(S-iPr)-Ade (6b)

1

19.2 / 20.8 min

YMC-Pack Pro C8 Semi-prep

H-Sec(S-tBu)-Ade (6c)

1

21.1 / 23.4 min

YMC-Pack Pro C8 Semi-prep

H-Sec(S-Ph)-Ade (6d)

1

22.0 / 24.5 min

YMC-Pack Pro C8 Semi-prep

H-Sec(S-Bz)-Ade (6e)

1

22.7 / 25.0 min

YMC-Pack Pro C8 Semi-prep

Compound

* All adenosine donors are isolated as a mixture of interconverting 2’- and 3’-isomers.
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Table 4-2. HPLC Gradients for Purification and Characterization.
No.
1

Time
(min)

%B

No.

0:00
5:00
10:00
30:00
35:00
40:00
45:00

2
2
10
30
100
100
2

2

Time
(min)

%B

No.

0:00
5:00
10:00
15:00
20:00
25:00
27:00
30:00

1
1
30
40
100
100
1
1

3

Time
(min)

%B

0:00
5:00
25:00
30:00
35:00
45:00

2
2
20
100
100
2

* Solvent A: 0.1% trifluoroacetic acid in water; Solvent B: 0.1% trifluoroacetic acid in acetonitrile

Table 4-3. MALDI-TOF MS Characterization of Purified Adenosine Donors.
Compound

[M + H]+

[M + Na]+

Calculated

Found

Calculated

Found

H-Sec(S-Et)-Ade (6a)

479.05

479.02

501.04

500.98

H-Sec(S-iPr)-Ade (6b)

493.07

492.95

515.06

514.91

H-Sec(S-tBu)-Ade (6c)

507.09

507.12

529.08

529.09

H-Sec(S-Ph)-Ade (6d)

527.05

527.12

-

-

H-Sec(S-Bz)-Ade (6e)

541.07

541.05

563.06

563.05

Characterization of 2’- and 3’-Isomers of Adenosine Donors

As noted in our

previous work268, all adenosine donors were isolated as a mixture of 2’- and 3’-acylated
isomers. To ascertain this observation in our hemiselenide protected Sec donors, we
isolated the early and late peaks (assigned as 2’- and 3’-isomers based on the known
thermodynamic preference for 3'-acylation of adenosine301) of H-Sec(S-iPr)-Ade, reinjected them separately, and observed interconversion of the two species (Figure 4-13).
Since these two isomers co-exist in rapid equilibrium, we reasoned that it would be
unnecessary to obtain one pure isomer − as the 3’-isomer is consumed by AaT in chemo170

enzymatic reaction, the 2’-isomer will convert into the 3’-isomer by equilibrating, thus
supplementing substrates for the reaction.

6b

6b’

6b

6b’

Figure 4-13. Interconversion of 2’- and 3’-Isomers of H-Sec(S-iPr)-Ade 6b.
Early peak (assigned as 6b’) and late peak (assigned as 6b) were isolated, brought up in
H2O, and re-injected onto reverse phase HPLC. Chromotogram monitored at 260 nm on a
Jupiter C18 analytical column using gradient 1. In both cases, the interconversion rapidly
reached thermodynamic equilibrium of 1:3 6b’/6b under ambient conditions. MALDI-TOF MS:
+
+
[6b + H] , expected 493.07, found 493.06; [6b’ + H] , expected 493.07, found 493.05.

Versatility of Thiol Exchange on Hemiselenides

To demonstrate the versatility of

the thiol exchange reaction in derivatizing hemiselenides, we performed thiol exchange
on H-Sec(S-tBu)-Ade 6c and H-Sec(S-Bz)-Ade 6e, and showed that the two species could
be interconverted simply by adding different thiols in excess (Figure 4-14).
171

Figure 4-14. Interconversion of Adenosine Analogs as Driven by Excess of Different Thiols.
6c was readily converted into 6e by treatment with excess BzSH; vice versa, 6e could be
generated from 6c by treatment with excess tBuSH. HPLC chromatograms of crude reaction
mixtures monitored at 260 nm on a YMC-Pack Pro C8 semi-prep column using gradient 1.
+
+
MALDI-TOF MS: [6c + H] , expected 507.12, found 507.08; [6e + H] , expected 541.05,
found 541.07. Star signs indicate the absence of the original adenosine donor added.

Expression and Purification of E. coli Aminoacyl Transferase (AaT)

His10-

tagged E. coli amino acyl transferase (AaT) was expressed from a pEG6 plasmid (ampicillin resistant) in E. coli BL21-Gold (DE3) cells using a procedure adapted from Graciet
et al.302 In particular, no β-mercaptoethanol (BME) was used in our purification, to avoid
complications with the hemiselenide side chains. For protein expression, E. coli BL21Gold (DE3) cells were transformed with the plasmid, and selected on an LB plate in the
presence of ampicillin (Amp, 100 μg/mL) by overnight growth at 37 °C. 5 mL LB media
was inoculated with a single colony, and then grown at 37 °C in the presence of Amp
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(100 μg/mL) until OD600 ≥ 0.5. The primary culture was diluted into 1 L of LB media
with Amp (100 mg/L), and grown at 37 °C until OD600 = 0.6. 100 mg of isopropyl β-Dthiogalactoside (IPTG, 0.1 mM final concentration) was added to induced AaT expression, and then the cells were grown at 25 °C for another 16 ~ 18 h.

For purification, cells were harvested at 6,000 rpm using a GS3 rotor on a Sorvall
RC-5 centrifuge. Cell pellets were resuspended in Ni-NTA binding buffer (50 mM Tris,
10 mM imidazole, 300 mM KCl, pH 8.0 with protease inhibitor cocktail, 1 mM phenylmethanesulfonyl fluoride and 10 units/mL DNAse1–Grade II), and then lysed by sonication. The crude was centrifuged at 13,200 rpm for 15 min, and then supernatant was
recovered and incubated with Ni-NTA resin for 1 h on ice with gentle shaking. The resin
was collected by filtration, rinsed with 4 volumes of wash buffer (50 mM Tris, 50 mM
imidazole, 300 mM KCl, pH 8.0), and then eluted with 8 volumes of elution buffer (50
mM Tris, 250 mM imidazole, 300 mM KCl, pH 8.0). Pure fractions of AaT were
identified by SDS-PAGE, and then collected and dialyzed into a storage buffer (50 mM
Tris, 30 % glycerol, 120 mM (NH4)2SO4, pH 8.0) at 4 °C overnight. After concentration
determination by Bradford assay303, the purified enzymes were stored at -80 °C until use.

AaT Activity Assay for Adenosine Donor Screening

H2O, acetone, a 10x buffer

stock (500 mM Tris, 1.5 M KCl, 100 mM MgCl2, pH 8.0), and a LysAlaAcm 7 stock (10
mM in water) were freshly degassed by the freeze-pump-thaw method. Sec adenosine
donor was brought up in degassed H2O, and adjusted to 10 mM based on UV-Vis absorption (ε260 = 15,400 M-1 cm-1). Under an argon atmosphere, H2O (41.6 µL), buffer stock
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(6.25 µL), LysAlaAcm stock (0.625 µL) and Sec adenosine donor stock (6.25 µL) were
thoroughly mixed, and then AaT (7.81 µL, 0.8 mg/mL) was added to initiate the reaction.
The reaction was allowed to proceed at 37 ˚C for 4 h under an argon atmosphere. Upon
completion, the reaction was quenched with 1% acetic acid in degassed H2O (187.5 μL).
Degassed acetone (1 mL) was added, and then the mixture was kept at -20 °C for 1 h to
precipitate the enzyme. Supernatant was recovered after centrifugation at 13,200 rpm and
4 ˚C for 20 min, and then excess acetone was removed by rotary evaporation. The residue
was diluted into degassed H2O (800 μL), and then analyzed by reverse phase HPLC on a
Jupiter C18 analytical column using gradient 2.

For quantification, peak identities were assigned based on MALDI-TOF MS (Table
4-4), and then transfer efficiencies were calculated from peak areas monitored at 325 nm.
For each adenosine donor, the transfer efficiency was reported as the average value with
standard deviation from three independent trials.

Table 4-4. Retention Time and MALDI-TOF MS Characterization of LysAlaAcm Peptides.
[M + H]+

[M + Na]+

Retention
Time

Calc’d

Found

Calc’d

LysAlaAcm (7)

11.1 min

375.20

375.29

397.19

Sec(S-Et)-LysAlaAcm (8a)

12.6 min

586.16

586.38

-

-

Sec(S-iPr)-LysAlaAcm (8b)

13.1 min

600.17

600.14

622.16

622.11

Sec(S-tBu)-LysAlaAcm (8c)

13.2 min

614.18

614.13

636.17

636.10

Sec(S-Ph)-LysAlaAcm (8d)

13.4 min

634.15

634.33

656.14

656.23

Sec(S-Bz)-LysAlaAcm (8e)

13.3 min

648.17

648.48

-

-

Phe-LysAlaAcm (8h)

12.4 min

522.26

522.33

544.25

544.31

Peptide

* Retention time obtained on a Jupiter C18 analytical column using gradient 2.
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Found

Oxygen Tolerance

Reactions were conducted similarly as the standard procedure,

except that non-degassed water and buffers were used (Figure 4-15). Transfer efficiencies
were reported as the average value from three independent trials.

8b
7

8b
7

Figure 4-15. Oxygen Tolerance of Chemoenzymatic AaT Reaction with H-Sec(S-iPr)-Ade.

Expression and Purification of αS6-140

Expression and purification were per-

formed by Anne M. Wagner as detailed in Angew. Chem. Int. Ed. 2013, 52, 6210-6213.
Briefly, a pET-16b plasmid encoding for HisTag-αS6-140 was transformed into E. coli
BL21 DE3 cells, and over-expressed with isopropyl-β-D-thiogalactopyranoside (IPTG)
induction. After lysis of the cells, target protein was pulled down by Ni-NTA resin, and
treated with Factor Xa to remove the HisTag. The protein was dialyzed into storage buffer
(20 mM Tris, 150 mM KCl, 10 mM Mg2Cl2, pH 8.0), quantified by BCA assay (Pierce),
and stored at -80 °C until use.

AaT-Mediated Chemoenzymatic Transfer of Sec(S-iPr) onto αS6-140

H-Sec(S-

iPr)-Ade 6b was brought up in H2O, and adjusted to 10 mM based on UV-Vis absorption
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(ε260 = 15,400 M-1 cm-1). H2O (35.2 µL), 10x reaction buffer (6.25 µL, 500 mM HEPES,
1.5 M KCl, 100 M MgCl2, pH 8.0), αS6-140 stock (6.94 µL, 0.9 mg/mL) and 6b stock
(6.25 µL) were thoroughly mixed. AaT stock (7.81 uL, 0.8 mg/mL) was added to initiate
the reaction. The reaction was allowed to proceed at 37 ˚C for 4 h; an additional dose of
6b stock (6.25 uL) was added each hour. Upon completion, the reaction was bufferexchanged into H2O using Amicon Ultra centrifugal filter units (3k Da MWCO). The
resulting crude mixture was then directly analyzed by MALDI-TOF MS.

Deselenization of Sec(S-iPr)-αS6-140

To confirm the presence of Sec, 50 µL of the

above reaction crude was mixed with 150 µL of a TCEP stock (50 mM Tris, 20 mM
TCEP, 10 mM DTT, pH 8.0). The reaction was allowed to proceed at 37 ˚C for 6 h under
an argon atmosphere. Upon completion, the reaction was buffer-exchanged into H2O
using Amicon Ultra centrifugal filter units (3k Da MWCO), and analyzed by MALDITOF MS. TCEP = tris(2-carboxyethyl)phosphine; DTT = dithiothreitol.

11

Figure 4-16. Deselenization of Sec(S-iPr)-αS6-140 into Ala- αS6-140 11.
+

MALDI-TOF MS: [11 + H] , expected 13899.99, found 13893.67.

Synthesis of H-Sec(S-iPr)-OH and H-Sec(S-Et)-OH (S1, S2)

Tetrahydrofuran

(THF) was freshly degassed by the freeze-pump-thaw method. N,N’-di-Boc-L-seleno176

cystine 2 (0.0730 g, 0.14 mmol, 1 equiv) was dissolved in degassed THF (1.6 mL), and
then ethanethiol (246 μL, 3.4 mmol, 25 equiv) or 2-propanethiol (316 μL, 3.4 mmol, 25
equiv) was added to initiate the thiolysis. The reaction was allowed to proceed at room
temperature for 4 h under an argon atmosphere. Upon completion, trifluoroacetic acid (2
mL) was added dropwise to initiate the Boc deprotection. The reaction was allowed to
proceed for 45 min under an argon atmosphere, and then the crude product was recovered
by ether precipitation. The residue was brought up in 1:10 CH3CN/H2O, and then purified
by reverse phase HPLC on a Vydac C8 semi-prep column using gradient 3. Retention
time: 21.3 min for S1; 14.2 min for S2. ESI+-LRMS: calc’d for C6H14NO2SSe+ 243.98,
found [S1 + H]+ 244.01; calc’d for C5H12NO2SSe+ 229.97, found [S2 + H]+ 230.02

Expression and Purification of Synthetases

Expression and purification of His6-

tagged S. cerevisiae phenylalaninyl synthetase (PheRS) and E. coli leucyl synthetase
(LeuRS, with a T252F mutation to block the editing site304) were conducted using a
similar procedure as AaT expression and purification, except that different buffers were
used. For PheRS: binding buffer, 50 mM Tris, 300 mM KCl, pH 8.0; wash buffer, 50 mM
Tris, 20 mM imidazole, 300 mM KCl, pH 8.0; elution buffer, 50 mM Tris, 40 mM
imidazole, 300 mM KCl, pH 8.0; storage buffer, 25 mM Tris, 50% glycerol, pH 7.6. For
LeuRS: binding buffer, 50 mM Tris, 10 mM imidazole, 300 mM KCl, pH 8.0; wash
buffer, 25 mM Tris, 20 mM imidazole, 300 mM KCl, pH 8.0; elution buffer, 50 mM Tris,
100 mM imidazole, 300 mM KCl, pH 8.0; storage buffer, 50 mM Tris, 50% glycerol, pH
7.6. E. coli methionine synthetase (MetRS) and its mutant MetRS L13G were expressed
and purified by John B. Warner following literature precedence by the Tirrell group264.
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Synthetase Activity Profiling in AaT-Mediate N-Terminal Modification

Synthe-

tase activities were tested in a fully enzymatic transfer assay using LysAlaAcm 7 as the
model peptide and H-Sec(S-iPr)-OH S1 as the amino acid substrate; in the case of MetRS
and its L13G mutant, H-Sec(S-Et)-OH S2 was also tested since it more closely resembles
the natural substrate Met. For each synthetase/mutant, a positive control with its natural
substrate and two negative controls (withholding amino acid or tRNA) were also included
as reference points (Figure 4-17). For a typical assay: a 15 mM H-Sec(SR)-OH amino
acid stock was freshly prepared from S1 or S2 in H2O. Milli-Q H2O (21.8 µL), 10x buffer
stock (6.25 µL, 500 mM HEPES, 1.5 M KCl, 100 mM Mg2Cl, pH 8.0), LysAlaAcm 7
stock (0.625 µL, 10 mM in H2O), Sec amino acid stock (4.17 µL) and ATP stock (3.13
µL, 50 mM in H2O) were thoroughly mixed. tRNA (12.5 µL, 200 µM), AaT (7.81 µL,
0.8 mg/mL) and synthetase (6.25 µL, 1 mg/mL) were then added to initiate the reaction.
The reaction was allowed to proceed at 37 ˚C for 4 h under an argon atmosphere, and
then worked up and analyzed similarly as the standard AaT assay. Unfortunately, none of
the synthetases showed activity towards the H-Sec(SR)-OH amino acids tested.

Rationally Designed LeuRS Mutants

Based on crystal structure305 and previous

mutagenesis work by Schultz et al.306, we rationally designed five LeuRS mutants with
various permutations of the amino acid binding pocket and tested them for activity in
AaT-mediated N-terminal modification assays. Unfortunately, none of these mutants
showed the desired activity. Mutants and primers are listed in Table 4-5 and Table 4-6.
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7

7

7

Phe-7

Figure 4-17. Synthetase (RS) Activity Profiling Assay using PheRS as an Example.
+

A) Assay scheme. B) HPLC chromatograms monitored at 325 nm. MALDI-TOF MS: [7 + H] ,
+
expected 375.20, found 375.20; [Phe-7 + H] , expected 522.26, found 522.25.

Table 4-5. Rationally Designed LeuRS Mutants.
Mutant

M40

T252

Y499

Y527

H533

H537

T252F
pWT
T252F
Y499S
H537G
1
M40A
T252F
H533A H537G
2
T252F
Y527T H533A H537G
3
T252F
Y499S
Y527T H533A
4
T252F
Y499S
Y527T H533A H537G
5
* A T252Y mutation was included in all mutants to block the editing site 304.
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Primers Used
2, 4
1, 5
3, 5
2, 3, 4
2, 3, 5

Table 4-6. Primers for LeuRS Mutagenesis.
No.

Mutation

1

M40A

2

3

4

5

Y499S

Y527T

H533/H537G

H533A/H537G

Primer Sequence
Forward

5'- G AAG TAT TAC TGC CTG TCT GCG CTT CCC
TAT CCT TCT GGT C -3'

Reverse

5'- G ACC AGA AGG ATA GGG AAG CGC AGA
CAG GCA GTA ATA CTT C -3'

Forward

5'- TTT ATG GAG TCC TCC TGG TCT TAT GCG
CGC TAC ACT TGC -3'

Reverse

5'- GCA AGT GTA GCG CGC ATA AGA CCA GGA
GGA CTC CAT AAA -3'

Forward

5’-TAC TGG CTG CCG GTG GAT ATC ACC ATT
GGT GGT ATT GAA-3’

Reverse

5’-TTC AAT ACC ACC AAT GGT GAT ATC CAC
CGG CAG CCA GTA-3’

Forward

5'- ATT GAA CAC GCC ATT ATG GGC CTG CTC
TAC TTC CGC TTC -3'

Reverse

5'- GAA GCG GAA GTA GAG CAG GCC CAT AAT
GGC GTG TTC AAT -3'

Forward

5'- C ATT GGT GGT ATT GAA GCG GCC ATT ATG
GGC CTG CTC TAC TTC CGC -3'

Reverse

5'- GCG GAA GTA GAG CAG GCC CAT AAT GGC
CGC TTC AAT ACC ACC AAT G -3'

* Desired mutations are highlighted in bold.

4.6 Acknowledgement
This work was supported by funding from the University of Pennsylvania, Searle
Scholars Program (10-SSP-214 to EJP), and the National Institute of Health (NIH
NS081033). Instruments supported by the National Science Foundation and National
Institutes of Health include: HRMS (NIH RR-023444) and MALDI-MS (NSF MRI0820996). We thank Dr. Rakesh Kohli for assistance with HRMS analysis, and Michael
Nicastri for assistance with LeuRS mutagenesis during his rotation.

180

BIBLIOGRAPHY

1.

Voet, D.; Voet, J. G., Biochemistry. John Wiley & Sons: Hoboken, NJ, 2011.

2.
Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P., Molecular
Biology of the Cell. Garland Science: New York, NY, 2007.
3.

Creighton, T. E., Proteins. W. H. Freeman: New York, NY, 1990.

4.
563.

Crick, F., Central dogma of molecular biology. Nature 1970, 227 (5258), 561–

5.
Anfinsen, C. B., Principles that govern the folding of protein chains. Science
1973, 181 (4096), 223–230.
6.
Onuchic, J. N.; Luthey-Schulten, Z.; Wolynes, P. G., Theory of protein folding:
the energy landscape perspective. Annu. Rev. Phys. Chem. 1997, 48 (1), 545−600.
7.
Boehr, D. D.; Nussinov, R.; Wright, P. E., The role of dynamic conformational
ensembles in biomolecular recognition. Nat. Chem. Biol. 2009, 5 (11), 789–796.
8.
Henzler-Wildman, K.; Kern, D., Dynamic personalities of proteins. Nature 2007,
450 (7172), 964−972.
9.
Li, C.; Liu, M., Protein dynamics in living cells studied by in-cell NMR
spectroscopy. FEBS Lett. 2013, 587 (8), 1008−1011.
10.
Stefani, M., Protein folding and misfolding on surfaces. Int. J. Mol. Sci. 2008, 9
(12), 2515−2542.
11.
Valastyan, J. S.; Lindquist, S., Mechanisms of protein-folding diseases at a
glance. Dis. Models Mech. 2014, 7 (1), 9−14.
12.
Soto, C., Unfolding the role of protein misfolding in neurodegenerative diseases.
Nat. Rev. Neurosci. 2003, 4 (1), 49−60.
13.
Mukherjee, A.; Morales-Scheihing, D.; Butler, P. C.; Soto, C., Type 2 diabetes as
a protein misfolding disease. Trends Mol. Med. 2015, 21 (7), 439−449.
14.
Gregersen, N.; Bross, P.; Vang, S.; Christensen, J. H., Protein misfolding and
human disease. Ann. Rev. Genom. Hum. G. 2006, 7 (1), 103−124.
15.
Herczenik, E.; Gebbink, M. F. B. G., Molecular and cellular aspects of protein
misfolding and disease. FASEB J. 2008, 22 (7), 2115−2133.
181

16.
Uversky, V. N., Fink, Anthony, Protein Misfolding, Aggregation and
Conformational Diseases. Springer: Singapore, 2007.
17.
Knowles, T. P. J.; Vendruscolo, M.; Dobson, C. M., The amyloid state and its
association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 2014, 15 (6),
384−396.
18.
Jucker, M.; Walker, L. C., Self-propagation of pathogenic protein aggregates in
neurodegenerative diseases. Nature 2013, 501 (7465), 45−51.
19.
Nordstedt, C.; Näslund, J.; Tjernberg, L. O.; Karlström, A. R.; Thyberg, J.;
Terenius, L., The Alzheimer Aβ peptide develops protease resistance in association with
its polymerization into fibrils. J. Biol. Chem. 1994, 269 (49), 30773−30776.
20.
de Lau, L. M. L.; Breteler, M. M. B., Epidemiology of Parkinson's disease. Lancet
Neurol. 2006, 5 (6), 525–535.
21.
Parkinson, J., An Essay on the Shaking Palsy. Whittingham and Rowland:
London, UK, 1817.
22.
Longo, D.; Fauci, A.; Kasper, D.; Hauser, S.; Jameson, J.; Loscalzo, J., Harrison's
Principles of Internal Medicine. McGraw-Hill Education: New York, NY, 2015.
23.

Hornykiewicz, O., A brief history of levodopa. J. Neurol. 2010, 257 (2), 249−252.

24.
Rodrigues e Silva, A. M.; Geldsetzer, F.; Holdorff, B.; Kielhorn, F. W.; BalzerGeldsetzer, M.; Oertel, W. H.; Hurtig, H.; Dodel, R., Who was the man who discovered
the “Lewy bodies”? Movement Disord. 2010, 25 (12), 1765−1773.
25.
Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.;
Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E. S.; Chandrasekharappa, S.;
Athanassiadou, A.; Papapetropoulos, T.; Johnson, W. G.; Lazzarini, A. M.; Duvoisin, R.
C.; Di Iorio, G.; Golbe, L. I.; Nussbaum, R. L., Mutation in the α-synuclein gene
identified in families with Parkinson's disease. Science 1997, 276 (5321), 2045−2047.
26.
Braak, H.; Tredici, K. D.; Rüb, U.; de Vos, R. A. I.; Jansen Steur, E. N. H.; Braak,
E., Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging
2003, 24 (2), 197–211.
27.
Jellinger, K. A., A critical evaluation of current staging of α-synuclein pathology
in Lewy body disorders. BBA - Mol. Basis Dis. 2009, 1792 (7), 730−740.
28.
Stefanis, L., α-Synuclein in Parkinson's disease. Cold Spring Harb. Perspect.
Med. 2012, 2 (2), a009399.

182

29.
Burré, J.; Sharma, M.; Tsetsenis, T.; Buchman, V.; Etherton, M. R.; Südhof, T.
C., α-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010,
329 (5999), 1663–1667.
30.
Fortin, D. L.; Nemani, V. M.; Voglmaier, S. M.; Anthony, M. D.; Ryan, T. A.;
Edwards, R. H., Neural activity controls the synaptic accumulation of α-synuclein. J.
Neurosci. 2005, 25 (47), 10913−10921.
31.
Pfefferkorn, C. M.; Jiang, Z.; Lee, J. C., Biophysics of α-synuclein membrane
interactions. BBA - Biomembranes 2012, 1818 (2), 162−171.
32.
Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek,
H.; Epplen, J. T.; Schols, L.; Riess, O., Ala30Pro mutation in the gene encoding αsynuclein in Parkinson's disease. Nat. Genet. 1998, 18 (2), 106−108.
33.
Zarranz, J. J.; Alegre, J.; Gómez-Esteban, J. C.; Lezcano, E.; Ros, R.; Ampuero,
I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atarés, B.; Llorens, V.; Tortosa, E. G.; del Ser,
T.; Muñoz, D. G.; de Yebenes, J. G., The new mutation, E46K, of α-synuclein causes
parkinson and Lewy body dementia. Ann. Neurol. 2004, 55 (2), 164−173.
34.
Appel-Cresswell, S.; Vilarino-Guell, C.; Encarnacion, M.; Sherman, H.; Yu, I.;
Shah, B.; Weir, D.; Thompson, C.; Szu-Tu, C.; Trinh, J.; Aasly, J. O.; Rajput, A.; Rajput,
A. H.; Jon Stoessl, A.; Farrer, M. J., Alpha-synuclein p.H50Q, a novel pathogenic
mutation for Parkinson's disease. Movement Disord. 2013, 28 (6), 811–813.
35.
Lesage, S.; Anheim, M.; Letournel, F.; Bousset, L.; Honoré, A.; Rozas, N.; Pieri,
L.; Madiona, K.; Dürr, A.; Melki, R.; Verny, C.; Brice, A., G51D α-synuclein mutation
causes a novel Parkinsonian–pyramidal syndrome. Ann. Neurol. 2013, 73 (4), 459−471.
36.
Ulmer, T. S.; Bax, A.; Cole, N. B.; Nussbaum, R. L., Structure and dynamics of
micelle-bound human α-synuclein. J. Biol. Chem. 2005, 280 (10), 9595−9603.
37.
Weinreb, P. H.; Zhen, W.; Poon, A. W.; Conway, K. A.; Lansbury, P. T., NACP,
a protein implicated in Alzheimer's disease and learning, Is natively unfolded.
Biochemistry 1996, 35 (43), 13709−13715.
38.
Serpell, L. C.; Berriman, J.; Jakes, R.; Goedert, M.; Crowther, R. A., Fiber
diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation.
P. Natl. Acad. Sci. USA 2000, 97 (9), 4897−4902.
39.
Jao, C. C.; Der-Sarkissian, A.; Chen, J.; Langen, R., Structure of membranebound α-synuclein studied by site-directed spin labeling. P. Natl. Acad. Sci. USA 2004,
101 (22), 8331−8336.
40.
Middleton, E. R.; Rhoades, E., Effects of curvature and composition on αsynuclein binding to lipid vesicles. Biophys. J. 2010, 99 (7), 2279−2288.
183

41.
Bartels, T.; Ahlstrom, L. S.; Leftin, A.; Kamp, F.; Haass, C.; Brown, M. F.;
Beyer, K., The N-terminus of the intrinsically disordered protein α-synuclein triggers
membrane binding and helix folding. Biophys. J. 2010, 99 (7), 2116–2124.
42.
Uversky, V. N.; Li, J.; Fink, A. L., Evidence for a partially folded intermediate in
α-synuclein fibril formation. J. Biol. Chem. 2001, 276 (14), 10737−10744.
43.
Bertoncini, C. W.; Jung, Y.-S.; Fernandez, C. O.; Hoyer, W.; Griesinger, C.;
Jovin, T. M.; Zweckstetter, M., Release of long-range tertiary interactions potentiates
aggregation of natively unstructured α-synuclein. P. Natl. Acad. Sci. USA 2005, 102 (5),
1430–1435.
44.
Lee, J. C.; Gray, H. B.; Winkler, J. R., Tertiary contact formation in α-synuclein
probed by electron transfer. J. Am. Chem. Soc. 2005, 127 (47), 16388−16389.
45.
McClendon, S.; Rospigliosi, C. C.; Eliezer, D., Charge neutralization and collapse
of the C-terminal tail of α-synuclein at low pH. Protein Sci. 2009, 18 (7), 1531−1540.
46.
Giasson, B. I.; Uryu, K.; Trojanowski, J. Q.; Lee, V. M.-Y., Mutant and wild type
human α-synucleins assemble into elongated filaments with distinct morphologies in
vitro. J. Biol. Chem. 1999, 274 (12), 7619−7622.
47.
Vilar, M.; Chou, H.-T.; Lührs, T.; Maji, S. K.; Riek-Loher, D.; Verel, R.;
Manning, G.; Stahlberg, H.; Riek, R., The fold of α-synuclein fibrils. P. Natl. Acad. Sci.
USA 2008, 105 (25), 8637−8642.
48.
Heise, H.; Hoyer, W.; Becker, S.; Andronesi, O. C.; Riedel, D.; Baldus, M.,
Molecular-level secondary structure, polymorphism, and dynamics of full-length αsynuclein fibrils studied by solid-state NMR. P. Natl. Acad. Sci. USA 2005, 102 (44),
15871−15876.
49.
Comellas, G.; Lemkau, L. R.; Nieuwkoop, A. J.; Kloepper, K. D.; Ladror, D. T.;
Ebisu, R.; Woods, W. S.; Lipton, A. S.; George, J. M.; Rienstra, C. M., Structured
regions of α-synuclein fibrils include the early-onset Parkinson's disease mutation sites. J.
Mol. Biol. 2011, 411 (4), 881–895.
50.
Gath, J.; Habenstein, B.; Bousset, L.; Melki, R.; Meier, B.; Böckmann, A., Solidstate NMR sequential assignments of α-synuclein. Biomol. NMR Assign. 2012, 6 (1),
51−55.
51.
Rodriguez, J. A.; Ivanova, M. I.; Sawaya, M. R.; Cascio, D.; Reyes, F. E.; Shi, D.;
Sangwan, S.; Guenther, E. L.; Johnson, L. M.; Zhang, M.; Jiang, L.; Arbing, M. A.;
Nannenga, B. L.; Hattne, J.; Whitelegge, J.; Brewster, A. S.; Messerschmidt, M.; Boutet,
S.; Sauter, N. K.; Gonen, T.; Eisenberg, D. S., Structure of the toxic core of α-synuclein
from invisible crystals. Nature 2015, 525 (7570), 486−490.
184

52.
Pornsuwan, S.; Giller, K.; Riedel, D.; Becker, S.; Griesinger, C.; Bennati, M.,
Long-range distances in amyloid fibrils of α-synuclein from PELDOR spectroscopy.
Angew. Chem. Int. Ed. 2013, 52 (39), 10290−10294.
53.
Eisenberg, D.; Nelson, R.; Sawaya, M. R.; Balbirnie, M.; Sambashivan, S.;
Ivanova, M. I.; Madsen, A.; Riekel, C., The structural biology of protein aggregation
diseases: fundamental questions and some answers. Accounts Chem. Res. 2006, 39 (9),
568–575.
54.
Biancalana, M.; Koide, S., Molecular mechanism of Thioflavin-T binding to
amyloid fibrils. BBA - Proteins Proteom. 2010, 1804 (7), 1405–1412.
55.
Wood, S. J.; Wypych, J.; Steavenson, S.; Louis, J.-C.; Citron, M.; Biere, A. L., αSynuclein fibrillogenesis is nucleation-dependent: implications for the pathogenesis of
Parkinson's disease. J. Biol. Chem. 1999, 274 (28), 19509−19512.
56.
Xue, W.-F.; Hellewell, A. L.; Gosal, W. S.; Homans, S. W.; Hewitt, E. W.;
Radford, S. E., Fibril fragmentation enhances amyloid cytotoxicity. J. Biol. Chem. 2009,
284 (49), 34272−34282.
57.
Mahul-Mellier, A. L.; Vercruysse, F.; Maco, B.; Ait-Bouziad, N.; De Roo, M.;
Muller, D.; Lashuel, H. A., Fibril growth and seeding capacity play key roles in αsynuclein-mediated apoptotic cell death. Cell Death Differ. 2015.
58.
Hoyer, W.; Antony, T.; Cherny, D.; Heim, G.; Jovin, T. M.; Subramaniam, V.,
Dependence of α-synuclein aggregate morphology on solution conditions. J. Mol. Biol.
2002, 322 (2), 383−393.
59.
Outeiro, T. F.; Klucken, J.; Bercury, K.; Tetzlaff, J.; Putcha, P.; Oliveira, L. M.
A.; Quintas, A.; McLean, P. J.; Hyman, B. T., Dopamine-induced conformational
changes in α-synuclein. PLoS ONE 2009, 4 (9), e6906.
60.
Lee, H.-J.; Baek, S. M.; Ho, D.-H.; Suk, J.-E.; Cho, E.-D.; Lee, S.-J., Dopamine
promotes formation and secretion of non-fibrillar α-synuclein oligomers. Exp. Mol. Med.
2011, 43, 216−222.
61.
Chan, T.; Chow, A. M.; Cheng, X. R.; Tang, D. W. F.; Brown, I. R.; Kerman, K.,
Oxidative stress effect of dopamine on α-synuclein: electroanalysis of solvent
interactions. ACS Chem. Neurosci. 2012, 3 (7), 569–574.
62.
Venda, L. L.; Cragg, S. J.; Buchman, V. L.; Wade-Martins, R., α-Synuclein and
dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2010, 33 (12),
559−568.

185

63.
Luk, K. C.; Kehm, V.; Carroll, J.; Zhang, B.; O’Brien, P.; Trojanowski, J. Q.;
Lee, V. M. Y., Pathological α-synuclein transmission initiates Parkinson-like
neurodegeneration in non-transgenic mice. Science 2012, 338 (6109), 949−953.
64.
Volpicelli-Daley, Laura A.; Luk, Kelvin C.; Patel, Tapan P.; Tanik, Selcuk A.;
Riddle, Dawn M.; Stieber, A.; Meaney, David F.; Trojanowski, John Q.; Lee, Virginia M.
Y., Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic
dysfunction and neuron death. Neuron 2011, 72 (1), 57−71.
65.
Luk, K. C.; Song, C.; O'Brien, P.; Stieber, A.; Branch, J. R.; Brunden, K. R.;
Trojanowski, J. Q.; Lee, V. M.-Y., Exogenous α-synuclein fibrils seed the formation of
Lewy body-like intracellular inclusions in cultured cells. P. Natl. Acad. Sci. USA 2009,
106 (47), 20051−20056.
66.
Guo, Jing L.; Covell, Dustin J.; Daniels, Joshua P.; Iba, M.; Stieber, A.; Zhang,
B.; Riddle, Dawn M.; Kwong, Linda K.; Xu, Y.; Trojanowski, John Q.; Lee, Virginia M.
Y., Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell
2013, 154 (1), 103−117.
67.
Petkova, A. T.; Leapman, R. D.; Guo, Z.; Yau, W.-M.; Mattson, M. P.; Tycko, R.,
Self-propagating, molecular-level polymorphism in Alzheimer's ß-amyloid fibrils.
Science 2005, 307 (5707), 262−265.
68.
Krishnan, V. V.; Rupp, B., Macromolecular Structure Determination: Comparison
of X-ray Crystallography and NMR Spectroscopy. In eLS, John Wiley & Sons: New
York, NY, 2001.
69.
Lakowicz, J. R., Principles of Fluorescence Spectroscopy. Springer: New York,
NY, 2006.
70.
Trexler, A. J.; Rhoades, E., Single molecule characterization of α-synuclein in
aggregation-prone states. Biophys. J. 2010, 99 (9), 3048−3055.
71.
Cremades, N.; Cohen, Samuel I.; Deas, E.; Abramov, Andrey Y.; Chen, Allen Y.;
Orte, A.; Sandal, M.; Clarke, Richard W.; Dunne, P.; Aprile, Francesco A.; Bertoncini,
Carlos W.; Wood, Nicholas W.; Knowles, Tuomas P.; Dobson, Christopher M.;
Klenerman, D., Direct observation of the interconversion of normal and toxic forms of αsynuclein. Cell 2012, 149 (5), 1048–1059.
72.
Demchenko, A. P., Advanced Fluorescence Reporters in Chemistry and Biology.
Springer: New York, NY, 2010.
73.
Choudhary, A.; Raines, R. T., An evaluation of peptide-bond isosteres.
ChemBioChem 2011, 12 (12), 1801–1807.

186

74.
Petersson, E. J.; Goldberg, J. M.; Wissner, R. F., On the use of thioamides as
fluorescence quenching probes for tracking protein folding and stability. Phys. Chem.
Chem. Phys. 2014, 16 (15), 6827−6837.
75.
Bondi, A., van der Waals volumes and radii. J. Phys. Chem. - US 1964, 68 (3),
441–451.
76.
Truter, M. R., An accurate determination of the crystal structure of thioacetamide.
J. Chem. Soc. 1960, 997−1007.
77.

Lippert, E., The strengths of chemical bonds. Angew. Chem. 1960, 72 (16), 602.

78.
Lee, C. M.; Kumler, W. D., The dipole moment and structure of thiolactams. J.
Org. Chem. 1962, 27 (6), 2052−2054.
79.
Wiberg, K. B.; Rablen, P. R., Why does thioformamide have a larger rotational
barrier than formamide? J. Am. Chem. Soc. 1995, 117 (8), 2201−2209.
80.
Pauling, L., The Nature of the Chemical Bond and the Structure of Molecules and
Crystals: An Introduction to Modern Structural Chemistry. Cornell University Press:
1960.
81.
Dudek, E. P.; Dudek, G. O., Proton magnetic resonance spectra of
thiocarboxamides. J. Org. Chem. 1967, 32 (3), 823–824.
82.
Min, B. K.; Lee, H.-J.; Choi, Y. S.; Park, J.; Yoon, C.-J.; Yu, J.-A., A
comparative study on the hydrogen bonding ability of amide and thioamide using near IR
spectroscopy. J. Mol. Struct. 1998, 471 (1–3), 283−288.
83.
Lee, H.-J.; Choi, Y.-S.; Lee, K.-B.; Park, J.; Yoon, C.-J., Hydrogen bonding
abilities of thioamide. J. Phys. Chem. A 2002, 106 (30), 7010−7017.
84.
Bordwell, F. G.; Algrim, D. J.; Harrelson, J. A., The relative ease of removing a
proton, a hydrogen atom, or an electron from carboxamides versus thiocarboxamides. J.
Am. Chem. Soc. 1988, 110 (17), 5903–5904.
85.
Wipf, P.; Hayes, G. B., Synthesis of oxazines and thiazines by cyclodehydration
of hydroxy amides and thioamides. Tetrahedron 1998, 54 (25), 6987−6998.
86.
Misra, S.; Tewari, U., Complexing behaviour of aromatic thioamides
(ArCSNHCOR). Transition metal complexes of N-carboethoxy-4-chlorobenzene- and Ncarboethoxy-4-bromobenzene thioamide ligands. Transit. Metal Chem. 2002, 27 (1), 120125.

187

87.
Judge, R. H.; Moule, D. C.; Goddard, J. D., Thioamide spectroscopy: long path
length absorption and quantum chemical studies of thioformamide vapour,
CHSNH2/CHSND2. Can. J. Chemistry 1987, 65 (9), 2100−2105.
88.
Reiner, A.; Wildemann, D.; Fischer, G.; Kiefhaber, T., Effect of thioxopeptide
bonds on α-helix structure and stability. J. Am. Chem. Soc. 2008, 130 (25), 8079−8084.
89.
Miwa, J. H.; Pallivathucal, L.; Gowda, S.; Lee, K. E., Conformational stability of
helical peptides containing a thioamide linkage. Org. Lett. 2002, 4 (26), 4655−4657.
90.
Pan, M.; Mabry, T. J.; Beale, J. M.; Mamiya, B. M., Nonprotein amino acids from
Cycas revoluta. Phytochemistry 1997, 45 (3), 517−519.
91.
Abas, S. A.; Hossain, M. B.; van der Helm, D.; Schmitz, F. J.; Laney, M.;
Cabuslay, R.; Schatzman, R. C., Alkaloids from the Tunicate Polycarpa aurata from
Chuuk Atoll. J. Org. Chem. 1996, 61 (8), 2709–2712.
92.
Kim, H. J.; Graham, D. W.; DiSpirito, A. A.; Alterman, M. A.; Galeva, N.;
Larive, C. K.; Asunskis, D.; Sherwood, P. M. A., Methanobactin, a copper-acquisition
compound from methane-oxidizing bacteria. Science 2004, 305 (5690), 1612−1615.
93.
Hayakawa, Y.; Sasaki, K.; Adachi, H.; Furihata, K.; Nagai, K.; Shin-ya, K.,
Thioviridamide, a novel apoptosis inducer in transformed cells from Streptomyces
olivoviridis. J. Antibiot. 2006, 59 (1), 1−5.
94.
Lincke, T.; Behnken, S.; Ishida, K.; Roth, M.; Hertweck, C., Closthioamide: An
Unprecedented Polythioamide Antibiotic from the Strictly Anaerobic Bacterium
Clostridium cellulolyticum. Angew. Chem. Int. Ed. 2010, 49 (11), 2011-2013.
95.
Behnken, S.; Hertweck, C., Anaerobic bacteria as producers of antibiotics. Appl.
Microbiol. Biotechnol. 2012, 96 (1), 61–67.
96.
Kloss, F.; Pidot, S.; Goerls, H.; Friedrich, T.; Hertweck, C., Formation of a
dinuclear copper(I) complex from the Clostridium-derived antibiotic closthioamide.
Angew. Chem. Int. Ed. 2013, 52 (41), 10745−10748.
97.
Ermler, U.; Grabarse, W.; Shima, S.; Goubeaud, M.; Thauer, R. K., Crystal
structure of methyl-coenzyme M reductase: the key enzyme of biological methane
formation. Science 1997, 278 (5342), 1457−1462.
98.
Acton, Q. A., Amides — Advances in Research and Application. Scholarly
Editions: Atlanta, GA, 2013.
99.
Jones, W. C.; Nestor, J. J.; Du Vigneaud, V., Synthesis and some pharmacological
properties of [1-deamino-9-thioglycine]oxytocin. J. Am. Chem. Soc. 1973, 95 (17),
5677−5679.
188

100. Clausen, K.; Spatola, A. F.; Lemieux, C.; Schiller, P. W.; Lawesson, S.-O.,
Evidence of a peptide backbone contribution toward selective receptor recognition for
leucine enkephalin thioamide analogs. Biochem. Bioph. Res. Co. 1984, 120 (1), 305–310.
101. Okano, A.; James, R. C.; Pierce, J. G.; Xie, J.; Boger, D. L., Silver(I)-promoted
conversion of thioamides to amidines: divergent synthesis of a key series of vancomycin
aglycon residue 4 amidines that clarify binding behavior to model ligands. J. Am. Chem.
Soc. 2012, 134 (21), 8790−8793.
102. Manna, D.; Roy, G.; Mugesh, G., Antithyroid drugs and their analogues:
synthesis, structure, and mechanism of action. Accounts Chem. Res. 2013, 46 (11),
2706−2715.
103. Bond, M. D.; Holmquist, B.; Vallee, B. L., Thioamide substrate probes of metalsubstrate interactions in carboxypeptidase A catalysis. J. Inorg. Biochem. 1986, 28 (2–3),
97–105.
104. Newberry, R. W.; VanVeller, B.; Guzei, I. A.; Raines, R. T., n→π* Interactions
of Amides and Thioamides: Implications for Protein Stability. J. Am. Chem. Soc. 2013,
135 (21), 7843-7846.
105. Bartlett, G. J.; Newberry, R. W.; VanVeller, B.; Raines, R. T.; Woolfson, D. N.,
Interplay of hydrogen bonds and n→π* interactions in proteins. J. Am. Chem. Soc. 2013,
135 (49), 18682–18688.
106. Newberry, R. W.; VanVeller, B.; Guzei, I. A.; Raines, R. T., n→π* interactions of
amides and thioamides: implications for protein stability. J. Am. Chem. Soc. 2013, 135
(21), 7843−7846.
107. Miwa, J. H.; Patel, A. K.; Vivatrat, N.; Popek, S. M.; Meyer, A. M., Compatibility
of the thioamide functional group with β-sheet secondary structure: incorporation of a
thioamide linkage into a β-hairpin peptide. Org. Lett. 2001, 3 (21), 3373−3375.
108. Culik, R. M.; Jo, H.; DeGrado, W. F.; Gai, F., Using thioamides to sitespecifically interrogate the dynamics of hydrogen bond formation in β-sheet folding. J.
Am. Chem. Soc. 2012, 134 (19), 8026–8029.
109. Newberry, R. W.; VanVeller, B.; Raines, R. T., Thioamides in the collagen triple
helix. Chem. Comm. 2015, 51 (47), 9624−9627.
110. Wildemann, D.; Schiene-Fischer, C.; Aumüller, T.; Bachmann, A.; Kiefhaber, T.;
Lücke, C.; Fischer, G., A nearly isosteric photosensitive amide-backbone substitution
allows enzyme activity switching in ribonuclease S. J. Am. Chem. Soc. 2007, 129 (16),
4910−4918.

189

111. Goldberg, J. M.; Batjargal, S.; Petersson, E. J., Thioamides as fluorescence
quenching probes: minimalist chromophores to monitor orotein dynamics. J. Am. Chem.
Soc. 2010, 132 (42), 14718−14720.
112. Goldberg, J. M.; Wissner, R. F.; Klein, A. M.; Petersson, E. J., Thioamide
quenching of intrinsic protein fluorescence. Chemical Communications 2012, 48, 15501552.
113. Rehm, D.; Weller, A., Kinetics of fluorescence quenching by electron and H-atom
transfer. Isr. J. Chem. 1970, 8 (2), 259−271.
114. Goldberg, J. M.; Batjargal, S.; Chen, B. S.; Petersson, E. J., Thioamide quenching
of fluorescent probes through photoinduced electron transfer: mechanistic studies and
applications. J. Am. Chem. Soc. 2013, 135 (49), 18651−18658.
115. Goldberg, J. M.; Speight, L. C.; Fegley, M. W.; Petersson, E. J., Minimalist
probes for studying protein dynamics: thioamide quenching of selectively excitable
fluorescent amino acids. J. Am. Chem. Soc. 2012, 134 (14), 6088−6091.
116. Goldberg, J. M.; Chen, X.; Meinhardt, N.; Greenbaum, D. C.; Petersson, E. J.,
Thioamide-based fluorescent protease sensors. J. Am. Chem. Soc. 2014, 136 (5),
2086−2093.
117. von Meyer, E., A History of Chemistry from Earliest Times to the Present Day.
Macmillan and Company: London, UK, 1891.
118. Metzner, P., Thiocarbonyl Compounds as Specific Tools for Organic Synthesis.
In Organosulfur Chemistry 1, Springer: New York, NY, 1999.
119. Hurd, R. N.; DeLaMater, G., The preparation and chemical properties of
thionamides. Chem. Rev. 1961, 61 (1), 45−86.
120. Ozturk, T.; Ertas, E.; Mert, O., A Berzelius reagent, phosphorus decasulfide
(P4S10), in organic syntheses. Chem. Rev. 2010, 110 (6), 3419−3478.
121. Scheeren, J. W.; Ooms, P. H. J.; Nivard, R. J. F., A general procedure for the
conversion of a carbonyl group into a thione group with tetraphosphorus decasulfide.
Synthesis 1973, 1973 (03), 149−151.
122. Cava, M. P.; Levinson, M. I., Thionation reactions of lawesson's reagents.
Tetrahedron 1985, 41 (22), 5061–5087.
123. Jesberger, M.; Davis, T. P.; Barner, L., Applications of Lawesson’s reagent in
organic and organometallic syntheses. Synthesis 2003, 2003 (13), 1929−1958.

190

124. Shalaby, M. A.; Grote, C. W.; Rapoport, H., Thiopeptide synthesis. α-amino
thionoacid derivatives of nitrobenzotriazole as thioacylating agents. J. Org. Chem. 1996,
61 (25), 9045−9048.
125. Mukherjee, S.; Verma, H.; Chatterjee, J., Efficient site-specific incorporation of
thioamides into peptides on a solid support. Org. Lett. 2015, 17 (12), 3150−3153.
126. Durek, T.; Becker, C. F. W., Protein semi-synthesis: new proteins for functional
and structural studies. Biomol. Eng. 2005, 22 (5–6), 153–172.
127. Verzele, D.; Madder, A., Patchwork protein chemistry: a practitioner's treatise on
the advances in synthetic peptide stitchery. ChemBioChem 2013, 14 (9), 1032−1048.
128. Dawson, P. E.; Muir, T. W.; Clark-Lewis, I.; Kent, S. B., Synthesis of proteins by
native chemical ligation. Science 1994, 266 (5186), 776–779.
129. Okamoto, R.; Izumi, M.; Kajihara, Y., Expanding the scope of native chemical
ligation in glycopeptide synthesis. Int. J. Pept. Res. Ther. 2010, 16 (3), 191−198.
130. Hackenberger, C. P. R.; Schwarzer, D., Chemoselective ligation and modification
strategies for peptides and proteins. Angew. Chem. Int. Ed. 2008, 47 (52), 10030−10074.
131. Fauvet, B.; Butterfield, S. M.; Fuks, J.; Brik, A.; Lashuel, H. A., One-pot total
chemical synthesis of human α-synuclein. Chem. Comm. 2013, 49 (81), 9254−9256.
132. Hejjaoui, M.; Butterfield, S.; Fauvet, B.; Vercruysse, F.; Cui, J.; Dikiy, I.;
Prudent, M.; Olschewski, D.; Zhang, Y.; Eliezer, D.; Lashuel, H. A., Elucidating the role
of C-terminal post-translational modifications using protein semisynthesis strategies: αsynuclein phosphorylation at tyrosine 125. J. Am. Chem. Soc. 2012, 134 (11),
5196−5210.
133. Haj-Yahya, M.; Fauvet, B.; Herman-Bachinsky, Y.; Hejjaoui, M.; Bavikar, S. N.;
Karthikeyan, S. V.; Ciechanover, A.; Lashuel, H. A.; Brik, A., Synthetic
polyubiquitinated α-synuclein reveals important insights into the roles of the ubiquitin
chain in regulating its pathophysiology. P. Natl. Acad. Sci. USA 2013, 110 (44),
17726−17731.
134. Burai, R.; Ait-Bouziad, N.; Chiki, A.; Lashuel, H. A., Elucidating the role of sitespecific nitration of α-synuclein in the pathogenesis of Parkinson’s disease via protein
semisynthesis and mutagenesis. J. Am. Chem. Society. 2015, 137 (15), 5041–5052.
135. Müller, M. M.; Muir, T. W., Histones: at the crossroads of peptide and protein
chemistry. Chem. Rev. 2015, 115 (6), 2296−2349.
136. Johnson, E. C. B.; Kent, S. B. H., Insights into the mechanism and catalysis of the
native chemical ligation Reaction. J. Am. Chem. Soc. 2006, 128 (20), 6640−6646.
191

137. Bang, D.; Pentelute, B. L.; Kent, S. B. H., Kinetically controlled ligation for the
convergent chemical synthesis of proteins. Angew. Chem. Int. Ed. 2006, 45 (24), 3985–
3988.
138. Shah, N. H.; Muir, T. W., Inteins: nature’s gift to protein chemists. Chem. Sci.
2014, 5 (1), 446−461.
139. Klabunde, T.; Sharma, S.; Telenti, A.; Jacobs, W. R.; Sacchettini, J. C., Crystal
structure of GyrA intein from Mycobacterium xenopi reveals structural basis of protein
splicing. Nat. Struct. Mol. Biol. 1998, 5 (1), 31−36.
140. Muir, T. W.; Sondhi, D.; Cole, P. A., Expressed protein ligation: a general method
for protein engineering. P. Natl. Acad. Sci. USA 1998, 95 (12), 6705−6710.
141. Zettler, J.; Schütz, V.; Mootz, H. D., The naturally split Npu DnaE intein exhibits
an extraordinarily high rate in the protein trans-splicing reaction. FEBS Lett. 2009, 583
(5), 909−914.
142. Lockless, S. W.; Muir, T. W., Traceless protein splicing utilizing evolved split
inteins. P. Natl. Acad. Sci. USA 2009, 106 (27), 10999−11004.
143. Topilina, N. I.; Mills, K. V., Recent advances in in vivo applications of inteinmediated protein splicing. Mob. DNA 2014, 5, 5.
144. Nilsson, B. L.; Kiessling, L. L.; Raines, R. T., Staudinger ligation: a peptide from
a thioester and azide. Org. Lett. 2000, 2 (13), 1939−1941.
145. Tam, A.; Soellner, M. B.; Raines, R. T., Water-soluble phosphinothiols for
traceless Staudinger ligation and integration with expressed protein ligation. J. Am.
Chem. Soc. 2007, 129 (37), 11421−11430.
146. Saxon, E.; Bertozzi, C. R., Cell surface engineering by a modified staudinger
reaction. Science 2000, 287 (5460), 2007−2010.
147. Kolakowski, R. V.; Shangguan, N.; Sauers, R. R.; Williams, L. J., Mechanism of
thioacid/azide amidation. J. Am. Chem. Soc. 2006, 128 (17), 5695−5702.
148. Shangguan, N.; Katukojvala, S.; Greenberg, R.; Williams, L. J., The reaction of
thioacids with azides: a new mechanism and new synthetic applications. J. Am. Chem.
Soc. 2003, 125 (26), 7754−7755.
149. Rohmer, K.; Mannuthodikayil, J.; Wittmann, V., Application of the thioacid-azide
ligation (TAL) for the preparation of glycosylated and fluorescently labeled amino acids.
Isr. J. Chem. 2015, 55 (3−4), 437−446.

192

150. Muhlberg, M.; Siebertz, K. D.; Schlegel, B.; Schmieder, P.; Hackenberger, C. P.
R., Controlled thioamide vs. amide formation in the thioacid-azide reaction under acidic
aqueous conditions. Chem. Comm. 2014, 50 (35), 4603−4606.
151. Bode, J. W.; Fox, R. M.; Baucom, K. D., Chemoselective amide ligations by
decarboxylative condensations of N-alkylhydroxylamines and α-ketoacids. Angew. Chem.
Int. Ed. 2006, 45 (8), 1248–1252.
152. Pusterla, I.; Bode, J. W., The mechanism of the α-ketoacid–hydroxylamine
amide-forming ligation. Angew. Chem. Int. Ed. 2012, 51 (2), 513−516.
153. Pattabiraman, V. R.; Ogunkoya, A. O.; Bode, J. W., Chemical protein pynthesis
by chemoselective α-ketoacid–hydroxylamine (KAHA) ligations with 5-oxaproline.
Angew. Chem. Int. Ed. 2012, 51 (21), 5114−5118.
154. Pusterla, I.; Bode, J. W., An oxazetidine amino acid for chemical protein
synthesis by rapid, serine-forming ligations. Nat. Chem. 2015, 7 (8), 668−672.
155. Carey, F. A.; Sundberg, R. J., Advanced Organic Chemistry: Part B: Reaction
and Synthesis. Springer: New York, NY, 2010.
156. von Eggelkraut-Gottanka, R.; Klose, A.; Beck-Sickinger, A. G.; Beyermann, M.,
Peptide α-thioester formation using standard Fmoc-chemistry. Tetrahedron Lett. 2003, 44
(17), 3551−3554.
157. Nagalingam, A. C.; Radford, S. E.; Warriner, S. L., Avoidance of epimerization in
the synthesis of peptide thioesters using Fmoc protection. Synlett 2007, 2007 (16),
2517−2520.
158. Bang, D.; Pentelute, B. L.; Gates, Z. P.; Kent, S. B., Direct on-resin synthesis of
peptide α-thiophenylesters for use in native chemical ligation. Org. Lett. 2006, 8 (6),
1049–1052.
159. Raz, R.; Rademann, J., Fmoc-based synthesis of peptide thioesters for native
chemical ligation employing a tert-butyl thiol linker. Org. Lett. 2011, 13 (7), 1606−1609.
160. Ingenito, R.; Bianchi, E.; Fattori, D.; Pessi, A., Solid phase synthesis of peptide
C-terminal thioesters by Fmoc/t-Bu chemistry. J. Am. Chem. Soc. 1999, 121 (49),
11369−11374.
161. Tofteng, A. P.; Sørensen, K. K.; Conde-Frieboes, K. W.; Hoeg-Jensen, T.; Jensen,
K. J., Fmoc solid-phase synthesis of C-terminal peptide thioesters by formation of a
backbone pyroglutamyl imide moiety. Angew. Chem. Int. Ed. 2009, 48 (40), 7411−7414.

193

162. Blanco-Canosa, J. B.; Dawson, P. E., An Efficient Fmoc-SPPS Approach for the
Generation of Thioester Peptide Precursors for Use in Native Chemical Ligation.
Angewandte Chemie 2008, 120 (36), 6957-6961.
163. Mahto, S. K.; Howard, C. J.; Shimko, J. C.; Ottesen, J. J., A reversible protection
strategy to improve Fmoc-SPPS of peptide thioesters by the N-acylurea approach.
ChemBioChem 2011, 12 (16), 2488−2494.
164. Blanco-Canosa, J. B.; Nardone, B.; Albericio, F.; Dawson, P. E., Chemical
protein synthesis using a second-generation N-acylurea linker for the preparation of
peptide-thioester precursors. J. Am. Chem. Soc. 2015, 137 (22), 7197–7209.
165. Ficht, S.; Payne, R. J.; Guy, R. T.; Wong, C.-H., Solid-phase synthesis of peptide
and glycopeptide thioesters through side-chain-anchoring strategies. Chem. - Eur. J.
2008, 14 (12), 3620−3629.
166. Nakamura, K.; Hanai, N.; Kanno, M.; Kobayashi, A.; Ohnishi, Y.; Ito, Y.;
Nakahara, Y., Design and synthesis of silyl ether-based linker for solid-phase synthesis of
glycopeptides. Tetrahedron Lett. 1999, 40 (3), 515−518.
167. Scott, P., Linker Strategies in Solid-Phase Organic Synthesis. John Wiley & Sons:
New York, NY, 2009.
168. Arnesen, T., Towards a functional understanding of protein N-terminal
acetylation. PLoS Biol. 2011, 9 (5), e1001074.
169. Kawakami, T.; Sumida, M.; Nakamura, K. i.; Vorherr, T.; Aimoto, S., Peptide
thioester preparation based on an N-S acyl shift reaction mediated by a thiol ligation
auxiliary. Tetrahedron Lett. 2005, 46 (50), 8805−8807.
170. Nakamura, K. i.; Kanao, T.; Uesugi, T.; Hara, T.; Sato, T.; Kawakami, T.;
Aimoto, S., Synthesis of peptide thioesters via an N–S acyl shift reaction under mild
acidic conditions on an N-4,5-dimethoxy-2-mercaptobenzyl auxiliary group. J. Pept. Sci.
2009, 15 (11), 731−737.
171. Kawakami, T.; Aimoto, S., The use of a cysteinyl prolyl ester (CPE)
autoactivating unit in peptide ligation reactions. Tetrahedron 2009, 65 (19), 3871−3877.
172. Kawakami, T.; Aimoto, S., Peptide ligation using a building block having a
cysteinyl prolyl ester (CPE) autoactivating unit at the carboxy terminus. Chem. Lett.
2007, 36 (1), 76−77.
173. Kawakami, T.; Aimoto, S., Sequential peptide ligation by using a controlled
cysteinyl prolyl ester (CPE) autoactivating unit. Tetrahedron Lett. 2007, 48 (11),
1903−1905.
194

174. Nagaike, F.; Onuma, Y.; Kanazawa, C.; Hojo, H.; Ueki, A.; Nakahara, Y.;
Nakahara, Y., Efficient microwave-assisted tandem N-to-S acyl transfer and thioester
exchange for the preparation of a glycosylated peptide thioester. Org. Lett. 2006, 8 (20),
4465−4468.
175. Hojo, H.; Murasawa, Y.; Katayama, H.; Ohira, T.; Nakahara, Y.; Nakahara, Y.,
Application of a novel thioesterification reaction to the synthesis of chemokine CCL27
by the modified thioester method. Org. Biomol. Chem. 2008, 6 (10), 1808−1813.
176. Ohta, Y.; Itoh, S.; Shigenaga, A.; Shintaku, S.; Fujii, N.; Otaka, A., Cysteinederived S-protected oxazolidinones: potential chemical devices for the preparation of
peptide thioesters. Org. Lett. 2006, 8 (3), 467−470.
177. Tsuda, S.; Shigenaga, A.; Bando, K.; Otaka, A., N→S acyl-transfer-mediated
synthesis of peptide thioesters using anilide derivatives. Org. Lett. 2009, 11 (4), 823−826.
178. Sato, K.; Shigenaga, A.; Tsuji, K.; Tsuda, S.; Sumikawa, Y.; Sakamoto, K.;
Otaka, A., N-Sulfanylethylanilide peptide as a crypto-thioester peptide. ChemBioChem
2011, 12 (12), 1840−1844.
179. Ollivier, N.; Vicogne, J.; Vallin, A.; Drobecq, H.; Desmet, R.; El Mahdi, O.;
Leclercq, B.; Goormachtigh, G.; Fafeur, V.; Melnyk, O., A one-pot three-segment
ligation strategy for protein chemical synthesis. Angew. Chem. Int. Ed. 2012, 51 (1),
209−213.
180. Jung, M. E.; Piizzi, G., gem-Disubstituent effect: theoretical basis and synthetic
applications. Chem. Rev. 2005, 105 (5), 1735−1766.
181. Burlina, F.; Papageorgiou, G.; Morris, C.; White, P. D.; Offer, J., In situ thioester
formation for protein ligation using α-methylcysteine. Chem. Sci. 2014, 5 (2), 766–770.
182. Zheng, J.-S.; Chang, H.-N.; Wang, F.-L.; Liu, L., Fmoc synthesis of peptide
thioesters without post-chain-assembly manipulation. J. Am. Chem. Soc. 2011, 133 (29),
11080−11083.
183. Terrier, V. P.; Adihou, H.; Arnould, M.; Delmas, A. F.; Aucagne, V., A
straightforward method for automated Fmoc-based synthesis of bio-inspired peptide
crypto-thioesters. Chem. Sci. 2015, 10.1039/C5SC02630J.
184. Adams, A. L.; Macmillan, D., Investigation of peptide thioester formation via
N→Se acyl transfer. J. Pept. Sci. 2013, 19 (2), 65–73.
185. Botti, P.; Villain, M.; Manganiello, S.; Gaertner, H., Native chemical ligation
through in situ O to S acyl shift. Org. Lett. 2004, 6 (26), 4861–4864.

195

186. George, E. A.; Novick, R. P.; Muir, T. W., Cyclic peptide inhibitors of
Staphylococcal virulence prepared by Fmoc-based thiolactone peptide synthesis. J. Am.
Chem. Soc. 2008, 130 (14), 4914−4924.
187. Liu, F.; Mayer, J. P., An Fmoc compatible, O to S shift-mediated procedure for
the preparation of C-terminal thioester peptides. J. Org. Chem. 2013, 78 (19),
9848−9856.
188. Tofteng, A. P.; Jensen, K. J.; Hoeg-Jensen, T., Peptide dithiodiethanol esters for
in situ generation of thioesters for use in native ligation. Tetrahedron Lett. 2007, 48 (12),
2105−2107.
189. Zheng, J.-S.; Cui, H.-K.; Fang, G.-M.; Xi, W.-X.; Liu, L., Chemical protein
dynthesis by kinetically controlled ligation of peptide O-esters. ChemBioChem 2010, 11
(4), 511−515.
190. Warren, J. D.; Miller, J. S.; Keding, S. J.; Danishefsky, S. J., Toward fully
synthetic glycoproteins by ultimately convergent routes: a solution to a long-standing
problem. J. Am. Chem. Soc. 2004, 126 (21), 6576−6578.
191. Fang, G.-M.; Li, Y.-M.; Shen, F.; Huang, Y.-C.; Li, J.-B.; Lin, Y.; Cui, H.-K.;
Liu, L., Protein chemical synthesis by ligation of peptide hydrazides. Angew. Chem. Int.
Ed. 2011, 50 (33), 7645−7649.
192. Zheng, J.-S.; Tang, S.; Qi, Y.-K.; Wang, Z.-P.; Liu, L., Chemical synthesis of
proteins using peptide hydrazides as thioester surrogates. Nat. Protocols 2013, 8 (12),
2483−2495.
193. Smith, H. B.; Hartman, F. C., Restoration of activity to catalytically deficient
mutants of ribulosebisphosphate carboxylase/oxygenase by aminoethylation. J. Biol.
Chem. 1988, 263 (10), 4921−4925.
194. Kochendoerfer, G. G.; Chen, S.-Y.; Mao, F.; Cressman, S.; Traviglia, S.; Shao,
H.; Hunter, C. L.; Low, D. W.; Cagle, E. N.; Carnevali, M.; Gueriguian, V.; Keogh, P. J.;
Porter, H.; Stratton, S. M.; Wiedeke, M. C.; Wilken, J.; Tang, J.; Levy, J. J.; Miranda, L.
P.; Crnogorac, M. M.; Kalbag, S.; Botti, P.; Schindler-Horvat, J.; Savatski, L.; Adamson,
J. W.; Kung, A.; Kent, S. B. H.; Bradburne, J. A., Design and chemical synthesis of a
homogeneous polymer-modified erythropoiesis protein. Science 2003, 299 (5608),
884−887.
195. Bochar, D. A.; Tabernero, L.; Stauffacher, C. V.; Rodwell, V. W.,
Aminoethylcysteine can replace the function of the essential active site lysine of
Pseudomonas mevalonii 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Biochemistry 1999, 38 (28), 8879–8883.

196

196. Heinrikson, R. L., The selective S-methylation of sulfhydryl groups in proteins
and peptides with methyl-p-nitrobenzenesulfonate. J. Biol. Chem. 1971, 246, 4090–4096.
197. Roelfes, G.; Hilvert, D., Incorporation of selenomethionine into proteins through
selenohomocysteine-mediated ligation. Angew. Chem. Int. Ed. 2003, 42 (20), 2275−2277.
198. Wong, C. T. T.; Tung, C. L.; Li, X., Synthetic cysteine surrogates used in native
chemical ligation. Mol. BioSyst. 2013, 9 (5), 826−833.
199. Yan, L. Z.; Dawson, P. E., Synthesis of peptides and proteins without cysteine
residues by native chemical ligation combined with desulfurization. J. Am. Chem. Soc.
2001, 123 (4), 526−533.
200. Wan, Q.; Danishefsky, S. J., Free-radical-based, specific desulfurization of
cysteine: a powerful advance in the synthesis of polypeptides and glycopolypeptides.
Angew. Chem. Int. Ed. 2007, 46 (48), 9248−9252.
201. Crich, D.; Banerjee, A., Native chemical ligation at phenylalanine. J. Am. Chem.
Soc. 2007, 129 (33), 10064–10065.
202. Chen, J.; Wan, Q.; Yuan, Y.; Zhu, J.; Danishefsky, S. J., Native chemical ligation
at valine: a contribution to peptide and glycopeptide synthesis. Angew. Chem. Int. Ed.
2008, 47 (44), 8521–8524.
203. Haase, C.; Rohde, H.; Seitz, O., Native chemical ligation at valine. Angew. Chem.
Int. Ed. 2008, 47 (36), 6807−6810.
204. Yang, R.; Pasunooti, K. K.; Li, F.; Liu, X.-W.; Liu, C.-F., Dual native chemical
ligation at lysine. J. Am. Chem. Soc. 2009, 131 (38), 13592−13593.
205. Ajish Kumar, K. S.; Haj-Yahya, M.; Olschewski, D.; Lashuel, H. A.; Brik, A.,
Highly efficient and chemoselective peptide ubiquitylation. Angew. Chem. Int. Ed. 2009,
48 (43), 8090–8094.
206. Tan, Z.; Shang, S.; Danishefsky, S. J., Insights into the finer issues of native
chemical ligation: an approach to cascade ligations. Angew. Chem. Int. Ed. 2010, 49 (49),
9500−503.
207. Chen, J.; Wang, P.; Zhu, J.; Wan, Q.; Danishefsky, S. J., A program for ligation at
threonine sites: application to the controlled total synthesis of glycopeptides. Tetrahedron
2010, 66 (13), 2277–2283.
208. Shang, S.; Tan, Z.; Dong, S.; Danishefsky, S. J., An advance in proline ligation. J.
Am. Chem. Soc. 2011, 133 (28), 10784−10786.

197

209. Siman, P.; Karthikeyan, S. V.; Brik, A., Native chemical ligation at glutamine.
Org. Lett. 2012, 14 (6), 1520−1523.
210. Malins, L. R.; Cergol, K. M.; Payne, R. J., Peptide ligation–desulfurization
chemistry at arginine. ChemBioChem 2013, 14 (5), 559−563.
211. Cergol, K. M.; Thompson, R. E.; Malins, L. R.; Turner, P.; Payne, R. J., One-pot
peptide ligation–desulfurization at glutamate. Org. Lett. 2014, 16 (1), 290–293.
212. Thompson, R. E.; Chan, B.; Radom, L.; Jolliffe, K. A.; Payne, R. J.,
Chemoselective peptide ligation–desulfurization at aspartate. Angew. Chem. Int. Ed.
2013, 52 (37), 9723−9727.
213. Sayers, J.; Thompson, R. E.; Perry, K. J.; Malins, L. R.; Payne, R. J.,
Thiazolidine-protected β-thiol asparagine: applications in one-pot ligation–
desulfurization chemistry. Org. Lett. 2015, 17 (19), 4902−4905.
214. Malins, L. R.; Cergol, K. M.; Payne, R. J., Chemoselective sulfenylation and
peptide ligation at tryptophan. Chem. Sci. 2014, 5 (1), 260−266.
215. Sun, X.-H.; Yu, H.-Z.; Yang, M.-M.; Yang, Y.-M.; Dang, Z.-M., Relative facility
of the desulfurization of amino acids and their carboxylic derivatives. J. Phys. Org. Chem
2015, 28 (9), 586−590.
216. Metanis, N.; Keinan, E.; Dawson, P. E., Traceless ligation of cysteine peptides
using selective deselenization. Angew. Chem. Int. Ed. 2010, 49 (39), 7049−7053.
217. Townsend, S. D.; Tan, Z.; Dong, S.; Shang, S.; Brailsford, J. A.; Danishefsky, S.
J., Advances in proline ligation. J. Am. Chem. Soc. 2012, 134 (8), 3912−3916.
218. Malins, L. R.; Payne, R. J., Synthesis and utility of β-selenol-phenylalanine for
native chemical ligation–deselenization chemistry. Org. Lett. 2012, 14 (12), 3142−3145.
219. Malins, L. R.; Mitchell, N. J.; Payne, R. J., Peptide ligation chemistry at selenol
amino acids. J. Pept. Sci. 2014, 20 (2), 64−77.
220. Woollins, J. D.; Laitinen, R., Selenium and Tellurium Chemistry: From Small
Molecules to Biomolecules and Materials. Springer: New York, NY, 2011.
221. Malins, L. R.; Mitchell, N. J.; McGowan, S.; Payne, R. J., Oxidative
deselenization of selenocysteine: applications for programmed ligation at serine. Angew.
Chem. Int. Ed. 2015, 54 (43), 12716−12721.
222. Dery, S.; Reddy, P. S.; Dery, L.; Mousa, R.; Dardashti, R. N.; Metanis, N.,
Insights into the deselenization of selenocysteine into alanine and serine. Chem. Sci.
2015, 6 (11), 6207–6212.
198

223. Wessjohann Ludger, A.; Schneider, A.; Abbas, M.; Brandt, W., Selenium in
chemistry and biochemistry in comparison to sulfur. Biol. Chem. 2007, 388 (10),
997−1006.
224. Allen, F., The Cambridge Structural Database: a quarter of a million crystal
structures and rising. Acta Crystall. B - Stru. 2002, 58, 380–388.
225. Huber, R. E.; Criddle, R. S., Comparison of the chemical properties of
selenocysteine and selenocystine with their sulfur analogs. Arch. Biochem. and Biophys.
1967, 122 (1), 164−173.
226. Nauser, T.; Steinmann, D.; Koppenol, W., Why do proteins use selenocysteine
instead of cysteine? Amino Acids 2012, 42 (1), 39−44.
227. Jacob, C.; Giles, G. I.; Giles, N. M.; Sies, H., Sulfur and selenium: the role of
oxidation state in protein structure and function. Angew. Chem. Int. Ed. 2003, 42 (39),
4742−4758.
228. Zhong, L.; Holmgren, A., Essential role of selenium in the catalytic activities of
mammalian thioredoxin reductase revealed by characterization of recombinant enzymes
with selenocysteine mutations. J. Biol. Chem. 2000, 275 (24), 18121−18128.
229. Chaudiere, J.; Wilhelmsen, E. C.; Tappel, A. L., Mechanism of seleniumglutathione peroxidase and its inhibition by mercaptocarboxylic acids and other
mercaptans. J. Biol. Chem. 1984, 259 (2), 1043–1050.
230. Johansson, L.; Gafvelin, G.; Arnér, E. S. J., Selenocysteine in proteins −
properties and biotechnological use. BBA - Gen. Subjects 2005, 1726 (1), 1−13.
231. Hondal, R. J.; Nilsson, B. L.; Raines, R. T., Selenocysteine in native chemical
ligation and expressed protein ligation. J. Am. Chem. Soc. 2001, 123 (21), 5140−5141.
232. McGrath, N. A.; Raines, R. T., Chemoselectivity in chemical biology: acyl
transfer reactions with sulfur and selenium. Accounts Chem. Res. 2011, 44 (9), 752−761.
233. Berry, S. M.; Gieselman, M. D.; Nilges, M. J.; van der Donk, W. A.; Lu, Y., An
engineered azurin variant containing a selenocysteine copper ligand. J. Am. Chem. Soc.
2002, 124 (10), 2084–2085.
234. Okumura, M.; Shimamoto, S.; Hidaka, Y., A chemical method for investigating
disulfide-coupled peptide and protein folding. FEBS J. 2012, 279 (13), 2283−2295.
235. Pegoraro, S.; Fiori, S.; Cramer, J.; Rudolph-Böhner, S.; Moroder, L., The
disulfide-coupled folding pathway of apamin as derived from diselenide-quenched
analogs and intermediates. Protein Sci. 1999, 8 (8), 1605-1613.
199

236. Walewska, A.; Zhang, M.-M.; Skalicky, J. J.; Yoshikami, D.; Olivera, B. M.;
Bulaj, G., Integrated oxidative folding of cysteine/selenocysteine containing peptides:
improving chemical synthesis of conotoxins. Angew. Chem. Int. Ed. 2009, 48 (12),
2221−2224.
237. Luthra, N. P.; Costello, R. C.; Odom, J. D.; Dunlap, R. B., Demonstration of the
feasibility of observing nuclear magnetic resonance signals of 77Se covalently attached to
proteins. J. Biol. Chem. 1982, 257 (3), 1142−1144.
238. Gettins, P.; Wardlaw, S. A., NMR relaxation properties of 77Se-labeled proteins.
J. Biol. Chem. 1991, 266 (6), 3422−3426.
239. House, K. L.; Dunlap, R. B.; Odom, J. D.; Wu, Z. P.; Hilvert, D., Structural
characterization of selenosubtilisin by selenium-77 NMR spectroscopy. J. Am. Chem.
Soc. 1992, 114 (22), 8573−8579.
240. Schaefer, S. A.; Dong, M.; Rubenstein, R. P.; Wilkie, W. A.; Bahnson, B. J.;
Thorpe, C.; Rozovsky, S., 77Se Enrichment of proteins expands the biological NMR
toolbox. J. Mol. Biol. 2013, 425 (2), 222−231.
241. Gieselman, M. D.; Xie, L.; van der Donk, W. A., Synthesis of a selenocysteinecontaining peptide by native chemical ligation. Org. Lett. 2001, 3 (9), 1331−1334.
242. Flemer, S., Fmoc-Sec(Xan)-OH: synthesis and utility of Fmoc selenocysteine
SPPS derivatives with acid-labile sidechain protection. J. Pept. Sci. 2015, 21 (1), 53−59.
243. Schroll, A. L.; Hondal, R. J.; Flemer, S., The use of 2,2′-dithiobis(5-nitropyridine)
(DTNP) for deprotection and diselenide formation in protected selenocysteine-containing
peptides. J. Pept. Sci. 2012, 18 (3), 155−162.
244. Böck, A.; Forchhammer, K.; Heider, J.; Leinfelder, W.; Sawers, G.; Veprek, B.;
Zinoni, F., Selenocysteine: the 21st amino acid. Mol. Microbiol. 1991, 5 (3), 515–520.
245. Turanov, A. A.; Xu, X.-M.; Carlson, B. A.; Yoo, M.-H.; Gladyshev, V. N.;
Hatfield, D. L., Biosynthesis of selenocysteine, the 21st amino acid in the genetic code,
and a novel pathway for cysteine biosynthesis. Adv. Nutr. 2011, 2 (2), 122−128.
246. Ganichkin, O. M.; Xu, X.-M.; Carlson, B. A.; Mix, H.; Hatfield, D. L.;
Gladyshev, V. N.; Wahl, M. C., Structure and catalytic mechanism of eukaryotic
selenocysteine synthase. J. Biol. Chem. 2008, 283 (9), 5849−5865.
247. Gonzalez-Flores, J. N.; Gupta, N.; DeMong, L. W.; Copeland, P. R., The
selenocysteine-specific elongation factor contains a novel and multi-functional domain.
Journal of Biological Chemistry 2012, 287 (46), 38936−38945.

200

248. Fletcher, J. E.; Copeland, P. R.; Driscoll, D. M.; Krol, A., The selenocysteine
incorporation machinery: interactions between the SECIS RNA and the SECIS-binding
protein SBP2. RNA 2001, 7 (10), 1442−1453.
249. Stoytcheva, Z.; Tujebajeva, R. M.; Harney, J. W.; Berry, M. J., Efficient
incorporation of multiple selenocysteines involves an inefficient decoding step serving as
a potential translational checkpoint and ribosome bottleneck. Mol. Cell. Biol. 2006, 26
(24), 9177−9184.
250. Kryukov, G. V.; Castellano, S.; Novoselov, S. V.; Lobanov, A. V.; Zehtab, O.;
Guigó, R.; Gladyshev, V. N., Characterization of mammalian selenoproteomes. Science
2003, 300 (5624), 1439−1443.
251. Reeves, M. A.; Hoffmann, P. R., The human selenoproteome: recent insights into
functions and regulation. Cell. Mol. Life Sci. 2009, 66 (15), 2457−2478.
252. Su, D.; Li, Y.; Gladyshev, V. N., Selenocysteine insertion directed by the 3′-UTR
SECIS element in Escherichia coli. Nucleic Acids Res. 2005, 33 (8), 2486−2492.
253. Novoselov, S. V.; Lobanov, A. V.; Hua, D.; Kasaikina, M. V.; Hatfield, D. L.;
Gladyshev, V. N., A highly efficient form of the selenocysteine insertion sequence
element in protozoan parasites and its use in mammalian cells. P. Natl. Acad. Sci. USA
2007, 104 (19), 7857β7862.
254. Schaefer-Ramadan, S.; Thorpe, C.; Rozovsky, S., Site-specific insertion of
selenium into the redox-active disulfide of the flavoprotein augmenter of liver
regeneration. Arch. Biochem. and Biophys. 2014, 548, 60−65.
255. Jiang, Z.; Arnér, E. S. J.; Mu, Y.; Johansson, L.; Shi, J.; Zhao, S.; Liu, S.; Wang,
R.; Zhang, T.; Yan, G.; Liu, J.; Shen, J.; Luo, G., Expression of selenocysteinecontaining glutathione S-transferase in Escherichia coli. Biochem. Bioph. Res. Co. 2004,
321 (1), 94−101.
256. Mogk, A.; Schmidt, R.; Bukau, B., The N-end rule pathway for regulated
proteolysis: prokaryotic and eukaryotic strategies. Trends Cell Biol. 2007, 17 (4),
165−172.
257. Kaji, A.; Kaji, H.; Novelli, G. D., Soluble amino acid-incorporating system I.
Preparation of system and nature of reaction. J. Biol. Chem. 1965, 240, 1185−1191.
258. Leibowitz, M. J.; Soffer, R. L., Enzymatic modification of proteins: III.
purification and properties of a leucyl, phenylalanyl transfer ribonucleic acid-protein
transferase from Escherichia coli. J. Biol. Chem. 1970, 245 (8), 2066−2073.
259. Soffer, R. L., Peptide acceptors in the leucine, phenylalanine transfer reaction. J.
Biol. Chem. 1973, 248 (24), 8424−8428.
201

260. Tobias, J. W.; Shrader, T. E.; Rocap, G.; Varshavsky, A., The N-end rule in
bacteria. Science 1991, 254 (5036), 1374−1377.
261. Watanabe, K.; Toh, Y.; Suto, K.; Shimizu, Y.; Oka, N.; Wada, T.; Tomita, K.,
Protein-based peptide-bond formation by aminoacyl-tRNA protein transferase. Nature
2007, 449 (7164), 867−871.
262. Fung, A. W.; Ebhardt, H. A.; Abeysundara, H.; Moore, J.; Xu, Z.; Fahlman, R. P.,
An alternative mechanism for the catalysis of peptide bond formation by L/F transferase:
substrate binding and orientation. J. Mol. Biol. 2011, 409 (4), 617−629.
263. Abramochkin, G.; Shrader, T. E., Aminoacyl-tRNA recognition by the
leucyl/phenylalanyl-tRNA-protein transferase. J. Biol. Chem. 1996, 271 (37), 22901–
22907.
264. Connor, R. E.; Piatkov, K.; Varshavsky, A.; Tirrell, D. A., Enzymatic N-terminal
addition of noncanonical amino acids to peptides and proteins. ChemBioChem 2008, 9
(3), 366–369.
265. Taki, M.; Kuno, A.; Matoba, S.; Kobayashi, Y.; Futami, J.; Murakami, H.; Suga,
H.; Taira, K.; Hasegawa, T.; Sisido, M., Leucyl/phenylalanyl-tRNA-protein transferasemediated chemoenzymatic coupling of N-terminal Arg/Lys units in post-translationally
processed proteins with non-natural amino acids. ChemBioChem 2006, 7 (11),
1676−1679.
266. Taki, M.; Sisido, M., Leucyl/phenylalanyl(L/F)-tRNA-protein transferasemediated aminoacyl transfer of a nonnatural amino acid to the N-terminus of peptides
and proteins and subsequent functionalization by bioorthogonal reactions. Peptide Sci.
2007, 88 (2), 263−271.
267. Taki, M.; Kuroiwa, H.; Sisido, M., Chemoenzymatic transfer of fluorescent nonnatural amino acids to the N-terminus of a protein/peptide. ChemBioChem 2008, 9 (5),
719−722.
268. Wagner, A. M.; Fegley, M. W.; Warner, J. B.; Grindley, C. L. J.; Marotta, N. P.;
Petersson, E. J., N-terminal protein modification using simple aminoacyl transferase
substrates. J. Am. Chem. Soc. 2011, 133 (38), 15139−15147.
269. Tanaka, T.; Wagner, A. M.; Warner, J. B.; Wang, Y. J.; Petersson, E. J.,
Expressed protein ligation at methionine: N-terminal attachment of homocysteine,
ligation, and masking. Angew. Chem. Int. Ed. 2013, 52 (24), 6210−6213.
270. Amblard, M.; Fehrentz, J.-A.; Martinez, J.; Subra, G., Methods and protocols of
modern solid phase peptide synthesis. Mol. Biotechnol. 2006, 33 (3), 239–254.

202

271. Brinkley, M., A brief survey of methods for preparing protein conjugates with
dyes, haptens and crosslinking reagents. Bioconjugate Chem. 1992, 3 (1), 2–13.
272. England, P. M., Unnatural amino acid mutagenesis: a precise tool for probing
protein structure and function. Biochemistry 2004, 43 (37), 11623–11629.
273. Tzvetkova, S.; Kluger, R., Biomimetic aminoacylation of ribonucleotides and
RNA with aminoacyl phosphate esters and lanthanum salts. J. Am. Chem. Soc. 2007, 129
(51), 15848−15854.
274. Maini, R.; Dedkova, L. M.; Paul, R.; Madathil, M. M.; Chowdhury, S. R.; Chen,
S.; Hecht, S. M., Ribosome-mediated incorporation of dipeptides and dipeptide analogues
into proteins in vitro. J. Am. Chem. Soc. 2015, 137 (35), 11206−11209.
275. Chen, J.; Warren, J. D.; Wu, B.; Chen, G.; Wan, Q.; Danishefsky, S. J., A route to
cyclic peptides and glycopeptides by native chemical ligation using in situ derived
thioesters. Tetrahedron Lett. 2006, 47 (12), 1969–1972.
276. Blanco-Canosa, J. B.; Dawson, P. E., An efficient Fmoc-SPPS approach for the
generation of thioester peptide precursors for use in native chemical ligation. Angew.
Chem. Int. Ed. 2008, 47 (36), 6851–6855.
277. Pátek, M.; Lebl, M., Safety-catch and multiply cleavable linkers in solid-phase
synthesis. Peptide Sci. 1998, 47 (5), 353−363.
278. Botti, P.; Villain, M.; Manganiello, S.; Gaertner, H., Native Chemical Ligation
through in Situ O to S Acyl Shift. Organic Letters 2004, 6 (26), 4861-4864.
279. Breydo, L.; Wu, J. W.; Uversky, V. N., α-Synuclein misfolding and Parkinson's
disease. BBA - Mol. Basis Dis. 2012, 1822 (2), 261–285.
280. Goldberg, J. M.; Wissner, R. F.; Klein, A. M.; Petersson, E. J., Thioamide
quenching of intrinsic protein fluorescence. Chem. Comm. 2012, 48 (10), 1550−1552.
281. Lorenzen, N.; Nielsen, S. B.; Buell, A. K.; Kaspersen, J. D.; Arosio, P.; Vad, B.
S.; Paslawski, W.; Christiansen, G.; Valnickova-Hansen, Z.; Andreasen, M.; Enghild, J.
J.; Pedersen, J. S.; Dobson, C. M.; Knowles, T. P. J.; Otzen, D. E., The role of stable αsynuclein oligomers in the molecular events underlying amyloid formation. J. Am. Chem.
Soc. 2014, 136 (10), 3859−3868.
282. Ireland, R. E.; Liu, L., An improved procedure for the preparation of the DessMartin periodinane. J. Org. Chem. 1993, 58 (10), 2899−2899.
283. Batjargal, S.; Wang, Y. J.; Goldberg, J. M.; Wissner, R. F.; Petersson, E. J.,
Native chemical ligation of thioamide-containing peptides: development and application
203

to the synthesis of labeled α-Synuclein for misfolding studies. J. Am. Chem. Soc. 2012,
134 (22), 9172–9182.
284. Thirunavukkuarasu, S.; Jares-Erijman, E. A.; Jovin, T. M., Multiparametric
fluorescence detection of early stages in the amyloid protein aggregation of pyrenelabeled α-synuclein. J. Mol. Biol. 2008, 378 (5), 1064−1073.
285. Yushchenko, D. A.; Fauerbach, J. A.; Thirunavukkuarasu, S.; Jares-Erijman, E.
A.; Jovin, T. M., Fluorescent ratiometric MFC probe sensitive to early stages of αsynuclein aggregation. J. Am. Chem. Soc. 2010, 132 (23), 7860−7861.
286. Echols, N.; Harrison, P.; Balasubramanian, S.; Luscombe, N. M.; Bertone, P.;
Zhang, Z.; Gerstein, M., Comprehensive analysis of amino acid and nucleotide
composition in eukaryotic genomes, comparing genes and pseudogenes. Nucleic Acids
Res. 2002, 30 (11), 2515–2523.
287. Zhou, W.; Freed, C. R., Tyrosine-to-cysteine modification of human α-synuclein
enhances protein aggregation and cellular toxicity. J. Biol. Chem. 2004, 279 (11),
10128−10135.
288. Wissner, R. F.; Wagner, A. M.; Warner, J. B.; Petersson, E. J., Efficient, traceless
semi-synthesis of α-synuclein labeled with a fluorophore/thioamide FRET Pair. Synlett
2013, 24 (18), 2454−2458.
289. Trost, B. M.; Fleming, I., Comprehensive Organic Synthesis: Selectivity, Strategy,
and Efficiency in Modern Organic Chemistry. Elsevier: Oxford, UK, 1991.
290. Kornfeld, E. C., Raney nickel hydrogenolysis of thioamides: a new amine
synthesis. J. Org. Chem. 1951, 16 (1), 131−138.
291. Hendrickson, T. L.; Imperiali, B., Metal ion dependence of oligosaccharyl
transferase: implications for catalysis. Biochemistry 1995, 34 (29), 9444−9450.
292. Engman, L.; Stern, D., Thiol/diselenide exchange for the generation of
benzeneselenolate ion. Catalytic reductive ring-opening of α,β-epoxy ketones. J. Org.
Chem. 1994, 59 (18), 5179–5183.
293. Ji, S.; Cao, W.; Yu, Y.; Xu, H., Dynamic diselenide bonds: exchange reaction
induced by visible light without catalysis. Angew. Chem. Int. Ed. 2014, 53 (26),
6781−6785.
294. Thompson, R. E.; Liu, X.; Alonso-García, N.; Pereira, P. J. B.; Jolliffe, K. A.;
Payne, R. J., Trifluoroethanethiol: an additive for efficient one-pot peptide ligationdesulfurization chemistry. J. Am. Chem. Soc. 2014, 136 (23), 8161−8164.

204

295. Cox, B. G., Acids and Bases: Solvent Effects on Acid-Base Strength. OUP
Oxford: Oxford, UK, 2013.
296. Fu, Y.; Lin, B.-L.; Song, K.-S.; Liu, L.; Guo, Q.-X., Substituent effects on the
S−H bond dissociation energies of thiophenols. J. Chem. Soc. Perk. T. 2 2002, (7),
1223−1230.
297. Luo, Y.-R., BDEs of S−, Se−, Te−, Po−X bonds. In Comprehensive Handbook of
Chemical Bond Energies, CRC Press: 2007; pp 424-454.
298. Caban, K.; Copeland, P. R., Size matters: a view of selenocysteine incorporation
from the ribosome. Cell. Mol. Life Sci. 2006, 63 (1), 73–81.
299. Balzi, E.; Choder, M.; Chen, W. N.; Varshavsky, A.; Goffeau, A., Cloning and
functional analysis of the arginyl-tRNA-protein transferase gene ATE1 of
Saccharomyces cerevisiae. J. Biol. Chem. 1990, 265 (13), 7464–7471.
300. Varshavsky, A., The N-end rule pathway and regulation by proteolysis. Protein
Sci. 2011, 20 (8), 1298−1345.
301. Taiji, M.; Yokoyama, S.; Miyazawa, T., Transacylation rates of
aminoacyladenosine moiety at the 3'-terminus of aminoacyl-transfer ribonucleic acid.
Biochemistry 1983, 22 (13), 3220−3225.
302. Graciet, E.; Hu, R.-G.; Piatkov, K.; Rhee, J. H.; Schwarz, E. M.; Varshavsky, A.,
Aminoacyl-transferases and the N-end rule pathway of prokaryotic/eukaryotic specificity
in a human pathogen. P. Natl. Acad. Sci. USA 2006, 103 (9), 3078−3083.
303. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976,
72 (1), 248–254.
304. Tang, Y.; Tirrell, D. A., Attenuation of the editing activity of the Escherichia coli
leucyl-tRNA synthetase allows incorporation of novel amino acids into proteins in vivo.
Biochemistry 2002, 41 (34), 10635−10645.
305. Palencia, A.; Crépin, T.; Vu, M. T.; Lincecum, T. L.; Martinis, S. A.; Cusack, S.,
Structural dynamics of the aminoacylation and proofreading functional cycle of bacterial
leucyl-tRNA synthetase. Nat. Struct. Mol. Biol. 2012, 19 (7), 677−684.
306. Brustad, E.; Bushey, M. L.; Brock, A.; Chittuluru, J.; Schultz, P. G., A
promiscuous aminoacyl-tRNA synthetase that incorporates cysteine, methionine, and
alanine homologs into proteins. Bioorg. Med. Chem. Lett. 2008, 18 (22), 6004–6006.

205

